WO2026013602A1

WO2026013602A1 - Oral products

Info

Publication number: WO2026013602A1
Application number: PCT/IB2025/056973
Authority: WO
Inventors: Steven Lee ALDERMAN; Anthony Richard Gerardi; Kristen Ann Spielbauer; Michael Andrew Zawadzki; Gary M. Dull
Original assignee: RAI Strategic Holdings Inc
Current assignee: RAI Strategic Holdings Inc
Priority date: 2024-07-10
Filing date: 2025-07-09
Publication date: 2026-01-15
Anticipated expiration: 2027-01-10

Abstract

The disclosure provides compositions configured for oral use, products including such compositions, and methods of manufacturing the compositions and products. Example compositions configured for oral use include a filler component, water, and a 3-(1- methylpyrrolidin-2-yl)pyridine bearing one or more substituents on the pyrrolidine ring, and optionally on the pyridine ring. Other example compositions configured for oral use include a filler component, water, and an optionally substituted 3-(azetidin-2-yl)pyridine or an optionally substituted 3-(azetidin-2-ylmethoxy)pyridine, wherein the optional substituents are on the azetidine ring, the pyridine ring, or both.

Description

ORAL PRODUCTS TECHNICAL FIELD [0001] The present disclosure relates to an oral product. In particular, the present disclosure relates to products intended for human consumption. The products are configured for oral use and deliver substances such as flavors and/or active ingredients during use. BACKGROUND [0002] There are many categories of products intended for oral use and enjoyment. For example, oral tobacco products containing nicotine, which is known to have both stimulant and anxiolytic properties, have been available for many years. Conventional formats for so-called "smokeless" tobacco products include moist snuff, snus, and chewing tobacco, which are typically formed almost entirely of particulate, granular, or shredded tobacco, and which are either portioned by the user or presented to the user in individual portions, such as in single- use pouches or sachets. See for example, the types of smokeless tobacco formulations, ingredients, and processing methodologies set forth in US Pat. Nos. 6,668,839 to Williams; 6,834,654 to Williams; 6,953,040 to Atchley et al.; 7,032,601 to Atchley et al.; and 7,694,686 to Atchley et al.; 7,810,507 to Dube et al.; 7,819,124 to Strickland et al.; 7,861,728 to Holton, Jr. et al.; 7,901,512 to Quinter et al.; 8,627,828 to Strickland et al.; 11,246,334 to Atchley, each of which is incorporated herein by reference. In addition, traditional tobacco materials and non- tobacco materials have been combined with other ingredients to form product formats distinct from traditional smokeless products, with example formats including lozenges, pastilles, gels, and the like. See, for example, the types of products described in US Patent App. Pub. Nos. 2008/0196730 to Engstrom et al.; 2008/0305216 to Crawford et al.; 2009/0293889 to Kumar et al.; 2010/0291245 to Gao et al; 2011/0139164 to Mua et al.; 2012/0037175 to Cantrell et al.; 2012/0055494 to Hunt et al.; 2012/0138073 to Cantrell et al.; 2012/0138074 to Cantrell et al.; 2013/0074855 to Holton, Jr.; 2013/0074856 to Holton, Jr.; 2013/0152953 to Mua et al.; 2013/0274296 to Jackson et al.; 2015/0068545 to Moldoveanu et al.; 2015/0101627 to Marshall et al.; and 2015/0230515 to Lampe et al., each of which is incorporated herein by reference. [0003] There is continuing interest in the development of new types of oral products that deliver advantageous sensorial or biological activity. Such products typically contain flavorants and/or active ingredients such as nicotine, caffeine, botanicals, or cannabidiol. The format of such products can vary and include pouched products containing a powdered or granular composition, lozenges, pastilles, liquids, gels, emulsions, meltable compositions, and the like. See, for example, the types of products described in US Patent App. Pub. Nos. 2022/0160675 to Gerardi et al.; 2022/0071984 to Poole et al.; 2021/0378948 to Gerardi et al.; 2021/0330590 to Hutchens et al.; 2021/0186081 to Gerardi et al.; 2021/0177754 to Keller et al; 2021/0177043 to Gerardi et al.; 2021/0177038 to Gerardi et al.; 2021/0169867 to Holton, Jr. et al.; 2021/0169792 to Holton, Jr. et al.; 2021/0169132 to Holton, Jr. et al.; 2021/0169121 to St. Charles, and 2021/0169122 to St. Charles, each of which is incorporated herein by reference. BRIEF SUMMARY [0004] The present disclosure generally provides compositions configured for oral use and products comprising such compositions, along with a method of manufacturing such compositions and products. In some embodiments, the compositions include a filler component, water, and a substituted 3-(1-methylpyrrolidin-2-yl)pyridine, an optionally substituted 3-(azetidin-2-yl)pyridine, or an optionally substituted 3-(azetidin-2- ylmethoxy)pyridine, wherein the substituents or optional substituents are on the pyrrolidine ring, the azetidine ring, the pyridine ring, or a combination thereof. The disclosure includes, without limitations, the following embodiments. [0005] Embodiment 1: A composition configured for oral use, the composition comprising: a filler component; water in an amount from about 1 to about 60% by weight, based on the total weight of the composition; and a substituted 3-(1-methylpyrrolidin-2-yl)pyridine having a structure according to Formula I: , wherein: R¹ and R² are each independently selected from the group consisting of hydrogen, alkyl, alkoxy, cycloalkyl, alkenyl, alkynyl, aryl, alkylaryl, amino, halogen, and cyano, wherein any of said alkyl, alkoxy, cycloalkyl, alkenyl, alkenyl, alkynyl, aryl, alkylaryl, and amino may optionally be substituted; R³ is selected from the group consisting of hydrogen and CH₃; R⁴ is selected from the group consisting of hydrogen and C1-C3 alkyl; and at least one of R³ and R⁴ is not hydrogen. [0006] Embodiment 2: The composition of embodiment 1, wherein: R¹ is optionally substituted C1-C6 alkyl, F, Cl, Br, OCH3, OCH2CH3, or CN; and R² is H. [0007] Embodiment 3: The composition of embodiment 1, wherein: R¹ is H; and R² is optionally substituted C₁-C₆ alkyl, F, Cl, Br, OCH₃, OCH₂CH₃, or CN. [0008] Embodiment 4: The composition of embodiment 1, wherein: R¹ is hydrogen or C1-C3 alkyl; and R² is H. [0009] Embodiment 5: The composition of embodiment 1, wherein R¹ and R² are H; and wherein: R³ is H and R⁴ is CH3; R³ is CH₃ and R⁴ is H; or R³ and R⁴ are both CH3. [0010] Embodiment 6: The composition of embodiment 1, wherein: R¹ and R² are H; R³ is H; and R⁴ is CH3. [0011] Embodiment 7: The composition of embodiment 1, wherein: R¹ and R² are H; R³ is CH3; and R⁴ is H. [0012] Embodiment 8: The composition of embodiment 1, wherein: R¹ is CH₃; R² is H; R³ is H; and R⁴ is CH3. [0013] Embodiment 9: The composition of embodiment 1, wherein: R¹ is CH3, R² is H, R³ is CH3 and R⁴ is H. [0014] Embodiment 10: The composition of any one of embodiments 1-9, wherein the substituted 3-(1-methylpyrrolidin-2-yl)pyridine is racemic. [0015] Embodiment 11: The composition of any one of embodiments 1-9, wherein the substituted 3-(1-methylpyrrolidin-2-yl)pyridine has an (R)-configuration or an (S)- configuration at the 2' position, such as wherein the substituted 3-(1-methylpyrrolidin-2- yl)pyridine has an (S)-configuration at the 2' position. [0016] Embodiment 12: The composition of any one of embodiments 1-11, wherein the composition is substantially free of 3-(1-methylpyrrolidin-2-yl)pyridine; optionally, wherein the composition is completely free of 3-(1-methylpyrrolidin-2-yl)pyridine. [0017] Embodiment 13: The composition of any one of embodiments 1-12, further comprising an organic acid, an alkali metal salt of an organic acid, or a combination thereof; optionally, wherein the organic acid has a logP value in a range from about 0 to about 12, from about 3 to about 12, from about 3 to about 10, or from about 3 to about 8, and optionally, wherein at least a portion of the substituted 3-(1-methylpyrrolidin-2-yl)pyridine is present in the form of an ion pair with the organic acid, the alkali metal salt of an organic acid, or a combination thereof. [0018] Embodiment 14: The composition of any one of embodiments 1-13, wherein at least a portion of the substituted 3-(1-methylpyrrolidin-2-yl)pyridine is present in the form of a salt, a co-crystal, or a salt co-crystal. [0019] Embodiment 15: The composition of any one of embodiments 1-14, wherein at least a portion of the substituted 3-(1-methylpyrrolidin-2-yl)pyridine is bound to a polymeric resin. [0020] Embodiment 16: The composition of any one of embodiments 1-15, wherein the substituted 3-(1-methylpyrrolidin-2-yl)pyridine is present in an amount from about 0.05 to about 5% by weight of the composition, calculated as the free base and based on the total weight of the composition. [0021] Embodiment 17: The composition of any one of embodiments 1-29, wherein the filler component is cellulosic, optionally, wherein the filler component comprises microcrystalline cellulose. [0022] Embodiment 18: The composition of any one of embodiments 1-30, further comprising one or more flavoring agents, one or more salts, one or more sweeteners, one or more binding agents, one or more humectants, one or more gums, or combinations thereof. [0023] Embodiment 19: The composition of any one of embodiments 1-31, in the form of a gel, pastille, gum, chew, melt, tablet, lozenge, film, granular material, or powder. [0024] Embodiment 20: The composition of any one of embodiments 1-32, enclosed in a pouch to form a pouched product, the composition optionally being in a granular form. [0025] Embodiment 21: The composition of embodiment 20, having a moisture content from about 30 to about 60% by weight, based on the weight of the pouched product. [0026] Embodiment 22: A composition configured for oral use, the composition comprising 3-(1,2-dimethylpyrrolidin-2-yl)pyridine in an amount from about 0.05 to about 5% by weight, based on the total weight of the composition; a filler component; and water in an amount from about 1 to about 60% by weight, or from about 30 to about 60% by weight, based on the total weight of the composition. [0027] Embodiment 23: A composition configured for oral use, the composition comprising 5-(1,2-dimethylpyrrolidin-2-yl)-2-methylpyridine in an amount from about 0.05 to about 5% by weight, based on the total weight of the composition; a filler component; and water in an amount from about 1 to about 60% by weight, or from about 30 to about 60% by weight, based on the total weight of the composition. [0028] Embodiment 24: The composition of embodiment 22 or 23, wherein the filler component is cellulosic, optionally, wherein the filler component comprises microcrystalline cellulose. [0029] Embodiment 25: The composition of any one of embodiments 1-24, further comprising a buffer; optionally, wherein the buffer is an alkali metal citrate. [0030] Embodiment 26: The composition of any one of embodiments 1-25, wherein at least about 60% of a total amount of substituted 3-(1-methylpyrrolidin-2-yl)pyridine by weight present in the composition is released when said composition is placed in 500 mL of phosphate buffer at pH 7.4, at 37°C for 50 minutes in a basket-type USP dissolution apparatus at a stirring speed of 50 RPM. [0031] Embodiment 27: The composition of embodiment 26, wherein at least about 20% of a total amount of substituted 3-(1-methylpyrrolidin-2-yl)pyridine by weight present in the composition is released at 10 minutes. [0032] Embodiment 28: A composition configured for oral use, the composition comprising: a filler component; water in an amount from about 1 to about 60% by weight, based on the total weight of the composition; and an azetidinyl pyridine having a structure according to Formula II: , wherein: L is a bond or -OCH₂-*, where the asterisk indicates an attachment point to the azetidine ring; R⁵, R⁶, R⁷, and R⁸ are each independently selected from the group consisting of hydrogen, alkyl, alkoxy, halogen, and cyano; R⁹ is H or CH₃; and R¹⁰ is H or CH3. [0033] Embodiment 29: The composition of embodiment 28, wherein L is a bond. [0034] Embodiment 30: The composition of embodiment 29, wherein R⁵ is CH3, F, Cl, Br, OCH₃, OEt, or CN. [0035] Embodiment 31: The composition of embodiment 29, wherein: R⁵ is H or CH₃; and R⁶, R^7, and R⁸ are each H. [0036] Embodiment 32: The composition of embodiment 31, wherein: R⁹ and R¹⁰ are both H; R⁹ and R¹⁰ are both CH3; R⁹ is H and R¹⁰ is CH3; or R⁹ is CH3 and R¹⁰ is H. [0037] Embodiment 33: The composition of any one of embodiments 28-32, wherein the azetidinyl pyridine has a structure selected from the group consisting of: . the azetidinyl pyridine has a structure selected from the group consisting of: . [0039] Embodiment 35: The composition of embodiment 28, wherein L is -OCH2-*. [0040] Embodiment 36: The composition of embodiment 35, wherein R⁵ is CH₃, F, Cl, Br, OCH3, OEt, or CN. [0041] Embodiment 37: The composition of embodiment 35, wherein: R⁵ is H or CH3; and R⁶, R^7, and R⁸ are each H. [0042] Embodiment 38: The composition of embodiment 37, wherein: R⁹ and R¹⁰ are both H; R⁹ and R¹⁰ are both CH3; R⁹ is H and R¹⁰ is CH₃; or R⁹ is CH3 and R¹⁰ is H. [0043] Embodiment 39: The composition of any one of embodiments 35-38, wherein the azetidinyl pyridine has a structure selected from the group consisting of: . the azetidinyl pyridine has a structure selected from the group consisting of: . [0045] Embodiment 41: The composition of any one of embodiments 28-40, wherein the composition is substantially free of 3-(1-methylpyrrolidin-2-yl)pyridine; optionally, wherein the composition is completely free of 3-(1-methylpyrrolidin-2-yl)pyridine. [0046] Embodiment 42: The composition of any one of embodiments 28-41, further comprising an organic acid, an alkali metal salt of an organic acid, or a combination thereof; optionally, wherein the organic acid has a logP value in a range from about 0 to about 12, from about 3 to about 12, from about 3 to about 10, or from about 3 to about 8, and optionally, wherein at least a portion of the azetidinyl pyridine is present in the form of an ion pair with the organic acid, the alkali metal salt of an organic acid, or a combination thereof. [0047] Embodiment 43: The composition of any one of embodiments 28-42, wherein at least a portion of the azetidinyl pyridine is present in the form of a salt, a co-crystal, or a salt co- crystal. [0048] Embodiment 44: The composition of any one of embodiments 1-14, wherein at least a portion of the azetidinyl pyridine is bound to a polymeric resin. [0049] Embodiment 45: The composition of any one of embodiments 28-43, wherein the azetidinyl pyridine is present in an amount from about 0.05 to about 5% by weight of the composition, calculated as the free base and based on the total weight of the composition. [0050] Embodiment 46: The composition of any one of embodiments 28-44, wherein the filler component is cellulosic, optionally, wherein the filler component comprises microcrystalline cellulose. [0051] Embodiment 47: The composition of any one of embodiments 28-45, further comprising one or more flavoring agents, one or more salts, one or more sweeteners, one or more binding agents, one or more humectants, one or more gums, or combinations thereof. [0052] Embodiment 48: The composition of any one of embodiments 28-46, in the form of a gel, pastille, gum, chew, melt, tablet, lozenge, film, granular material, or powder. [0053] Embodiment 49: The composition of any one of embodiments 28-47, enclosed in a pouch to form a pouched product, the composition optionally being in a granular form. [0054] Embodiment 50: The composition of embodiment 49, having a moisture content from about 30 to about 60% by weight, based on the weight of the pouched product. [0055] Embodiment 51: The composition of embodiment 49 or 50, wherein the filler component is cellulosic, optionally, wherein the filler component comprises microcrystalline cellulose. [0056] Embodiment 52: The composition of any one of embodiments 28-51, further comprising a buffer; optionally, wherein the buffer is an alkali metal citrate. [0057] Embodiment 53: The composition of any one of embodiments 28-52, wherein at least about 60% of a total amount of azetidinyl pyridine by weight present in the composition is released when said composition is placed in 500 mL of phosphate buffer at pH 7.4, at 37°C for 50 minutes in a basket-type USP dissolution apparatus at a stirring speed of 50 RPM. [0058] Embodiment 54: The composition of embodiment 53, wherein at least about 20% of a total amount of azetidinyl pyridine by weight present in the composition is released at 10 minutes. [0059] Embodiment 55: The composition of any of embodiments 1 to 54, wherein the active ingredient is replaced by, or combined with, cytisine, varenicline, acetylcholine, choline, epibatidine, iobeline, analogs thereof, or combinations thereof. [0060] These and other features, aspects, and advantages of the disclosure will be apparent from a reading of the following detailed description together with the accompanying drawings, which are briefly described below. The scope of the disclosure includes any combination of two, three, four, or more of the above-noted embodiments as well as combinations of any two, three, four, or more features or elements set forth in this disclosure, regardless of whether such features or elements are expressly combined in a specific embodiment description herein. This disclosure is intended to be read holistically such that any separable features or elements of the disclosed embodiments should be viewed as intended to be combinable or separately/in isolation unless the context clearly dictates otherwise. BRIEF DESCRIPTION OF THE DRAWINGS [0061] Having thus described aspects of the disclosure in the foregoing general terms, reference will now be made to the accompanying drawings, which are not necessarily drawn to scale. The drawings are examples only and should not be construed as limiting the disclosure. [0062] FIG.1 is a cross-sectional view of a non-limiting pouched product embodiment, taken across the width of the product, showing an outer pouch filled with a mixture of the present disclosure. [0063] FIG.2 illustrates the steps of a method of preparing a composition configured for oral use according to a non-limiting embodiment of the present disclosure. DETAILED DESCRIPTION [0064] The present disclosure will now be described more fully hereinafter with reference to example embodiments thereof. These example embodiments are described so that this disclosure will be thorough and complete, and will fully convey the scope of the disclosure to those skilled in the art. Indeed, the disclosure may be embodied in many different forms and should not be construed as limited to the embodiments set forth herein; rather, these embodiments are provided so that this disclosure will satisfy applicable legal requirements. [0065] As used in this specification and the claims, the singular forms "a," "an," and "the" include plural referents unless the context clearly dictates otherwise. [0066] The term "about" used throughout this specification is used to describe and account for small fluctuations. For example, the term "about" can refer to less than or equal to ±10%, such as less than or equal to ±5%, less than or equal to ±2%, less than or equal to ±1%, less than or equal to ±0.5%, less than or equal to ±0.2%, less than or equal to ±0.1% or less than or equal to ±0.05%. All numeric values herein are modified by the term "about," whether or not explicitly indicated. A value modified by the term "about" of course includes the specific value. For instance, "about 5.0" must include 5.0. [0067] Reference to "dry weight percent" or "dry weight basis" refers to weight on the basis of dry ingredients (i.e., all ingredients except water). Reference to "wet weight" refers to the weight of the composition including water. Unless otherwise indicated, reference to "weight percent" of a composition reflects the total wet weight of the composition (i.e., including water). Composition configured for oral use [0068] The present disclosure provides compositions configured for oral use, products comprising such compositions, and methods of preparing the compositions. In some embodiments, the compositions generally comprise a substituted 3-(1-methylpyrrolidin-2- yl)pyridine, an optionally substituted 3-(azetidine-2-yl)pyridine, or an optionally substituted 3- (azetidin-2-ylmethoxy)pyridine as an active ingredient, a filler component, and water. The composition, products including such compositions, and the components of each thereof are further described herein below. [0069] In some embodiments, the compositions and products of the disclosure can be characterized as completely free or substantially free of nicotine (3-(1-methylpyrrolidin-2- yl)pyridine). By "substantially free" it is meant that no nicotine has been intentionally added, beyond trace amounts that may be present e.g., as an impurity in another component, including as a minor impurity in the substituted 3-(1-methylpyrrolidin-2-yl)pyridine. For example, some embodiments can be characterized as having less than 0.001% by weight of nicotine, or less than 0.0001%, or even 0% by weight of nicotine, calculated as the free base and based on the total weight of the composition. In some embodiments the composition is completely free of (R)-, (S)-, and (R/S)-3-(1-methylpyrrolidin-2-yl)pyridine (e.g., having 0% by weight of nicotine, including racemic nicotine and nicotine enantiomers, calculated as the free base and based on the total weight of the composition). Substituted 3-(1-methylpyrrolidin-2-yl)pyridine [0070] Disclosed herein are compositions configured for oral use comprising a substituted 3- (1-methylpyrrolidin-2-yl)pyridine. As used herein, the term "substituted 3-(1- methylpyrrolidin-2-yl)pyridine" refers to a compound having a 3-(1-pyrrolidin-2-yl)pyridine) scaffold and bearing one or more non-hydrogen substituents on the pyrrolidine ring, and optionally on the pyridine ring. Compositions of the disclosure do not contain nicotine and do not contain any compounds obtained by chemical reactions utilizing nicotine as a starting material. In preferred embodiments, the substituted 3-(1-methylpyrrolidin-2-yl)pyridine present is not synthetically derived from nicotine. [0071] In some embodiments, the substituted 3-(1-methylpyrrolidin-2-yl)pyridine has a structure according to Formula I: , wherein: R¹ and R² are each the group consisting of hydrogen, alkyl, alkoxy, cycloalkyl, alkenyl, alkynyl, aryl, alkylaryl, amino, halogen, and cyano, wherein any of said alkyl, alkoxy, cycloalkyl, alkenyl, alkenyl, alkynyl, aryl, alkylaryl, and amino may optionally be substituted; R³ is selected from the group consisting of hydrogen and CH₃; R⁴ is selected from the group consisting of hydrogen and C1-C3 alkyl; and at least one of R³ and R⁴ is not hydrogen. [0072] Certain substituted 3-(1-methylpyrrolidin-2-yl)pyridines with various R¹, R², R³, and R⁴ substituents have been reported previously. See for example, U.S. Patent Nos. 4,321,387, 4,155,909; 5,015,741, 5,138,062, and 5,703,100, each of which is incorporated by reference herein and describe example substituted 3-(1-methylpyrrolidin-2-yl)pyridines, their synthesis, and pharmacological properties. Certain substituted 3-(1-methylpyrrolidin-2-yl)pyridines and their pharmacological profiles have also been disclosed in Wang et al., Drug Development Research 1998, Volume 45, Issue 1, Pages 10-16; Dukat et al. European Journal of Medicinal Chemistry 1999, 34(1): 31–40; Lin et al., J. Med. Chem. (1994), 37, 3542-3553. [0073] In some embodiments, R¹ and R² are H; R³ is CH₃; and R⁴ is H. In such embodiments, the compound of Formula I may be referred to as 3-(1,2-dimethylpyrrolidin-2-yl)pyridine, or 2'-methyl-5-(1-methylpyrrolidin-2-yl)pyridine, and has a structure: . The compound 3-(1,2-dimethylpyrroli idine is known in the literature, and has a Chemical Abstracts Registry Number of 220650-38-4. The synthesis of this compound has been reported in Rouchaud et al., J Het Chem 2012, 49(1), 161-166; Wang et al., Drug Dev Res 1998, 45(1), 10-16; Secor et al., Tetrahedron Lett. (1981), 22(33), 3151-3154; US Patent Application Publication No. 2013/0157995; PCT Application Publication No. WO2012/031220; and US Patent Publication No. 9,440,948, each of which are incorporated by reference herein with respect to the synthesis of 3-(1,2-dimethylpyrrolidin-2-yl)pyridine. [0074] In some embodiments, R¹ and R² are H; R³ is H; and R⁴ is CH3. In such embodiments, the compound of Formula I may be referred to as 3-(1,4-dimethylpyrrolidin-2-yl)pyridine, or 4'-methyl-5-(1-methylpyrrolidin-2-yl)pyridine, and has a structure: . The compound 3-(1,4- is known in the literature, has a Chemical Abstracts Registry Number of 74805-00-8, and is commercially available from, for example, Enamine Stock Building Blocks and Aurora Building Blocks. The synthesis of this compound has been reported in US Patent Publication No. 9,440,948; and EP Patent No. 559495, each of which are incorporated by reference herein with respect to the synthesis of 3- (1,4-dimethylpyrrolidin-2-yl)pyridine. [0075] In some embodiments, R¹ is CH₃; R² is H; R³ is CH₃; and R⁴ is H. In such embodiments, the compound of Formula I may be referred to as 5-(1,2-dimethylpyrrolidin-2-yl)-2- methylpyridine, and has a structure: . [0076] The compound 5-(1,2- yl)-2-methylpyridine may be readily synthesized according to known reactions. For example, commercially available 2-methyl-5- (2-methylpyrrolidin-2-yl)pyridine (Chemical Abstracts Registry Number of 1528955-30-7; Aurora Building Blocks, Adlab Chemicals Building Blocks) can be N-methylated with formaldehyde and formic acid, or alternatively with formaldehyde and a reducing agent such as sodium cyanoborohydride to afford 5-(1,2-dimethylpyrrolidin-2-yl)-2-methylpyridine. Alternatively, 5-(1,2-dimethylpyrrolidin-2-yl)-2-methylpyridine may be synthesized by lithiation of 2-methyl-5-bromopyridine, reaction of the lithiated pyridine with N- methylpyrrolidone, and addition of methyl lithium to the perchlorate salt of the resulting imine. This reaction sequence is shown below in Scheme 1. Scheme 1 CH₃, provided that at least one of R³ and R⁴ is CH3. Accordingly, in some embodiments, the substituted 3-(1-methylpyrrolidin-2-yl)pyridine has a structure selected from the group consisting of: . [0078] In some or CH₃, and R⁴ is H or CH3, provided that at least one of R³ and R⁴ is CH3. Accordingly, in some embodiments, the substituted 3-(1-methylpyrrolidin-2-yl)pyridine has a structure selected from the group consisting of:

. [00 be present as a single enantiomer or as a mixture of enantiomers. In some embodiments, the substituted 3-(1-methylpyrrolidin-2-yl)pyridine is present in racemic form, meaning there are equal amounts of (R)- and (S)-enantiomers present. In some embodiments, the composition comprises unequal amounts of (R)- and (S)-enantiomer (i.e., is enriched in either the (R)- or (S)-enantiomer). In some embodiments, the composition predominantly comprises the substituted 3-(1-methylpyrrolidin-2-yl)pyridine in the (R)-configuration, for example, about 90% or more of the total quantity of substituted 3-(1-methylpyrrolidin-2-yl)pyridine present is in the (R)-configuration. In some embodiments, the composition predominantly comprises the substituted 3-(1-methylpyrrolidin-2-yl)pyridine in the (S)-configuration, for example, about 90% or more of the total quantity of substituted 3-(1-methylpyrrolidin-2-yl)pyridine present is in the (S)-configuration. In some embodiments, the composition comprises 95% or more of the (S)-configuration of the substituted 3-(1-methylpyrrolidin-2-yl)pyridine, based on the total amount of substituted 3-(1-methylpyrrolidin-2-yl)pyridine present. [0080] In some embodiments, the substituted 3-(1-methylpyrrolidin-2-yl)pyridine is non- racemic, and has one of the following structures:

. [0 s non- racemic, and has a structure selected from the group consisting of: . [0082] Such may be obtained through classical resolution techniques using salt formation with chiral acids to form diastereomeric salts separable by crystallization. Suitable chiral acids include, but are not limited to, (R)- or (S)-dibenzoyl tartaric acid, di-p-toluoyl tartaric acid, or di-p-anisolyl tartaric acid; (R)- or (S)-mandelic acid, and (R)- or (S)-10-camphorsulfonic acid. Alternatively, one of skill in the art will recognize opportunities for chiral syntheses using either commercially available starting materials with established chiral centers or through the use of chiral auxiliary chemistries. For example, preparation of the 2S,4R enantiomer of 3-(1,4-dimethylpyrrolidin- 2-yl)pyridine has been reported in, for example, US Patent Publication No. 4,332,945, incorporated herein by reference with respect to syntheses of chiral nicotine analogs. [0083] The pharmacology of various substituted 3-(1-methylpyrrolidin-2-yl)pyridines such as those described herein has been reported in, for example, Lin et al., J. Med. Chem., 1994, 37, 3542-3553; Dukat et al. European Journal of Medicinal Chemistry, 31(11), 1996, 875-888; US9440948; Wang et al., Drug Dev Res 1998, 45(1), 10-16 (each of which is incorporated herein by reference), among many others. Generally, small substituents such as methyl groups are well tolerated at the 2'- or 4'-positions of the nicotine pyrrolidine ring, and small substituents such as alkyl, halogen, alkoxy, and the like are well tolerated at the 5- or 6-position of the nicotine pyridine ring. For example, 3-(1-methylpyrrolidin-2-yl)pyridines bearing a methyl substituent at the 2' or 4' position are equipotent or even more potent than nicotine with respect to binding affinity to the nicotinic acetylcholine receptor, and are expected to preserve the pharmacological effects of nicotine in vivo. See, for example US Patent Publication No. 5,278,176, Lin et al., J. Med. Chem., 1994, 37, 3542-3553, and is believed that certain alkyl substitutions for hydrogen on the pyridine and/or pyrrolidine rings of the substituted 3-(1- methylpyrrolidin-2-yl)pyridine compound preserve the general pharmacological Wang et al., Drug Dev Res 1998, 45(1), 10-16. Without wishing to be bound by any particular theory, these compounds are believed to provide the general pharmacological profile and physiological effects of nicotine while offering the potential for one or more of greater potency, reduced product consumption, more rapid and/or complete absorption, and the like. Particularly, it is believed that in some embodiments, substituted 3-(1-methylpyrrolidin-2-yl)pyridines of the disclosure are readily absorbed through oral mucosa by virtue of their lipophilicity. [0084] Lipophilicity is conveniently measured in terms of logP, the partition coefficient of a molecule between a lipophilic phase and an aqueous phase, usually octanol and water, respectively. Accordingly, in some embodiments, the substituted 3-(1-methylpyrrolidin-2- yl)pyridine of Formula I has a calculated or experimental logP of about 1 or greater, where logP is the log₁₀ of the partitioning coefficient of the substituted 3-(1-methylpyrrolidin-2- yl)pyridine between octanol and water. LogP values may be measured experimentally according to protocols well known to one of skill in the art. Alternatively, logP values may be calculated using commercially available software. In some embodiments, the substituted 3-(1- methylpyrrolidin-2-yl)pyridine of Formula I has a calculated logP from 1 to about 2, such as 1.1, 1.2, 1.3, 1.4, 1.5, 1.6, 1.7, 1.8, or 1.9. In some embodiments, the substituted 3-(1- methylpyrrolidin-2-yl)pyridine of Formula I has a calculated logP from about 1.2 to about 1.7. [0085] The quantity of substituted 3-(1-methylpyrrolidin-2-yl)pyridine present in the composition may vary. Typically, the substituted 3-(1-methylpyrrolidin-2-yl)pyridine, calculated as the free base) is present in a concentration of at least about 0.001% by weight of the composition, such as in a range from about 0.01% to about 10%. In some embodiments, the substituted 3-(1-methylpyrrolidin-2-yl)pyridine is present in a concentration from about 0.1% w/w to about 10% by weight, such as, e.g., from about from about 0.1% w/w, about 0.2%, about 0.3%, about 0.4%, about 0.5% about 0.6%, about 0.7%, about 0.8%, or about 0.9%, to about 1%, about 2%, about 3%, about 4%, about 5%, about 6%, about 7%, about 8%, about 9%, or about 10% by weight, calculated as the free base and based on the total weight of the composition. In some embodiments, the substituted 3-(1-methylpyrrolidin-2-yl)pyridine is present in a concentration from about 0.1% w/w to about 3% by weight, such as, e.g., from about 0.1% w/w to about 2.5%, from about 0.1% to about 2.0%, from about 0.1% to about 1.5%, or from about 0.1% to about 1% by weight, calculated as the free base and based on the total weight of the composition. In some embodiments, the substituted 3-(1-methylpyrrolidin- 2-yl)pyridine is present in a concentration from about 0.05% w/w to about 5% by weight. One of skill in the art will recognize that the amount of any particular substituted 3-(1- methylpyrrolidin-2-yl)pyridine present in the composition may vary based on the potency of the compound, the composition matrix, and the desired physiological effect for the composition. [0086] In some embodiments, the amount of substituted 3-(1-methylpyrrolidin-2-yl)pyridine in the composition is determined by potency relative to nicotine. For example, in some embodiments, the amount of substituted 3-(1-methylpyrrolidin-2-yl)pyridine is determined based on the ratio of the ^₄^₂ nicotinic receptor binding affinity (K_i) for nicotine to the ^₄^₂ K_i for the specific substituted 3-(1-methylpyrrolidin-2-yl)pyridine. This ratio is referred to herein as the "affinity factor." Such affinity factors indicate the amount of substituted 3-(1- methylpyrrolidin-2-yl)pyridine estimated to provide physiological activity in a user which is roughly equivalent to that of a given weight of nicotine. [0087] In some embodiments, a substituted 3-(1-methylpyrrolidin-2-yl)pyridine of the disclosure has an affinity factor from about 0.5 to about 2 (i.e., the K_i of the substituted 3-(1- methylpyrrolidin-2-yl)pyridine is from about twice to about half that of nicotine). [0088] In some embodiments, the amount of substituted 3-(1-methylpyrrolidin-2-yl)pyridine in the composition is 1 nicotine equivalent. Accordingly, in some embodiments, 1 nicotine equivalent of substituted 3-(1-methylpyrrolidin-2-yl)pyridine is an amount by weight from about 2 to about 0.5 times that of nicotine. For example, a product comprising 2 mg of nicotine, when the nicotine is replaced by a substituted 3-(1-methylpyrrolidin-2-yl)pyridine of the disclosure, may include from about 1 mg to about 4 mg of the substituted 3-(1- methylpyrrolidin-2-yl)pyridine. Similarly, a product comprising 20 mg of nicotine, when the nicotine is replaced by a substituted 3-(1-methylpyrrolidin-2-yl)pyridine, may contain from about 10 mg to about 40 mg of the substituted 3-(1-methylpyrrolidin-2-yl)pyridine. [0089] In some embodiments, the substituted 3-(1-methylpyrrolidin-2-yl)pyridine has the structure: , having an affinity factor of about embodiments, the amount of substituted 3-(1-methylpyrrolidin-2-yl)pyridine present may be about 74% of the amount of nicotine required to achieve the same effect. [0090] In some embodiments, the substituted 3-(1-methylpyrrolidin-2-yl)pyridine has the structure: , having an affinity factor of about in some embodiments, the amount of substituted 3-(1-methylpyrrolidin-2-yl)pyridine present may be about 110% of the amount of nicotine required to achieve the same effect. [0091] The substituted 3-(1-methylpyrrolidin-2-yl)pyridine may be present in the composition as the free base, as a salt with a suitable acid, or in the form of an ion pair with an organic acid. Each of these forms is described further herein below. 3-(azetidin-2-yl)pyridines and 3-(azetidin-2-ylmethoxy)pyridines [0092] Disclosed herein are compositions configured for oral use comprising an optionally substituted 3-(azetidin-2-yl)pyridine or an optionally substituted 3-(azetidin-2- ylmethoxy)pyridine. As used herein, the term "substituted 3-(azetidin-2-yl)pyridine" refers to a compound having a 3-(azetidin-2-yl)pyridine scaffold and bearing one or more non-hydrogen substituents on the azetidine ring, and optionally on the pyridine ring. As used herein, the term "substituted 3-(azetidin-2-ylmethoxy)pyridine" refers to a compound having a 3-(azetidin-2- ylmethoxy)pyridine scaffold and bearing one or more non-hydrogen substituents on the azetidine ring, and optionally on the pyridine ring. [0093] As described above, compositions of the disclosure do not contain nicotine and do not contain any compounds obtained by chemical reactions utilizing nicotine as a starting material. [0094] In some embodiments, the 3-(azetidin-2-yl)pyridine or 3-(azetidin-2- ylmethoxy)pyridine has a structure according to Formula II: , wherein: L is a bond or -OCH₂-*, where the asterisk indicates an attachment point to the azetidine ring; R⁵, R⁶, R⁷, and R⁸ are each independently selected from the group consisting of hydrogen, alkyl, alkoxy, halogen, and cyano; R⁹ is H or CH₃; and R¹⁰ is H or CH3. [0095] In some embodiments, L is a bond. [0096] In some embodiments, R⁵ is CH₃, F, Cl, Br, OCH₃, OEt, or CN. [0097] In some embodiments, R⁵ is H or CH3; and R⁶, R^7, and R⁸ are each H. [0098] In some embodiments: R⁹ and R¹⁰ are both H; R⁹ and R¹⁰ are both CH₃; R⁹ is H and R¹⁰ is CH3; or R⁹ is CH3 and R¹⁰ is H. [0099] In some embodiments, the 3-(azetidin-2-yl) pyridine is 3-(azetidin-2-yl)pyridine, and has a structure . [0100] The compound 3-(azetidin-2- known in the literature. The synthesis of this compound has been reported in JOC 1979, 44(18), 3136; Med Chem Res (1993) 2:552- 5633; in International Patent Application Publication No. WO2012/031220, and in US Patent Nos.4,163,855 and 4,163,856, all of which are incorporated herein in their entireties. [0101] In some embodiments, the 3-(azetidin-2-yl) pyridine is 3-(1-methylazetidin-2- yl)pyridine, having the structure . The compound 3-(1-methylazetidin-2- known in the literature. The synthesis of this compound has been reported in International Patent Application Publication No. WO2012/031220, previously incorporated by reference herein. [0102] In some embodiments, the 3-(azetidin-2-yl) pyridine has a structure selected from the group consisting of: . [0103] Such compounds prepared according to adaptations of methods utilized for preparation of related 3-(azetidin-2-yl) pyridines and 3-(1- methylpyrrolidin-2-yl)pyridines described herein above. See, e.g., U.S. Patent No 4,163,855, previously incorporated by reference herein. The compound 5-(2-azetidinyl)-2-methylpyridine is known in the literature and has a Chemical Abstracts Registry (CAS) Number of 1270467- 65-6, and the R- and S-enantiomers have CAS numbers 1213081-15-2 and 1212969-96-4, respectively. [0104] In some embodiments, the composition comprises a 3-(azetidin-2-ylmethoxy)pyridine (i.e., L is -OCH₂-*). [0105] In some embodiments, R⁵ is CH3, F, Cl, Br, OCH3, OEt, or CN. [0106] In some embodiments, R⁵ is H or CH3; and R⁶, R^7, and R⁸ are each H. [0107] In some embodiments: R⁹ and R¹⁰ are both H; R⁹ and R¹⁰ are both CH₃; R⁹ is H and R¹⁰ is CH3; or R⁹ is CH₃ and R¹⁰ is H. [0108] In some embodiments, the 3-(azetidin-2-ylmethoxy)pyridine has a structure selected from the group consisting of: . These of these compounds has been reported in International Patent Application Publication No. WO2012/031220, previously incorporated by reference herein. [0109] In some embodiments, the 3-(azetidin-2-ylmethoxy)pyridine has a structure selected from the group consisting of: . [0110] Such according to adaptations of methods utilized for preparation of related the 3-(azetidin-2-ylmethoxy)pyridine, and/or the 3-(azetidin-2-yl)pyridines and substituted 3-(1-methylpyrrolidin-2-yl)pyridines described herein above. [0111] An optionally substituted 3-(azetidin-2-yl)pyridine or optionally substituted 3- (azetidin-2-ylmethoxy)pyridine as described herein may be present as a single enantiomer or as a mixture of enantiomers. In some embodiments, the optionally substituted 3-(azetidin-2- yl)pyridine or optionally substituted 3-(azetidin-2-ylmethoxy)pyridine is present in racemic form, meaning there are equal amounts of (R)- and (S)-enantiomers present. In some embodiments, the composition comprises unequal amounts of (R)- and (S)-enantiomer (i.e., is enriched in either the (R)- or (S)-enantiomer). In some embodiments, the composition predominantly comprises the optionally substituted 3-(azetidin-2-yl)pyridine or optionally substituted 3-(azetidin-2-ylmethoxy)pyridine in the (R)-configuration, for example, about 90% or more of the total quantity of optionally substituted 3-(azetidin-2-yl)pyridine or optionally substituted 3-(azetidin-2-ylmethoxy)pyridine present is in the (R)-configuration. In some embodiments, the composition predominantly comprises the optionally substituted 3-(azetidin- 2-yl)pyridine or optionally substituted 3-(azetidin-2-ylmethoxy)pyridine in the (S)- configuration, for example, about 90% or more of the total quantity of optionally substituted 3-(azetidin-2-yl)pyridine or optionally substituted 3-(azetidin-2-ylmethoxy)pyridine present is in the (S)-configuration. In some embodiments, the composition comprises 95% or more of the (S)-configuration of the optionally substituted 3-(azetidin-2-yl)pyridine or optionally substituted 3-(azetidin-2-ylmethoxy)pyridine, based on the total amount of optionally substituted 3-(azetidin-2-yl)pyridine or optionally substituted 3-(azetidin-2- ylmethoxy)pyridine present. [0112] In some embodiments, the optionally substituted 3-(azetidin-2-yl)pyridine is non- racemic, and has one of the following structures: . [0113] In some embodiments, the optionally substituted 3-(azetidin-2-ylmethoxy)pyridine is non-racemic, and has one of the following structures: . obtained through classical resolution techniques using salt formation with chiral acids to form diastereomeric salts separable by crystallization. Suitable chiral acids include, but are not limited to, (R)- or (S)-dibenzoyl tartaric acid, di-p-toluoyl tartaric acid, or di-p-anisolyl tartaric acid; (R)- or (S)-mandelic acid, and (R)- or (S)-10-camphorsulfonic acid. Alternatively, one of skill in the art will recognize opportunities for chiral syntheses using either commercially available starting materials with established chiral centers or through the use of chiral auxiliary chemistries. For example, preparation of the (2S,4R)-enantiomer of 3-(1,4-dimethylpyrrolidin- 2-yl)pyridine has been reported in, for example, US Patent Publication No. 4,332,945, incorporated herein by reference with respect to syntheses of chiral nicotine analogs. [0115] The pharmacology of certain 3-(azetidin-2-yl)pyridines and 3-(azetidin-2- ylmethoxy)pyridines has been previously disclosed, for example, in the references cited herein with respect to synthesis of such compounds. Generally, these compounds exhibit high affinity for one or more subtypes of nicotinic acetylcholine receptors, particularly the ^4^2 subtype. The overall pharmacological profiles have been shown to be or are expected to be comparable to that of nicotine. [0116] The quantity of optionally substituted 3-(azetidin-2-yl)pyridine or 3-(azetidin-2- ylmethoxy)pyridine present in the composition may vary. Typically, the optionally substituted 3-(azetidin-2-yl)pyridine or 3-(azetidin-2-ylmethoxy)pyridine, calculated as the free base, is present in a concentration of at least about 0.001% by weight of the composition, such as in a range from about 0.001% to about 1%. In some embodiments, the optionally substituted 3- (azetidin-2-yl)pyridine or 3-(azetidin-2-ylmethoxy)pyridine is present in a concentration from about 0.001% w/w to about 0.5% by weight, such as, e.g., from about 0.002% w/w to about 0.3% w/w by weight, calculated as the free base and based on the total weight of the composition. In some embodiments, the optionally substituted 3-(azetidin-2-yl)pyridine or 3- (azetidin-2-ylmethoxy)pyridine is present in a concentration from about 0.001% w/w, about 0.002%, about 0.003%, about 0.004%, about 0.005%, about 0.006%, about 0.007%, about 0.008%, about 0.009%, or about 0.01%, to about 0.2%, about 0.3%, about 0.4%, about 0.5%, about 0.6%, about 0.7%, about 0.8%, about 0.9%, or about 1% by weight, calculated as the free base and based on the total weight of the composition. One of skill in the art will recognize that the amount of any particular optionally substituted 3-(azetidin-2-yl)pyridine or 3-(azetidin- 2-ylmethoxy)pyridine present in the composition may vary based on the potency of the compound, the composition matrix, and the desired physiological effect for the composition. [0117] In some embodiments, the amount of optionally substituted 3-(azetidin-2-yl)pyridine or 3-(azetidin-2-ylmethoxy)pyridine in the composition is determined by affinity relative to nicotine. For example, in some embodiments, the amount of optionally substituted 3-(azetidin- 2-yl)pyridine or 3-(azetidin-2-ylmethoxy)pyridine is based on the affinity factor as described above for substituted 3-(1-methylpyrrolidin-2-yl)pyridines. In some embodiments, an optionally substituted 3-(azetidin-2-yl)pyridine or 3-(azetidin-2-ylmethoxy)pyridine of the disclosure has an affinity factor from about 0.1 to about 30, such as from about 2 to about 30. [0118] In some embodiments, the amount of optionally substituted 3-(azetidin-2-yl)pyridine or 3-(azetidin-2-ylmethoxy)pyridine in the composition is 1 nicotine equivalent. Accordingly, in some embodiments, 1 nicotine equivalent of optionally substituted 3-(azetidin-2-yl)pyridine or 3-(azetidin-2-ylmethoxy)pyridine is an amount by weight from about 10 to about 0.03 times that of nicotine. In some embodiments, 1 nicotine equivalent of optionally substituted 3- (azetidin-2-yl)pyridine or 3-(azetidin-2-ylmethoxy)pyridine is an amount by weight from about 0.5 to about 0.03 times that of nicotine. [0119] For example, a product comprising 2 mg of nicotine, when the nicotine is replaced by an optionally substituted 3-(azetidin-2-yl)pyridine or 3-(azetidin-2-ylmethoxy)pyridine of the disclosure, may include from about 0.06 mg to about 1 mg of the optionally substituted 3- (azetidin-2-yl)pyridine or 3-(azetidin-2-ylmethoxy)pyridine. Similarly, a product comprising 20 mg of nicotine, when the nicotine is replaced by an optionally substituted 3-(azetidin-2- yl)pyridine or 3-(azetidin-2-ylmethoxy)pyridine, may contain from about 0.6 mg to about 100 mg of the optionally substituted 3-(azetidin-2-yl)pyridine or 3-(azetidin-2-ylmethoxy)pyridine. [0120] In some embodiments, the optionally substituted 3-(azetidin-2-yl)pyridine has the structure: , having an affinity factor of about in some embodiments, the amount of optionally substituted 3-(azetidin-2-yl)pyridine present may be about 3% of the amount of nicotine required to achieve the same effect. [0121] In some embodiments, the optionally substituted 3-(azetidin-2-ylmethoxy)pyridine has the structure: , having an affinity factor of about 3, meaning that in some embodiments, the amount of 3- (azetidin-2-ylmethoxy)pyridine present may be about 33% of the amount of nicotine required to achieve the same effect. [0122] The optionally substituted 3-(azetidin-2-yl)pyridine or 3-(azetidin-2- ylmethoxy)pyridine may be present in the composition as the free base, as a salt with a suitable acid, or in the form of an ion pair with an organic acid. Each of these forms is described further herein below. Other Active Ingredients [0123] In some embodiments, the substituted 3-(1-methylpyrrolidin-2-yl)pyridine, optionally substituted 3-(azetidin-2-yl)pyridine, or optionally 3-(azetidin-2-ylmethoxy)pyridine of the present disclosure is replaced with, or combined with, other active ingredients that provide the same general pharmacological profile and/or physiological effects of nicotine. Certain of these active ingredients may be equipotent or even more potent than nicotine with respect to binding affinity to the nicotinic acetylcholine receptor, and are expected to preserve the pharmacological effects of nicotine in vivo. Without wishing to be bound by any particular theory, in some embodiments, these compounds are believed to provide the general pharmacological profile and physiological effects of nicotine while offering the potential for one or more of greater potency, reduced product consumption, more rapid and/or complete absorption, and the like. [0124] Example active ingredients of this type include, without limitation, cytisine, varenicline, acetylcholine, choline, epibatidine, lobeline, analogs thereof, or combinations thereof. Suitable analogs include any of the above-noted compounds having one or more substituents on any of the carbon atoms thereof, with example substituents including alkyl (e.g., C₁-C₃ alkyl), alkoxy, cycloalkyl, alkenyl, alkynyl, aryl, alkylaryl, amino, halogen, and cyano. [0125] In some embodiments, the other active ingredient is cytisine or an analog thereof. Cytisine is a naturally occurring alkaloid present in certain plant genera, such as Laburnum and Cytisus of the family Fabaceae. Cytisine (CAS Registry No.485-35-8) has the structure: . Cytisine is commercially available in post-Soviet states for more than 40 years as an aid to smoking cessation under the brand name Tabex (Sopharma AD). Cytisine is a partial agonist of the ^4^2 nicotinic acetylcholine receptor. [0126] In some embodiments, the other active ingredient is varenicline or an analog thereof. Varenicline is commercially available as Chantix^® (Pfizer) and is a medication used as an aid for smoking cessation. Varenicline (CAS Registry No.249296-44-4) has the structure: . Like cytisine, varenicline is a acetylcholine receptor. [0127] The quantity of the other active ingredient present in the composition may vary. Typically, the other active ingredient, calculated as the free base, is present in a concentration of at least about 0.001% by weight of the composition, such as in a range from about 0.01% to about 10%. In some embodiments, the other active ingredient is present in a concentration from about 0.05% w/w to about 5% by weight, such as, e.g., from about from about 0.05% w/w. about 0.1% w/w, about 0.2%, about 0.3%, about 0.4%, about 0.5% about 0.6%, about 0.7%, about 0.8%, or about 0.9%, to about 1%, about 2%, about 3%, about 4%, or about 5% by weight, calculated as the free base and based on the total weight of the composition. In some embodiments, the other active ingredient is present in a concentration from about 0.05% w/w to about 4% by weight, such as, e.g., from about 0.05% w/w to about 3.5%, from about 0.07% to about 2.5%, from about 0.1% to about 2.0%, from about 0.1% to about 1.5%, or from about 0.1% to about 1% by weight, calculated as the free base and based on the total weight of the composition. One of skill in the art will recognize that the amount of any particular other active ingredient present in the composition may vary based on the potency of the compound, the composition matrix, and the desired physiological effect for the composition. [0128] The other active ingredient may be present in the composition as the free base, as a salt with a suitable acid, or in the form of an ion pair with an organic acid. Each of these forms is described further herein below. Free base [0129] In some embodiments, the substituted 3-(1-methylpyrrolidin-2-yl)pyridine, optionally substituted 3-(azetidin-2-yl)pyridine, optionally 3-(azetidin-2-ylmethoxy)pyridine, or other active ingredient exhibits sufficient stability, aqueous solubility, and oral bioavailability such that the free base is suitable for inclusion in the composition. Accordingly, in some embodiments, the substituted 3-(1-methylpyrrolidin-2-yl)pyridine, optionally substituted 3- (azetidin-2-yl)pyridine, optionally 3-(azetidin-2-ylmethoxy)pyridine or other active ingredient is present substantially or completely as the free base. In such embodiments, one of skill in the art will recognize that the composition is substantially free of acidic components. By "substantially free" it is meant that no acidic component (e.g., inorganic acid, organic acid, or acids capable of salt, ion pair, or co-crystal formation) has been intentionally added, beyond trace amounts that may be present e.g., as an impurity in another component. For example, some embodiments can be characterized as having less than 0.001% by weight of any acid component, or less than 0.0001%, or even 0% by weight of any acid component, based on the total weight of the composition. In some embodiments, the composition is completely free of any acid component (i.e., characterized as 0% or as having an amount below the limit of detection). In some embodiments, the substituted 3-(1-methylpyrrolidin-2-yl)pyridine, optionally substituted 3-(azetidin-2-yl)pyridine, optionally 3-(azetidin-2-ylmethoxy)pyridine, or other active ingredient is present in the free base form and is adsorbed in a carrier such as a microcrystalline cellulose material to form an adsorption complex. Salt [0130] In some embodiments, at least a portion of the substituted 3-(1-methylpyrrolidin-2- yl)pyridine, optionally substituted 3-(azetidin-2-yl)pyridine, optionally 3-(azetidin-2- ylmethoxy)pyridine, or other active ingredient can be employed in the form of a salt. A "salt" of such compounds is a form characterized by interaction between the said compound in ionic form and a coformer in ionic form (e.g., an acid) via the transfer of one or more protons from the coformer donor to the compound acceptor. The structure of substituted 3-(1- methylpyrrolidin-2-yl)pyridines, optionally substituted 3-(azetidin-2-yl)pyridines, and optionally 3-(azetidin-2-ylmethoxy)pyridines as disclosed herein are such that they comprise two nitrogen atoms that are capable of accepting protons from a coformer and, accordingly, can be present in non-protonated, mono-protonated, and/or di-protonated form in a given sample. Salts of substituted 3-(1-methylpyrrolidin-2-yl)pyridine, optionally substituted 3- (azetidin-2-yl)pyridine, optionally 3-(azetidin-2-ylmethoxy)pyridine, or other active ingredient can be provided using the types of ingredients and techniques set forth for nicotine in US Pat. No.2,033,909 to Cox et al. and Perfetti, Beitrage Tabakforschung Int., 12: 43-54 (1983), which are incorporated herein by reference. Suitable salts are generally water soluble. Suitable acids for formation of salts (mono- and di-) include, but are not limited to, acetic acid, adipic acid, ascorbic acid, capric acid, citric acid, D-glucuronic acid, D-gluconic acid, lactic acid, galactaric acid, hippuric acid, hydrochloric acid, L-aspartic acid, L-glutamic acid, L-glutaric acid, glycerophosphoric acid, glycolic acid, lauric acid, DL-malic acid, L-malic acid; tartaric acid, palmitic acid, phosphoric acid, sebacic acid, stearic acid, succinic acid, sulfuric acid, thiocyanic acid, (+)-camphoric acid, 1,5-naphthalenedisulfonic acid, 1-hydroxy-2-naphthoic, 2,5- dihydroxybenzoic acid, benzenesulfonic acid, benzoic acid, caprylic acid, cyclamic acid, ethanesulfonic acid, fumaric acid, D-glucoheptonic acid, 4-hydroxybenzoic acid, isobutyric acid, ketoglutaric acid, 2-ketobutyric acid, lactobionic acid, maleic acid, malonic acid, methanesulfonic acid, naphthalene-2-sulfonic acid, nicotinic acid, oleic acid, orotic acid, oxalic acid, pamoic acid, pivalic acid, propionic acid, L-pyroglutamic acid, p-toluenesulfonic acid, (1S)-camphor-10-sulfonic acid, 4-acetamidobenzoic acid, 4-aminosalicylic acid, N-acetyl-4- aminosalicylic acid, caproic acid, dichloroacetic acid, hydrobromic acid, DL-mandelic acid, L- mandelic acid, nitric acid, formic acid, salicylic acid, cinnamic acid, undecylenic acid, isothionic acid, lauric acid, 2-hydroxybenzoic acid, trans-2-hexenoic acid, trimesic acid, 5- nitroisophthalic acid, and zinc chloride monohydrate (forming a hydrated zinc chloride complex salt). [0131] In some embodiments, a hydrophilic acid is chosen so as to increase water solubility and/or decrease lipophilicity of the salt. Lipophilicity of a salt of a compound as disclosed herein can also be expressed as logD, which is the logarithm of the distribution coefficient, a measure of the pH-dependent differential solubility between an octanol phase and an aqueous phase of all species (ionized and un-ionized) in an octanol/aqueous system, represented by the formula: . LogD is a LogD values can be calculated using commercial software or may be determined experimentally in a similar manner to logP but instead of using water, the aqueous phase is adjusted to a specific pH using a buffer. LogD is pH dependent and therefore requires that the pH at which the logD was measured be specified. [0132] When the substituted 3-(1-methylpyrrolidin-2-yl)pyridine, optionally substituted 3- (azetidin-2-yl)pyridine, optionally 3-(azetidin-2-ylmethoxy)pyridine, or other active ingredient is present in the form of a salt, it is generally preferred that the salt have a relatively low logD, indicative of good water solubility. Without wishing to be bound by theory, it is believed that highly water-soluble salt forms may exhibit a high rate of dissolution, which may be favorable in certain embodiments. Accordingly, in some embodiments, the substituted 3-(1- methylpyrrolidin-2-yl)pyridine, optionally substituted 3-(azetidin-2-yl)pyridine, optionally 3- (azetidin-2-ylmethoxy)pyridine, or other active ingredient salt has a logD from about -1.0 to about 3 at a pH in a range from about 3 to about 11, such as from about -0.5 to about 2, about -0.3 to about 1, or about -0.1 to about 0. [0133] In some embodiments, the selection of acid used to make a salt is performed on the basis of sensory effects of the salt, such as taste. Surprisingly, according to the present disclosure, it has been found that salts of certain organic acids, such as galactaric acid, offer a better taste sensation relative to salts of acids such as tartaric or phthalic acids. [0134] In some embodiments, the substituted 3-(1-methylpyrrolidin-2-yl)pyridine, optionally substituted 3-(azetidin-2-yl)pyridine, optionally 3-(azetidin-2-ylmethoxy)pyridine, or other active ingredient is present in the form of a salt with tartaric acid, succinic acid, orotic acid, fumaric acid, pyroglutamic acid, or galactaric acid. In some embodiments, the substituted 3- (1-methylpyrrolidin-2-yl)pyridine, optionally substituted 3-(azetidin-2-yl)pyridine, or optionally 3-(azetidin-2-ylmethoxy)pyridine is present in the form of a salt with succinic acid or galactaric acid. [0135] The stoichiometry of the salts as described herein can vary. For example, in some embodiments, the stoichiometry can range from about 5:1 to about 1:5 compound:acid. In some embodiments, the ratio of compound to acid is 2:1, 1:1, or 1:2. Hydrates and other solvates of salts are further contemplated herein. [0136] The salts as described herein can, in some embodiments, exist in various polymorphic and pseudopolymorphic forms. Polymorphism is the ability of a crystalline material to exist in more than one form or crystal structure. Polymorphism can result, e.g., from the existence of different crystal packing structures (packing polymorphism) or from the existence of different conformers of the same molecule (conformational polymorphism). Pseudopolymorphism is the result of hydration or solvation of a material and is also referred to as solvomorphism. Resin Complex [0137] In some embodiments, at least a portion of the substituted 3-(1-methylpyrrolidin-2- yl)pyridine, optionally substituted 3-(azetidin-2-yl)pyridine, optionally 3-(azetidin-2- ylmethoxy)pyridine, or other active ingredient may be present in the form of a polymer complex, where the compound is bound to an acidic polymer. The polymer of such a complex can be any polymer (including homopolymers or all types of copolymers) with acidic functionalities, e.g., a polymeric cation exchange resin. In some embodiments, the polymer comprises acidic sites that can be classified as strongly acidic, weakly acidic, or of intermediate acidity (depending, e.g., on the strength of the acid from which they are derived). In some embodiments, the polymer comprises weakly acidic sites and can be referred to as a weakly acidic cation exchange resin. Non-limiting examples of acidic sites include, e.g., carboxylic acids, sulfonic acids, phosphonous acids, phosphonic acids, phosphoric acids, iminodiacetic acids, and phenolic groups (e.g., as disclosed in Adams et al., J. Soc. Chem. Ind.54, IT (1935), which is incorporated herein by reference). Suitable polymers include, but are not limited to, addition polymers of styrene and divinylbenzene, divinylbenzene and methacrylic acid, divinylbenzene and acrylic acid, phenolic resins, or cellulose, dextran or pectin cross-linked with, e.g., epichlorohydrin. In some embodiments, the polymer comprises cross-linked moieties. Various acidic ion-exchange resins which are known in the art and are suitable for formation of complexes, include, but are not limited to, polymethacrylic acid resins such as DuPont™ Amberlite™ IRP64, DuPont™ Amberlite™ IRP69, Purolite™ C115HMR, Doshion™ P551, and polyacrylic carbomers, such as Carbopol 974P. See, for example, US Pat. No. 3,901,248 to Lichtneckert et al., which is incorporated herein by reference. In some embodiments, when the substituted 3-(1-methylpyrrolidin-2-yl)pyridine, optionally substituted 3-(azetidin-2-yl)pyridine, or optionally 3-(azetidin-2-ylmethoxy)pyridine is present in the form of a polymer complex, the composition further comprises a divalent metal buffer, such as a calcium or magnesium salt (e.g., carbonate, bicarbonate, oxide, acetate, or the like). Cocrystal [0138] In some embodiments, at least a portion of the substituted 3-(1-methylpyrrolidin-2- yl)pyridine, optionally substituted 3-(azetidin-2-yl)pyridine, optionally 3-(azetidin-2- ylmethoxy)pyridine, or other active ingredient may be present in the form of a co-crystal with at least one other component ("coformer"), both in neutral form. Specifically, as defined in a US FDA industry guidance document, a co-crystal is a solid that is a crystalline material composed of two or more molecules in the same crystal lattice, where the components are in a neutral state and interact via nonionic interactions. See U.S. Department of Health and Human Services, Food and Drug Administration, Guidance for Industry: Regulatory Classification of Pharmaceutical Co-Crystals (April 2013), which is incorporated herein by reference. This form is different and distinct from both salts and ion pairs, each described herein. Specifically, co- crystals can generally be distinguished from salts (and ion pairs) by the absence of a proton transfer between the components (i.e., a substituted 3-(1-methylpyrrolidin-2-yl)pyridine and the one or more coformers) in a co-crystal. The crystalline structure of the co-crystal is generally held together by freely reversible, non-covalent interactions. Co-crystals typically comprise the substituted 3-(1-methylpyrrolidin-2-yl)pyridine, optionally substituted 3- (azetidin-2-yl)pyridine, or optionally 3-(azetidin-2-ylmethoxy)pyridine and coformer in a defined stoichiometric ratio. In some embodiments, co-crystals can encompass hydrates, solvates, and clathrates. Co-crystals can comprise the substituted 3-(1-methylpyrrolidin-2- yl)pyridine, optionally substituted 3-(azetidin-2-yl)pyridine, optionally 3-(azetidin-2- ylmethoxy)pyridine, or other active ingredient in combination with an organic and/or an inorganic coformer. [0139] Examples of suitable coformers include, but are not limited to, acetamidobenzoic acid, L-proline, tromethamine, urea, xylitol, caffeine, glycine/glycine anhydride, vanillin, methyl 4- hydroxybenzoate(methylparaben), succinimide, L-alanine, mannitol, L-phenylalanine, saccharin, propylparaben, N-methylglucamine, L-tyrosine, gentisic acid, sorbic acid, benzoic acid, L-methionine, maltol, L-lysine, tromethamine, nicotinamide, isonicotinamide, phenylalanine, benzoquinone, terephthalaldehyde, 4-hydroxybenzoic acid, pyruvic acid, 1- hydroxy-2-naphthoic acid, 4-aminobenzoic acid, vanillic acid, ethyl vanillin, isonicotinic acid, gallic acid, menthol (e.g., racemic menthol or (−)-menthol), paracetamol, aspirin, ibuprofen, naproxen, ketoprofen, flurbiprofen, glucose, serine, malic acid, acetamide, sulfacetamide, benzoic acid, creatine, 2-hydroxyethanesulfonic acid, clofibric acid, taurine (tauric acid), iproniazid, L-histadine, L-arginine, L-asparagine, glutamine, L-cysteine, alanine, valine, isoleucine, leucine, morpholine, theronine, N-methylglucamine, 3-hydroxy-2-oxopropionic acid; 2-oxobutyric acid (2-ketobutyric acid), 3-methyl-2-oxobutanoic acid; 3-methyl-2- oxopentanoic acid; 4-methyl-2-oxopentanoic acid; and 2-oxopentanedioic acid, 2-oxo-3- phenylpropionic acid; 5-oxooctanoic acid; and 5-oxodecanoic acid, aldonic acids (e.g., glyceric acid, xylonic acid, gluconic acid, and ascorbic acid), ulosonic acids (e.g., neuraminic acid and ketodeoxyoctulosonic acid), uronic acids (e.g., glucuronic acid, galacturonic acid, and iduronic acid), aldaric acids (e.g., tartaric acid, meso-galactaric acid/mucic acid, and D-glucaric acid/saccharic acid), galactaric acid), and polyfunctional aromatic acids. [0140] In some embodiments, the conformer is a polyfunctional aromatic acid. Polyfunctional aromatic acids often comprise a substituted or unsubstituted phenyl group as the aromatic component, but can alternatively comprise another aromatic moiety, e.g., pyridine, pyrazine, imidazole, pyrazole, oxazole, thiophene, naphthalene, anthracene, and phenanthrene. Substituents on the optionally substituted aromatic acids may be any type of substituent, including, but not limited to, halo (e.g., Cl, F, Br, and I); alkyl, halogenated alkyl (e.g., CF3, 2- Br-ethyl, CH₂F, CH₂Cl, CH₂CF₃, or CF₂CF₃); alkenyl, hydroxyl; amino; carboxylate; carboxamido; alkylamino; arylamino; alkoxy; aryloxy; nitro; azido; cyano; thio; sulfonic acid; sulfate; phosphonic acid; phosphate; and phosphonate groups. Example polyfunctional aromatic acids can be, for example: [0141] substituted and unsubstituted aromatic dicarboxylic acids (e.g., 1,2- benzenedicarboxylic acid (phthalic acid), 1,3-benzenedicarboxylic acid (isophthalic acid), 1,4- benzenedicarboxylic acid (terephthalic acid), 2-iodo-1,3-benzenedicarboxylic acid, 2-hydroxy- 1,4-benzenedicarboxylic acid, 2-nitro-1,4-benzenedicarboxylic acid, 3-fluoro-1,2- benzenedicarboxylic acid, 3-amino-1,2-benzenedicarboxylic acid, 3-nitro-1,2- benzenedicarboxylic acid, 4-bromo-1,3-benzenedicarboxylic acid, 4-hydroxy-1,3- benzenedicarboxylic acid, 4-amino-1,2-benzenedicarboxylic acid, 4-nitro-1,2- benzenedicarboxylic acid, 4-sulfo-1,2-benzenedicarboxylic acid, 4-amino-1,3- benzenedicarboxylic acid, 5-bromo-1,3-benzenedicarboxylic acid, 5-hydroxy-1,3- benzenedicarboxylic acid, 5-amino-1,3-benzenedicarboxylic acid, 5-nitro-1,3- benzenedicarboxylic acid, 5-ethynyl-1,3-benzenedicarboxylic acid, 5-cyano-1,3- benzenedicarboxylic acid, 5-nitro-1,3-benzenedicarboxylic acid, 2,5-hydroxy-1,4- benzenedicarboxylic acid, and 2,3,5,6-tetrafluoro-1,4-benzenedicarboxylic acid; [0142] substituted and unsubstituted hydroxybenzoic acids (e.g., 2-hydroxybenzoic acid (salicylic acid), 3-hydroxybenzoic acid, 4-hydroxybenzoic acid, 2-methyl-4-hydroxybenzoic acid, 3-tert-butyl-4-hydroxybenzoic acid, 4-ethoxy-2-hydroxybenzoic acid, 3-chloro-5- hydroxybenzoic acid, 5-chloro-2-hydroxybenzoic acid, 3-bromo-4-hydroxybenzoic acid, 3- bromo-5-hydroxybenzoic acid, 4-bromo-2-hydroxybenzoic acid, 5-bromo-2-hydroxybenzoic acid, 2-fluoro-5-hydroxybenzoic acid, 3-fluoro-4-hydroxybenzoic acid, 3-fluoro-2- hydroxybenzoic acid, 3-fluoro-5-hydroxybenzoic acid, 2-fluoro-6-hydroxybenzoic acid, 4- fluoro-3-hydroxybenzoic acid, 2-fluoro-4-hydroxybenzoic acid, 5-fluoro-2-hydroxybenzoic acid, 2-amino-3-hydroxybenzoic acid, 2-amino-5-hydroxybenzoic acid, 3-amino-2- hydroxybenzoic acid, 3-amino-4-hydroxybenzoic acid, 3-amino-5-hydroxybenzoic acid, 4- amino-2-hydroxybenzoic acid, 4-amino-3-hydroxybenzoic acid, 5-amino-2-hydroxybenzoic acid (mesalamine), 5-aminomethyl-2-hydroxybenzoic acid, 4-formyl-3-hydroxybenzoic acid, 3-formyl-4-hydroxybenzoic acid, 5-(acetylamino)-2-hydroxybenzoic acid), 4-nitro-2- hydroxybenzoic acid, 3,5-diethyl-4-hydroxybenzoic acid, 3,5-di-tert-butyl-4-hydroxybenzoic acid, 3,5-diisopropyl-2-hydroxybenzoic acid, 3,4-dimethoxy-4-hydroxybenzoic acid (syringic acid), 3,5-dichloro-2-hydroxybenzoic acid, 3,5-dichloro-4-hydroxybenzoic acid, 3,6-dichloro- 2-hydroxybenzoic acid, 2,3-difluoro-4-hydroxybenzoic acid, 3,4-difluoro-2-hydroxybenzoic acid, 3,5-dibromo-2-hydroxybenzoic acid, 3,5-diodo-2-hydroxybenzoic acid, 4-amino-5- chloro-2-hydroxybenzoic acid, 3,5-dinitro-2-hydroxybenzoic acid, 2,4,6-tribromo-2- hydroxybenzoic acid, 2,3,5,6-tetrafluoro-4-hydroxybenzoic acid, and 2,3,4,5-tetrafluoro-6- hydroxybenzoic acid); [0143] substituted and unsubstituted dihydroxybenzoic acids (e.g., 2,3-dihydroxybenzoic acid (pyrocatechuic acid/hypogallic acid), 2,4-dihydroxybenzoic acid (β-resorcylic acid), 2,5- dihydroxybenzoic acid (gentisic acid/hydroquinonecarboxylic acid), 2,6-dihydroxybenzoic acid (γ-resorcylic acid), 3,4-dihydroxybenzoic acid (protocatechuic acid), 3,5- dihydroxybenzoic acid (α-resorcylic acid), 4-hydroxy-3-methoxybenzoic acid (vanillic acid), 6-methyl-2,4-dihydroxybenzoic acid (orsellenic acid), 4-bromo-3,5-dihydroxybenzoic acid, 5- bromo-2,4-dihydroxybenzoic acid, 5-bromo-3,4-dihydroxybenzoic acid, 6-carboxymethyl- 2,3-dihydroxybenzoic acid, 3,5-dibromo-2,4-dihydroxybenzoic acid, 3,5-dichloro-2,6- dihydroxybenzoic acid, and 5-amino-3-chloro-2,4-dihydroxybenzoic acid); [0144] substituted and unsubstituted trihydroxybenzoic acids (e.g., 2,3,4-trihydroxybenzoic acid, 2,4,5-trihydroxybenzoic acid, 2,4,6-trihydroxybenzoic acid (phloroglucinol carboxylic acid), and 3,4,5-trihydroxybenzoic acid (gallic acid)); [0145] substituted and unsubstituted aromatic tricarboxylic acids (e.g., 1,2,3- benzenetricarboxylic acid, 1,2,4-benzenetricarboxylic acid (trimellitic acid); and [0146] substituted and unsubstituted aromatic tetracarboxylic acids (e.g., 1,2,3,4- benzenetetracarboxylic acid (mellophanic acid) and 1,2,4,5-benzenetetracarboxylic acid (pyromellitic acid). Further contemplated are various combinations of any of the foregoing acids. [0147] In some embodiments, the coformer is L-malic acid, succinic acid, or a combination thereof. In some embodiments, the coformer is 1,1,6,6-tetraphenyl-2,4-hexidiyne-1,6-diol. In some embodiments, the coformer is di-iodotetrafluoro benzene, 4,4′-diiodooctafluorobiphenyl, or 1,4-bis(diphenylhydroxymethyl)benzene. In some embodiments, the coformer is orotic acid. [0148] In some embodiments, the substituted 3-(1-methylpyrrolidin-2-yl)pyridine, optionally substituted 3-(azetidin-2-yl)pyridine, optionally 3-(azetidin-2-ylmethoxy)pyridine, or other active ingredient is present in the form of a salt co-crystal. A "salt co-crystal" is a type of hybrid structure with both salt and co-crystal characteristics. Typically, a substituted 3-(1- methylpyrrolidin-2-yl)pyridine, optionally substituted 3-(azetidin-2-yl)pyridine, optionally 3- (azetidin-2-ylmethoxy)pyridine molecule, or other active ingredient within a salt co-crystal is associated with at least two coformers (which may be the same or different), wherein one coformer is in ionic form (e.g., an acid) and transfers a proton to the substituted 3-(1- methylpyrrolidin-2-yl)pyridine, optionally substituted 3-(azetidin-2-yl)pyridine, optionally 3- (azetidin-2-ylmethoxy)pyridine molecule, or other active ingredient, and wherein a second coformer does not transfer a proton to the substituted 3-(1-methylpyrrolidin-2-yl)pyridine, optionally substituted 3-(azetidin-2-yl)pyridine, optionally 3-(azetidin-2-ylmethoxy)pyridine molecule, or other active ingredient. Suitable acids and coformers are generally those described herein above with respect to salts and co-crystals. [0149] The stoichiometry of the co-crystals and salt co-crystals described herein can vary. For example, in certain embodiments, where two components are present, the stoichiometry can range in certain embodiments from about 5:1 to about 1:5 compound:coformer. Where more than one coformer is used to form a co-crystal or salt co-crystal, the ratios of the coformers with respect to both the substituted 3-(1-methylpyrrolidin-2-yl)pyridine, optionally substituted 3-(azetidin-2-yl)pyridine, optionally 3-(azetidin-2-ylmethoxy)pyridine, or other active ingredient and to one another can also vary. [0150] The co-crystals and salt co-crystals described herein can, in some embodiments, exist in various polymorphic and pseudopolymorphic forms, as well as solvates and hydrates. [0151] In some embodiments, the substituted 3-(1-methylpyrrolidin-2-yl)pyridine, optionally substituted 3-(azetidin-2-yl)pyridine, optionally 3-(azetidin-2-ylmethoxy)pyridine, or other active ingredient is present in the form of a salt-co-crystal. In some embodiments, the salt-co- crystal is a bis-orotic acid salt-co-crystal. In some embodiments, the bis-orotic acid salt-co- crystal is a hemi-hydrate. Ion pairing [0152] In some embodiments, at least a portion of the substituted 3-(1-methylpyrrolidin-2- yl)pyridine, optionally substituted 3-(azetidin-2-yl)pyridine, optionally 3-(azetidin-2- ylmethoxy)pyridine, or other active ingredient is present in the form of an ion pair. Ion pairing describes the partial association of oppositely charged ions in relatively concentrated solutions to form distinct chemical species called ion pairs. The strength of the association (i.e., the ion pairing) depends on the electrostatic force of attraction between the positive and negative ions (e.g., a substituted 3-(1-methylpyrrolidin-2-yl)pyridine and the conjugate base of a suitable acid). By "conjugate base" is meant the base resulting from deprotonation of the corresponding acid (e.g., benzoate is the conjugate base of benzoic acid). In embodiments comprising ion pairing, on average, a certain population of these ion pairs exists at any given time, although the formation and dissociation of ion pairs is continuous. In some embodiments, in the composition as disclosed herein, and/or upon oral use of said composition (e.g., upon contact with saliva), the substituted 3-(1-methylpyrrolidin-2-yl)pyridine, optionally substituted 3- (azetidin-2-yl)pyridine, optionally 3-(azetidin-2-ylmethoxy)pyridine, or other active ingredient and the conjugate base of an acid exist at least partially in the form of an ion pair. Ion pairing is further described in, for example, International Patent Application Publication No. WO2021/050741 to Poole et al., and US Application Publication Nos.2021/0068447 to Keller et al., 2023/0138306A1 to Zawadzki et al., and 2022/0346434 to Von Cosmos et al., each of which is incorporated herein by reference. [0153] One of skill in the art will recognize that the extent of ion pairing in the disclosed composition, both before and during use by the consumer, may vary based on, for example, pH, the nature of the acid, the concentration of substituted 3-(1-methylpyrrolidin-2-yl)pyridine, optionally substituted 3-(azetidin-2-yl)pyridine, optionally 3-(azetidin-2-ylmethoxy)pyridine, or other active ingredient, the concentration of the acid or conjugate base of the acid present in the composition, the moisture content of the composition, the ionic strength of the composition, and the like. One of skill in the art will also recognize that ion pairing is an equilibrium process influenced by the foregoing variables. Accordingly, quantification of the extent of ion pairing is difficult or impossible by calculation or direct observation. However, the presence of ion pairing may be demonstrated through surrogate measures, such as partitioning of the substituted 3-(1-methylpyrrolidin-2-yl)pyridine, optionally substituted 3-(azetidin-2- yl)pyridine, optionally 3-(azetidin-2-ylmethoxy)pyridine, or other active ingredient between octanol and water, or by performing membrane permeation studies of aqueous solutions of, for example, the substituted 3-(1-methylpyrrolidin-2-yl)pyridine plus acids and/or their conjugate bases. An octanol-water partitioning favoring distribution of an ion pair into octanol is predictive of good absorption of the substituted 3-(1-methylpyrrolidin-2-yl)pyridine, optionally substituted 3-(azetidin-2-yl)pyridine, optionally 3-(azetidin-2-ylmethoxy)pyridine (e.g., 2-methyl-5-(1-methylpyrrolidin-2-yl)pyridine), or other active ingredient through the oral mucosa. However, as described above, in some embodiments, the properties of the substituted 3-(1-methylpyrrolidin-2-yl)pyridine, optionally substituted 3-(azetidin-2- yl)pyridine, optionally 3-(azetidin-2-ylmethoxy)pyridine (e.g., 2-methyl-5-(1- methylpyrrolidin-2-yl)pyridine), or other active ingredient are such that no ion pairing is required, and accordingly, the composition is substantially or completely free of any ion pairing. By "substantially free" it is meant that no measurable degree of ion pairing is present. [0154] In embodiments where ion pairing is desired, the composition comprises an organic acid, an alkali metal salt of an organic acid, or both. In such embodiments, at least a portion of the substituted 3-(1-methylpyrrolidin-2-yl)pyridine, optionally substituted 3-(azetidin-2- yl)pyridine, optionally 3-(azetidin-2-ylmethoxy)pyridine, or other active ingredient is associated with at least a portion of the organic acid, the alkali metal salt thereof, or a combination thereof in the form an ion pair. As used herein, the term "organic acid" refers to an organic (i.e., carbon-based) compound that is characterized by acidic properties. Typically, organic acids are relatively weak acids (i.e., they do not dissociate completely in the presence of water), such as carboxylic acids (-CO2H) or sulfonic acids (-SO2OH). As used herein, reference to organic acid means an organic acid that is intentionally added. In this regard, an organic acid may be intentionally added as a specific composition ingredient as opposed to merely being inherently present as a component of another composition ingredient (e.g., the small amount of organic acid which may inherently be present in a composition ingredient). For the avoidance of doubt, reference herein to an "organic acid" is intended to distinguish the acid present in ion paired forms over the acid which may be present in salts, co-crystal, and salt co-crystals. While one of skill in the art will recognize that certain organic acids suitable for formation of ion pairs overlap with those identified as suitable for salt or co-crystal formation, it is to be understood that the particular acid used for each of salts, co-crystals, and ion pairs are to be selected specifically for each such embodiment, and reference herein to an organic acid is specific to acids suitable for ion pairing. Accordingly, the presence in the composition of an organic acid as defined below is to be interpreted solely with respect to ion pairing, even if such organic acid is also suitable for salt formation or co-crystal formation, and the presence of such an organic acid does not imply that a salt or co-crystal is present unless explicitly identified. Further, in embodiments where there is no ion pairing intended, the composition may be characterized as substantially or completely free of organic acids (i.e., having less than 0.001% by weight of organic acid, or less than 0.0001%, or even 0% by weight of organic acid, based on the total weight of the composition, or as having an amount of organic acid below the limit of detection). This is not to be interpreted as meaning that the composition is substantially or completely free of substituted 3-(1-methylpyrrolidin-2-yl)pyridine salts or substituted 3-(1-methylpyrrolidin-2-yl)pyridine co-crystals unless explicitly recited. Organic acid [0155] In embodiments where ion pairing is desired, the composition comprises an organic acid as defined herein above, and/or an alkali metal salt thereof. Suitable organic acids for ion pairing will typically have a range of lipophilicities (i.e., a polarity giving an appropriate balance of water and organic solubility). Typically, lipophilicities of suitable organic acids, as indicated by logP, will vary between about 0 and about 12 (more soluble in octanol than in water). In some embodiments, the organic acid has a logP value from about 0 to about 12, e.g., from about 0.5, 1.0. about 1.5, about 2.0, about 2.5, about 3.0, about 3.5, about 4.0, about 4.5, about 5.0, about 5.5, about 6.0, about 6.5, about 7.0, about 7.5, or about 8.0, to about 8.5, about 9.0, about 9.5, about 10.0, about 10.5, about 11.0, about 11.5, or about 12.0. [0156] Without wishing to be bound by theory, it is believed that moderately lipophilic organic acids (e.g., logP of from about 1.4 to about 4.5) produce ion pairs which are of a polarity providing good octanol-water partitioning of the ion pair, and hence partitioning of substituted 3-(1-methylpyrrolidin-2-yl)pyridine, optionally substituted 3-(azetidin-2-yl)pyridine, optionally 3-(azetidin-2-ylmethoxy)pyridine, or other active ingredient, into octanol versus water. As discussed above, such partitioning into octanol is predictive of favorable oral availability. [0157] In some embodiments, the organic acid for ion pairing has a logP value from about 3.0 to about 8.0, about 10.0, or even 12.0. In some embodiments, the presence of certain solvents or solubilizing agents (e.g., inclusion in the composition of glycerin or propylene glycol) may be beneficial in solubilizing organic acids and the corresponding salts or ion pairs thereof for highly lipophilic organic acids (e.g., higher than about 4.5). [0158] In some embodiments, the organic acid is a carboxylic acid or a sulfonic acid. The carboxylic acid or sulfonic acid functional group may be attached to any alkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl group having, for example, from one to twenty carbon atoms (C₁-C₂₀). In some embodiments, the organic acid is an alkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl carboxylic or sulfonic acid. [0159] As used herein, "alkyl" refers to any straight chain or branched chain hydrocarbon. The alkyl group may be saturated (i.e., having all sp³ carbon atoms), or may be unsaturated (i.e., having at least one site of unsaturation). As used herein, the term "unsaturated" refers to the presence of a carbon-carbon, sp² double bond in one or more positions within the alkyl group. Unsaturated alkyl groups may be mono- or polyunsaturated. Representative straight chain alkyl groups include, but are not limited to, methyl, ethyl, n-propyl, n-butyl, n-pentyl, and n-hexyl. Branched chain alkyl groups include, but are not limited to, isopropyl, sec-butyl, isobutyl, tert- butyl, isopentyl, and 2-methylbutyl. Representative unsaturated alkyl groups include, but are not limited to, ethylene or vinyl, allyl, 1-butenyl, 2-butenyl, isobutylenyl, 1-pentenyl, 2- pentenyl, 3-methyl-1-butenyl, 2-methyl-2-butenyl, 2,3-dimethyl-2-butenyl, and the like. An alkyl group can be unsubstituted or substituted. [0160] "Cycloalkyl" as used herein refers to a carbocyclic group, which may be mono- or bicyclic. Cycloalkyl groups include rings having 3 to 7 carbon atoms as a monocycle or 7 to 12 carbon atoms as a bicycle. Examples of monocyclic cycloalkyl groups include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, and cyclooctyl. A cycloalkyl group can be unsubstituted or substituted, and may include one or more sites of unsaturation (e.g., cyclopentenyl or cyclohexenyl). [0161] The term "aryl" as used herein refers to a carbocyclic aromatic group. Examples of aryl groups include, but are not limited to, phenyl and naphthyl. An aryl group can be unsubstituted or substituted. [0162] "Heteroaryl" and "heterocycloalkyl" as used herein refer to an aromatic or non-aromatic ring system, respectively, in which one or more ring atoms is a heteroatom, e.g., nitrogen, oxygen, and sulfur. The heteroaryl or heterocycloalkyl group comprises up to 20 carbon atoms and from 1 to 3 heteroatoms selected from N, O, and S. A heteroaryl or heterocycloalkyl may be a monocycle having 3 to 7 ring members (for example, 2 to 6 carbon atoms and 1 to 3 heteroatoms selected from N, O, and S) or a bicycle having 7 to 10 ring members (for example, 4 to 9 carbon atoms and 1 to 3 heteroatoms selected from N, O, and S), for example: a bicyclo[4,5], [5,5], [5,6], or [6,6] system. Examples of heteroaryl groups include by way of example and not limitation, pyridyl, thiazolyl, tetrahydrothiophenyl, pyrimidinyl, furanyl, thienyl, pyrrolyl, pyrazolyl, imidazolyl, tetrazolyl, benzofuranyl, thianaphthalenyl, indolyl, indolenyl, quinolinyl, isoquinolinyl, benzimidazolyl, isoxazolyl, pyrazinyl, pyridazinyl, indolizinyl, isoindolyl, 3H-indolyl, 1H-indazolyl, purinyl, 4H-quinolizinyl, phthalazinyl, naphthyridinyl, quinoxalinyl, quinazolinyl, cinnolinyl, pteridinyl, 4aH-carbazolyl, carbazolyl, phenanthridinyl, acridinyl, pyrimidinyl, phenanthrolinyl, phenazinyl, phenothiazinyl, furazanyl, phenoxazinyl, isochromanyl, chromanyl, imidazolidinyl, imidazolinyl, pyrazolidinyl, pyrazolinyl, benzotriazolyl, benzisoxazolyl, and isatinoyl. Examples of heterocycloalkyls include by way of example and not limitation, dihydroypyridyl, tetrahydropyridyl (piperidyl), tetrahydrothiophenyl, piperidinyl, 4-piperidonyl, pyrrolidinyl, 2- pyrrolidonyl, tetrahydrofuranyl, tetrahydropyranyl, bis-tetrahydropyranyl, tetrahydroquinolinyl, tetrahydroisoquinolinyl, decahydroquinolinyl, octahydroisoquinolinyl, piperazinyl, quinuclidinyl, and morpholinyl. Heteroaryl and heterocycloalkyl groups can be unsubstituted or substituted. [0163] "Substituted" as used herein and as applied to any of the above alkyl, aryl, cycloalkyl, heteroaryl, heterocyclyl, means that one or more hydrogen atoms are each independently replaced with a substituent. Typical substituents include, but are not limited to, -Cl, Br, F, alkyl, -OH, -OCH₃, -NH₂, -NHCH₃, -N(CH₃)₂, -CN, -NC(=O)CH₃, -C(=O)-, -C(=O)NH₂, and - C(=O)N(CH3)2. Wherever a group is described as "optionally substituted," that group can be substituted with one or more of the above substituents, independently selected for each occasion. In some embodiments, the substituent may be one or more methyl groups or one or more hydroxyl groups. [0164] In some embodiments, the organic acid for ion pairing is an alkyl carboxylic acid. Non- limiting examples of alkyl carboxylic acids include formic acid, acetic acid, propionic acid, butyric acid, valeric acid, caproic acid, heptanoic acid, octanoic acid, nonanoic acid, decanoic acid, undecanoic acid, dodecanoic acid, stearic acid, oleic acid, linoleic acid, linolenic acid, and the like. [0165] In some embodiments, the organic acid for ion pairing is an alkyl sulfonic acid. Non- limiting examples of alkyl sulfonic acids include propanesulfonic acid, heptanesulfonic acid, and octanesulfonic acid. [0166] In some embodiments, the alkyl carboxylic or sulfonic acid is substituted with one or more hydroxyl groups. Non-limiting examples include glycolic acid, 4-hydroxybutyric acid, and lactic acid. [0167] In some embodiments, an organic acid for ion pairing may include more than one carboxylic acid group or more than one sulfonic acid group (e.g., two, three, or more carboxylic acid groups). Non-limiting examples include oxalic acid, fumaric acid, maleic acid, and glutaric acid. In organic acids containing multiple carboxylic acids (e.g., from two to four carboxylic acid groups), one or more of the carboxylic acid groups may be esterified. Non- limiting examples include succinic acid monoethyl ester, monomethyl fumarate, monomethyl or dimethyl citrate, and the like. [0168] In some embodiments, the organic acid for ion pairing may include more than one carboxylic acid group and one or more hydroxyl groups. Non-limiting examples of such acids include tartaric acid, citric acid, and the like. [0169] In some embodiments, the organic acid for ion pairing is an aryl carboxylic acid or an aryl sulfonic acid. Non-limiting examples of aryl carboxylic and sulfonic acids include benzoic acid, toluic acids, salicylic acid, benzenesulfonic acid, and p-toluenesulfonic acid. [0170] Further non-limiting examples of organic acids which may be useful for ion pairing in certain embodiments include 2-(4-isobutylphenyl)propanoic acid, 2,2-dichloroacetic acid, 2- hydroxyethanesulfonic acid, 2-oxoglutaric acid, 4-acetamidobenzoic acid, 4-aminosalicylic acid, adipic acid, ascorbic acid (L), aspartic acid (L), alpha-methylbutyric acid, camphoric acid (+), camphor-10-sulfonic acid (+), cinnamic acid, cyclamic acid, dodecylsulfuric acid, ethane- 1,2-disulfonic acid, ethanesulfonic acid, furoic acid, galactaric acid, gentisic acid, glucoheptonic acid, gluconic acid, glucuronic acid, glutamic acid, glycerophosphoric acid, glycolic acid, hippuric acid, isobutyric acid, isovaleric acid, lactobionic acid, lauric acid, levulinic acid, malic acid, malonic acid, mandelic acid, methanesulfonic acid, naphthalene-1,5- disulfonic acid, naphthalene-2-sulfonic acid, oleic acid, palmitic acid, pamoic acid, phenylacetic acid, pyroglutamic acid, pyruvic acid, sebacic acid, stearic acid, and undecylenic acid. Examples of suitable acids for ion pairing include, but are not limited to, the list of organic acids in Table 1. Table 1. Non-limiting examples of suitable organic acids for ion pairing Acid Name log(P)^* benzoic acid 1.9 phenylacetic 1.4 p-toluic acid 2.3 ethyl benzoic acid 2.9 isopropyl benzoic acid 3.5 Acid Name log(P)^* 4-phenylbutyric 2.4 2-(4-isobutylphenyl)propanoic acid 3.5 2-napthoxyacetic acid 2.5 napthylacetic acid 2.7 heptanoic acid 2.5 octanoic acid 3.05 nonanoic acid 3.5 decanoic acid 4.09 9-deceneoic acid 3.3 2-deceneoic acid 3.8 10-undecenoic acid 3.9 dodecandioic acid 3.2 dodecanoic acid 4.6 myristic acid 5.3 palmitic acid 6.4 stearic acid 7.6 cyclohexanebutanoic acid 3.4 1-heptanesulfonic acid 2.0 1-octanesulfonic acid 2.5 1-nonanesulfonic acid 3.1 monooctyl succinate 2.8 tocopherol succinate 10.2 monomenthyl succinate 3 monomenthyl glutarate 3.4 norbixin ((2E,4E,6E,8E,10E,12E,14E,16E,18E)-4,8,13,17- 7.2 tetramethylicosa-2,4,6,8,10,12,14,16,18-nonaenedioic acid) bixin ((2E,4E,6E,8E,10E,12E,14E,16Z,18E)-20-methoxy- 7.5 4,8,13,17-tetramethyl-20-oxoicosa-2,4,6,8,10,12,14,16,18- nonaenoic acid) *Values obtained from PubChem or calculated [0171] The selection of organic acid for ion pairing may further depend on additional properties in addition to consideration of the logP value. For example, an organic acid should be one recognized as safe for human consumption, and which has acceptable flavor, odor, volatility, stability, and the like. Determination of appropriate organic acids is within the purview of one of skill in the art. [0172] In some embodiments, the organic acid for ion pairing is a mono ester of a dicarboxylic acid or a poly-carboxylic acid. In some embodiments, the dicarboxylic acid is malonic acid, succinic acid, glutaric acid, adipic acid, fumaric acid, maleic acid, or a combination thereof. In some embodiments, the dicarboxylic acid is succinic acid, glutaric acid, fumaric acid, maleic acid, or a combination thereof. In some embodiments, the dicarboxylic acid is succinic acid, glutaric acid, or a combination thereof. [0173] In some embodiments, the alcohol forming the mono ester of the dicarboxylic acid is a lipophilic alcohol. Examples of suitable lipophilic alcohols include, but are not limited to, octanol, menthol, and tocopherol. In some embodiments, the organic acid is an octyl mono ester of a dicarboxylic acid, such as monooctyl succinate, monooctyl fumarate, or the like. In some embodiments, the organic acid is a monomenthyl ester of a dicarboxylic acid. Certain menthyl esters may be desirable in oral compositions as described herein by virtue of the cooling sensation they may provide upon use of the product comprising the composition. In some embodiments, the organic acid is monomenthyl succinate, monomenthyl fumarate, monomenthyl glutarate, or a combination thereof. In some embodiments, the organic acid is a monotocopheryl ester of a dicarboxylic acid. Certain tocopheryl esters may be desirable in oral compositions as described herein by virtue of the antioxidant effects they may provide. In some embodiments, the organic acid is tocopheryl succinate, tocopheryl fumarate, tocopheryl glutarate, or a combination thereof. [0174] In some embodiments, the organic acid for ion pairing is a carotenoid derivative having one or more carboxylic acids. Carotenoids are tetraterpenes, meaning that they are produced from 8 isoprene molecules and contain 40 carbon atoms. Accordingly, they are usually lipophilic due to the presence of long unsaturated aliphatic chains, and are generally yellow, orange, or red in color. Certain carotenoid derivatives can be advantageous in oral compositions by virtue of providing both ion pairing and serving as a colorant in the composition. In some embodiments, the organic acid is 2E,4E,6E,8E,10E,12E,14E,16Z,18E)-20-methoxy-4,8,13,17- tetramethyl-20-oxoicosa-2,4,6,8,10,12,14,16,18-nonaenoic acid (bixin) or an isomer thereof. Bixin is an apocarotenoid found in annatto seeds from the achiote tree (Bixa orellana) and is the naturally occurring pigment providing the reddish orange color to annatto. Bixin is soluble in fats and alcohols but insoluble in water, and is chemically unstable when isolated, converting via isomerization into the double bond isomer, trans-bixin (β-bixin), having the structure: . [0175] In ion pairing is - nonaenedioic acid (norbixin), a water-soluble hydrolysis product of bixin having the structure: . [0176] In some may be present. For example, the composition may comprise two, or three, or four, or more organic acids for ion pairing. Accordingly, reference herein to "an organic acid" contemplates mixtures of two or more organic acids. The relative amounts of the multiple organic acids may vary. For example, a composition may comprise equal amounts of two, or three, or more organic acids, or may comprise different relative amounts. In this manner, it is possible to include certain organic acids (e.g., citric acid or myristic acid) which have a logP value outside the desired range, when combined with other organic acids to provide the desired average logP range for the combination. In some embodiments, it may be desirable to include organic acids in the composition for ion pairing which have logP values outside the desired range for purposes such as, but not limited to, providing desirable organoleptic properties, stability, as flavor components, and the like. Further, certain lipophilic organic acids have undesirable flavor and or aroma characteristics which would preclude their presence as the sole organic acid (e.g., in equimolar or greater quantities relative to nicotine). Without wishing to be bound by theory, it is believed that a combination of different organic acids may provide the desired ion pairing while the concentration of any single organic acid in the composition remains below the threshold which would be found objectionable from a sensory perspective. [0177] In some embodiments, the composition comprises an organic acid for ion pairing which is a monoester of a dicarboxylic acid or is a carotenoid derivative having one or more carboxylic acids as described herein above, and further comprises an additional organic acid or salt thereof. In some embodiments, the additional organic acid is benzoic acid, an alkali metal salt thereof, or a combination thereof. [0178] In some embodiments, the composition comprises an alkali metal salt of an organic acid. For example, at least a portion of the organic acid may be present in the composition in the form of an alkali metal salt. Suitable alkali metal salts include lithium, sodium, and potassium. In some embodiments, the alkali metal is sodium or potassium. In some embodiments, the alkali metal is sodium. In some embodiments, the composition comprises an organic acid and a sodium salt of the organic acid. [0179] In some embodiments, the molar ratio of the organic acid to the sodium salt (or other alkali metal) of the organic acid is from about 0.1 to about 10, such as from about 0.1, about 0.25, about 0.3, about 0.5, about 0.75, or about 1, to about 2, about 5, or about 10. For example, in some embodiments, both an organic acid and the sodium salt thereof are added to the other components of the composition, wherein the organic acid is added in excess of the sodium salt, in equimolar quantities with the sodium salt, or as a fraction of the sodium salt. One of skill in the art will recognize that the relative amounts will be determined by the desired pH of the composition, as well as the desired ionic strength. For example, the organic acid may be added in a quantity to provide a desired pH level of the composition, while the alkali metal (e.g., sodium) salt is added in a quantity to provide the desired extent of ion pairing. As one of skill in the art will understand, the quantity of organic acid (i.e., the protonated form) present in the composition, relative to the alkali metal salt or conjugate base form present in the composition, will vary according to the pH of the composition and the pKa of the organic acid, as well as according to the actual relative quantities initially added to the composition. [0180] The amount of organic acid or alkali metal salt thereof present in the composition, relative to the substituted 3-(1-methylpyrrolidin-2-yl)pyridine, optionally substituted 3- (azetidin-2-yl)pyridine, optionally 3-(azetidin-2-ylmethoxy)pyridine (e.g., 2-methyl-5-(1- methylpyrrolidin-2-yl)pyridine), or other active ingredient, may vary. Generally, as the concentration of the organic acid (or the conjugate base thereof) increases, the percent of substituted 3-(1-methylpyrrolidin-2-yl)pyridine, optionally substituted 3-(azetidin-2- yl)pyridine, optionally 3-(azetidin-2-ylmethoxy)pyridine, or other active ingredient that is ion paired with the organic acid increases. This typically increases the partitioning of the substituted 3-(1-methylpyrrolidin-2-yl)pyridine, optionally substituted 3-(azetidin-2- yl)pyridine, optionally 3-(azetidin-2-ylmethoxy)pyridine, or other active ingredient in the form of an ion pair, into octanol versus water as measured by the logP (the log10 of the partitioning coefficient). In some embodiments, the composition comprises from about 0.05, about 0.1, about 1, about 1.5, about 2, or about 5, to about 10, about 15, or about 20 molar equivalents of the organic acid, the alkali metal salt thereof, or the combination thereof, relative to the substituted 3-(1-methylpyrrolidin-2-yl)pyridine, optionally substituted 3-(azetidin-2- yl)pyridine, optionally 3-(azetidin-2-ylmethoxy)pyridine, or other active ingredient, calculated as the free base of the substituted 3-(1-methylpyrrolidin-2-yl)pyridine, optionally substituted 3-(azetidin-2-yl)pyridine, optionally 3-(azetidin-2-ylmethoxy)pyridine, or other active ingredient. [0181] In some embodiments, the composition comprises from about 2 to about 10, or from about 2 to about 5 molar equivalents of the organic acid, the alkali metal salt thereof, or the combination thereof, relative to the substituted 3-(1-methylpyrrolidin-2-yl)pyridine, optionally substituted 3-(azetidin-2-yl)pyridine, optionally 3-(azetidin-2-ylmethoxy)pyridine, or other active ingredient on a free-base basis. In some embodiments, the organic acid, the alkali metal salt thereof, or the combination thereof, is present in a molar ratio with the substituted 3-(1- methylpyrrolidin-2-yl)pyridine, optionally substituted 3-(azetidin-2-yl)pyridine, optionally 3- (azetidin-2-ylmethoxy)pyridine, or other active ingredient from about 2, about 3, about 4, or about 5, to about 6, about 7, about 8, about 9, or about 10. In embodiments wherein more than one organic acid, alkali metal salt thereof, or both, are present, it is to be understood that such molar ratios reflect the totality of the organic acids present. In some embodiments, the composition comprises benzoic acid and sodium benzoate wherein a total amount of benzoate (i.e., benzoic acid and benzoate) is in a molar ratio in a range from about 3 to about 5 relative to the substituted 3-(1-methylpyrrolidin-2-yl)pyridine, optionally substituted 3-(azetidin-2- yl)pyridine, optionally 3-(azetidin-2-ylmethoxy)pyridine, or other active ingredient. In some embodiments, the molar ratio of the total amount of benzoate to the substituted 3-(1- methylpyrrolidin-2-yl)pyridine, optionally substituted 3-(azetidin-2-yl)pyridine, optionally 3- (azetidin-2-ylmethoxy)pyridine, or other active ingredient is about 3.2 or about 4.8. [0182] In some embodiments, the organic acid inclusion is sufficient to provide a composition pH of from about 4.0 to about 9.0, such as from about 4.5 to about 7.0, or from about 5.5 to about 7.0, from about 4.0 to about 5.5, or from about 7.0 to about 9.0. Reference herein to "a composition pH" means the pH of an aqueous solution of the composition prepared by dissolving or suspending 5 grams of composition in 95 grams of water and measuring the pH of the resulting solution with a calibrated pH meter. [0183] In some embodiments, the organic acid inclusion is sufficient to provide a composition pH of from about 4.5 to about 6.5, for example, from about 4.5, about 5.0, or about 5.5, to about 6.0, or about 6.5. In some embodiments, the desired composition pH is from about 4.5 to about 6.5, and the organic acid is provided in a quantity sufficient to provide such a pH. In some embodiments, the organic acid is provided in a quantity sufficient to provide a pH of the composition of from about 5.5 to about 6.5, for example, from about 5.5, about 5.6, about 5.7, about 5.8, about 5.9, or about 6.0, to about 6.1, about 6.2, about 6.3, about 6.4, or about 6.5. [0184] In some embodiments, a mineral acid (e.g., hydrochloric acid, sulfuric acid, phosphoric acid, or the like), alone or in combination with an organic acid, is added to adjust the pH of the composition to the desired value. In some embodiments, a buffer (e.g., a buffer as described herein below) is added to the composition to the desired value, and/or to maintain the pH of the composition at the desired value. [0185] In some embodiments, the oral composition further comprises a solubility enhancer to increase the solubility of one or more of the organic acid or salt thereof. Suitable solubility enhancers include, but are not limited to, humectants as described herein, such as glycerol or propylene glycol. Filler [0186] The composition as described herein comprises one or more fillers. Fillers may fulfill multiple functions, such as enhancing certain organoleptic properties such as texture and mouthfeel, enhancing cohesiveness or compressibility of the product, and the like. Generally, fillers are porous particulate materials and may be inorganic or organic (e.g., cellulose-based). For example, suitable organic fillers are any non-tobacco plant material or derivative thereof, including cellulose materials derived from such sources. Additional examples of organic fillers include maltodextrin, dextrose, lactose, and sugar alcohols. Examples of cellulosic non-tobacco plant material include cereal grains (e.g., maize, oat, barley, rye, buckwheat, and the like), sugar beet (e.g., FIBREX® brand filler available from International Fiber Corporation), bran fiber, and mixtures thereof. Non-limiting examples of derivatives of non-tobacco plant material include starches (e.g., from potato, wheat, rice, corn), natural cellulose, and modified cellulosic materials. Combinations of fillers can also be used, such as multiple organic fillers, inorganic fillers, or combinations of organic and inorganic fillers. [0187] In some embodiments, the filler comprises or is a cellulose material or cellulose derivative. One particularly suitable filler for use in the compositions described herein is microcrystalline cellulose ("mcc"). The mcc may be synthetic or semi-synthetic, or it may be obtained entirely from natural celluloses. The mcc may be selected from the group consisting of AVICEL® grades PH-100, PH-102, PH-103, PH-105, PH-112, PH-113, PH-200, PH-300, PH-302, VIVACEL® grades 101, 102, 12, 20 and EMOCEL® grades 50M and 90M, and the like, and mixtures thereof. In some embodiments, the composition comprises mcc as the particulate filler. The quantity of mcc present may vary according to the desired properties. [0188] In some embodiments, the filler comprises a starch or is derived from a starch. The term "starch" as used herein may refer to pure starch from any source, modified starch, or starch derivatives. Starch is present, typically in granular form, in almost all green plants and in various types of plant tissues and organs (e.g., seeds, leaves, rhizomes, roots, tubers, shoots, fruits, grains, and stems). Starch can vary in composition, as well as in granular shape and size. Often, starch from different sources has different chemical and physical characteristics. A specific starch can be selected for inclusion in the mixture based on the ability of the starch material to impart a specific organoleptic property to composition. Starches derived from various sources can be used. For example, major sources of starch include cereal grains (e.g., rice, wheat, and maize) and root vegetables (e.g., potatoes and cassava). Other examples of sources of starch include acorns, arrowroot, arracacha, bananas, barley, beans (e.g., favas, lentils, mung beans, peas, chickpeas), breadfruit, buckwheat, canna, chestnuts, colacasia, katakuri, kudzu, malanga, millet, oats, oca, Polynesian arrowroot, sago, sorghum, sweet potato, quinoa, rye, tapioca, taro, tobacco, water chestnuts, and yams. Certain starches are modified starches. A modified starch has undergone one or more structural modifications, often designed to alter its high heat properties. Some starches have been developed by genetic modifications and are considered to be "modified" starches. Other starches are obtained and subsequently modified. For example, modified starches can be starches that have been subjected to chemical reactions, such as esterification, etherification, oxidation, depolymerization (thinning) by acid catalysis or oxidation in the presence of base, bleaching, transglycosylation and depolymerization (e.g., dextrinization in the presence of a catalyst), cross-linking, enzyme treatment, acetylation, hydroxypropylation, and/or partial hydrolysis. Other starches are modified by heat treatments, such as pregelatinization, dextrinization, and/or cold-water swelling processes. Certain modified starches include monostarch phosphate, distarch glycerol, distarch phosphate esterified with sodium trimetaphosphate, phosphate distarch phosphate, acetylated distarch phosphate, starch acetate esterified with acetic anhydride, starch acetate esterified with vinyl acetate, acetylated distarch adipate, acetylated distarch glycerol, hydroxypropyl starch, hydroxypropyl distarch glycerol, starch sodium octenyl succinate. In some embodiments, the filler comprises or is a mixture of glucose and starch-derived polysaccharides. One such suitable mixture of glucose and starch-derived polysaccharides is EMDEX®, available from JRS PHARMA LP, USA, 2981 Route 22, Patterson, NY 12563- 2359. [0189] In some embodiments, the filler comprises or is an inorganic material. Examples of potential inorganic fillers include calcium carbonate, calcium phosphate, and bioceramic materials (e.g., porous hydroxyapatite). [0190] In certain embodiments of the present disclosure, a substantially spherical filler in particulate form is utilized, and such fillers can be defined by their sphericity, which is a measure of how closely an object resembles a perfect sphere. Sphericity (Ψ) can be measuring using the equation below, wherein V_p is the volume of the object and A_p is the surface area of the object. Ψ = (π^⅓(6V_p)^⅔)/A_p [0191] The sphericity of a sphere is unity by definition and any shape that is not a perfect sphere will have a sphericity less than 1. In certain embodiments, the sphericity of the substantially spherical fillers of the present disclosure will be about 0.7 or higher, such as about 0.8 or higher or about 0.9 or higher (e.g., about 0.7 to 1 or about 0.75 to 1 or about 0.8 to 1 or about 0.85 to 1, or about 0.9 to 1). [0192] The average diameter (mean) or D50 (median) particle size of the substantially spherical particulate filler particles provided herein can vary, and is not particularly limited. For example, in some embodiments, the spherical filler particles have an average diameter and/or a D50 value of about 100 µm to about 2000 µm, such as about 250 µm to about 750 µm. For example, in some embodiments, the average diameter is about 100 µm to about 500 µm, e.g., about 100 µm to about 400 µm, about 100 µm to about 300 µm, about 100 µm to about 200 µm, about 200 µm to about 500 µm, about 200 µm to about 400 µm, about 200 µm to about 300 µm, about 300 µm to about 500 µm, about 300 µm to about 400 µm, or about 400 µm to about 500 µm. In some embodiments, the average diameter is about 500 µm to about 1000 µm, e.g., about 500 µm to about 900 µm, about 500 µm to about 800 µm, about 500 µm to about 700 µm, about 500 µm to about 600 µm, about 600 µm to about 1000 µm, about 600 µm to about 900 µm, about 600 µm to about 800 µm, about 600 µm to about 700 µm, about 700 µm to about 1000 µm, about 700 µm to about 900 µm, about 700 µm to about 800 µm, about 800 µm to about 1000 µm, about 800 µm to about 900 µm, or about 900 µm to about 1000 µm. In some embodiments, the substantially spherical filler component has an average diameter and/or D50 value of about 300 to 650 microns, such as about 350 to about 500 microns. [0193] The distribution of diameters around this average diameter (i.e., the particle size distribution) can also vary; in some embodiments, the distribution of diameters is close to the listed value (e.g., +/- about 25% of the stated value, +/- about 20% of the stated value, +/- about 15% of the stated value, +/- about 10% of the stated value, +/- about 5% of the stated value, or +/- about 1% of the stated value. The disclosure is not, however, limited to materials with such narrow distributions; in other embodiments, the diameter of the spheres within a given material can vary within a wider range. Particle size distributions can be determined using a sieve analysis. [0194] In some embodiments, the substantially spherical filler comprises microcrystalline cellulose ("mcc"). The mcc may be synthetic or semi-synthetic, or it may be obtained entirely from natural celluloses. By "substantially spherical mcc" is meant a material comprising, consisting essentially of, or consisting of mcc, wherein the material is a substantially spherical particulate filler component as referenced herein above. [0195] The diameter of the substantially spherical mcc particles can vary within the scope of the disclosure, e.g., according to the values disclosed herein with respect to substantially spherical particulate filler components generally. Various commercial suppliers provide mcc spheres in designated diameter sizes and such commercial materials can be used in certain embodiments according to the present disclosure. Examples of suitable mcc spheres include, but are not limited to, Vivapur® mcc spheres from JRS Pharma, available, e.g., with particle sizes of 100-200 µm (Vivapur® 100), 200-355 µm (Vivapur® 200), 355-500 µm (Vivapur® 350), 500-710 µm (Vivapur® 500), 710-1000 µm (Vivapur®700), and 1000-1400 µm (Vivapur® 1000). Further examples of suitable mcc spheres include, but are not limited to, Celphere™ mcc spheres from Asahi Kasei Corporation, available, e.g., with particle sizes of 75-212 µm (Celphere™ SCP-100), 106-212 µm (Celphere™ CP-102), 150-300 µm (Celphere™ CP-203), 300-500 µm (Celphere™ CP-305), and 500-710 µm (Celphere™ CP- 507). It is noted that this application focuses on the use of substantially spherical mcc; however, this disclosure is not meant to be limiting. Other types of materials that can serve the function of a filler as provided herein and which can be provided in substantially spherical form can be used in place of (or in addition) to the exemplified substantially spherical mcc filler without deviating from the scope of the disclosure. [0196] Advantageously, the use of a filler in substantially spherical particulate form can endow the composition and product into which it is incorporated with unique physical properties. For example, in some embodiments, the replacement of at least a portion of conventional particulate filler within a pouched composition with substantially spherical particulate filler can allow for alternative moisture levels within the pouched composition as compared with compositions comprising all conventional particulate filler. For example, in some embodiments, use of the disclosed substantially spherical filler can provide for a drier pouch than typically feasible using conventional fillers (e.g., all other components and amounts thereof being roughly equivalent). For example, in some embodiments, the disclosed composition, comprising a substantially spherical particulate filler, can provide a pouched product having a moisture content/oven volatile content of about 32% or less, about 30% or less, about 28% or less, about 27% or less, about 26% or less, about 25% or less, about 24% or less, about 23% or less, about 22% or less, about 21% or less, about 20% or less, about 19% or less, about 18% or less, about 17% or less, about 16% or less, or about 15% or less. In some embodiments, the moisture content of the disclosed compositions can be about 5% to about 32%, e.g., about 5% to about 25%, about 5% to about 20%, about 5% to about 15%, about 10% to about 25%, about 10% to about 20%, or about 10% to about 15%. Moisture/oven volatile content can be measured by drying a sample in an oven and precisely measuring the weight of the sample before and after drying so that the difference gives the amount of water or other oven volatiles evaporated. [0197] In some embodiments, the provision of a drier pouch (e.g., about 32% moisture or less, as referenced in the prior paragraph) due to the inclusion of particulate filler in the form of a substantially spherical particulate filler can allow for different components to be suitably contained within the pouch as compared with inclusion of particulate filler in conventional form. For example, certain components that may desirably be included within a pouched composition may be more feasibly incorporated within a drier composition (e.g., where such components are water-soluble or water-reactive). For example, certain components encapsulated with a water-soluble exterior may more advantageously be included within a drier composition/product (e.g., a composition/product having a moisture content within the ranges referenced herein). [0198] In some embodiments, the replacement of at least a portion of conventional particulate filler within a pouched composition with substantially spherical particulate filler can provide for modified release rates of substituted 3-(1-methylpyrrolidin-2-yl)pyridine, optionally substituted 3-(azetidin-2-yl)pyridine, or optionally 3-(azetidin-2-ylmethoxy)pyridine relative to compositions comprising all conventional particulate filler. At the same moisture level, a substantially spherical particulate filler may release a substituted 3-(1-methylpyrrolidin-2- yl)pyridine, optionally substituted 3-(azetidin-2-yl)pyridine, or optionally 3-(azetidin-2- ylmethoxy)pyridine of the disclosure faster than a conventional particulate filler. In some embodiments, at the same moisture level, a substantially spherical particulate mcc filler will release a flavorant faster than a conventional particulate mcc filler. [0199] The amount of filler can vary but is typically up to about 75 percent of the composition by weight, based on the total weight of the composition. A typical range of filler (e.g., mcc, including spherical mcc) within the composition can be from about 10 to about 75 percent by total weight of the composition, for example, from about 10, about 15, about 20, about 25, or about 30, to about 35, about 40, about 45, or about 50 weight percent (e.g., about 20 to about 50 weight percent or about 25 to about 45 weight percent). In certain embodiments, the amount of filler is at least about 10 percent by weight, such as at least about 20 percent, or at least about 25 percent, or at least about 30 percent, or at least about 35 percent, or at least about 40 percent, based on the total weight of the composition. [0200] In some embodiments, the filler further comprises a cellulose derivative or a combination of such derivatives. In some embodiments, the composition comprises from about 1 to about 10% of the cellulose derivative by weight, based on the total weight of the composition, with certain embodiments comprising about 1 to about 5% by weight of cellulose derivative. In certain embodiments, the cellulose derivative is a cellulose ether (including carboxyalkyl ethers), meaning a cellulose polymer with the hydrogen of one or more hydroxyl groups in the cellulose structure replaced with an alkyl, hydroxyalkyl, or aryl group. Non- limiting examples of such cellulose derivatives include methylcellulose, hydroxypropylcellulose ("HPC"), hydroxypropylmethylcellulose ("HPMC"), hydroxyethyl cellulose, and carboxymethylcellulose ("CMC"). In some embodiments, the cellulose derivative is one or more of methylcellulose, HPC, HPMC, hydroxyethyl cellulose, and CMC. In some embodiments, the cellulose derivative is HPC. In some embodiments, the composition comprises from about 1 to about 3% HPC by weight, based on the total weight of the composition. Water [0201] The water content of the composition, prior to use by a consumer of the composition, may vary according to the desired properties. Typically, the composition is less than about 60 percent by weight of water, and generally is from about 1 to about 60% by weight of water, for example, from about 5 to about 55, about 10 to about 50, about 20 to about 45, or about 25 to about 40 percent water by weight, including water amounts of at least about 5% by weight, at least about 10% by weight, at least about 15% by weight, and at least about 20% by weight. As described herein below, in some embodiments, the composition is enclosed in a pouch to form a pouched product. In some embodiments, the water content of the pouched product is in a range from about 40 weight percent to about 60 weight percent, based on the total weight of the pouched product (i.e., the composition and the pouch together). In some embodiments, the water content of the pouched product is in a range from about 15 weight percent to about 60 weight percent, based on the total weight of the pouched product (i.e., the composition and the pouch together). In some embodiments, the water content of the pouched product is in a range from about 15 weight percent to about 20 weight percent, based on the total weight of the pouched product (i.e., the composition and the pouch together). In some embodiments, the water content of the pouched product is in a range from about 30 weight percent to about 50 weight percent, based on the total weight of the pouched product (i.e., the composition and the pouch together), such as from about 32 to about 49 weight percent. In some embodiments, the water content of the pouched product is about 32, about 35, or about 48 weight percent, based on the total weight of the pouched product. Flavoring agent [0202] In some embodiments, the composition as described herein comprises a flavoring agent. As used herein, a "flavoring agent" or "flavorant" is any flavorful or aromatic substance capable of altering the sensory characteristics associated with the oral product. Examples of sensory characteristics that can be modified by the flavoring agent include taste, mouthfeel, moistness, coolness/heat, and/or fragrance/aroma. Flavoring agents may be natural or synthetic, and the character of the flavors imparted thereby may be described, without limitation, as fresh, sweet, herbal, confectionary, floral, fruity, or spicy. [0203] Flavoring agents may be imitation, synthetic or natural ingredients or blends thereof. Flavoring agents may include naturally occurring flavor materials, botanicals, extracts of botanicals, synthetically obtained materials, or combinations thereof (e.g., tobacco, cannabis, licorice (liquorice), hydrangea, eugenol, Japanese white bark magnolia leaf, chamomile, fenugreek, clove, maple, matcha, menthol, Japanese mint, aniseed (anise), cinnamon, turmeric, Indian spices, Asian spices, herb, wintergreen, cherry, berry, red berry, cranberry, peach, apple, orange, mango, clementine, lemon, lime, tropical fruit, papaya, rhubarb, grape, durian, dragon fruit, cucumber, blueberry, mulberry, citrus fruits, Drambuie, bourbon, scotch, whiskey, gin, tequila, rum, spearmint, peppermint, lavender, aloe vera, cardamom, celery, cascarilla, nutmeg, sandalwood, bergamot, geranium, khat, naswar, betel, shisha, pine, honey essence, rose oil, vanilla, lemon oil, orange oil, orange blossom, cherry blossom, cassia, caraway, cognac, jasmine, ylang-ylang, sage, fennel, wasabi, piment, ginger, coriander, coffee, hemp, a mint oil from any species of the genus Mentha, eucalyptus, star anise, cocoa, lemongrass, rooibos, flax, ginkgo biloba, hazel, hibiscus, laurel, mate, orange skin, rose, tea such as green tea or black tea, thyme, juniper, elderflower, basil, bay leaves, cumin, oregano, paprika, rosemary, saffron, lemon peel, mint, beefsteak plant, curcuma, cilantro, myrtle, cassis, valerian, pimento, mace, damien, marjoram, olive, lemon balm, lemon basil, chive, carvi, verbena, tarragon, limonene, thymol, camphene), flavor enhancers, bitterness receptor site blockers, sensorial receptor site activators or stimulators, sugars and/or sugar substitutes (e.g., sucralose, acesulfame potassium, aspartame, saccharine, cyclamates, lactose, sucrose, glucose, fructose, sorbitol, or mannitol), and other additives such as charcoal, chlorophyll, minerals, botanicals, or breath freshening agents. [0204] Flavorants may further include flavor enhancers, sensorial receptor site activators or stimulators, and trigeminal sensates, As used herein, "trigeminal sensate" refers to a flavoring agent which has an effect on the trigeminal nerve, producing sensations including heating, cooling, tingling, and the like. Non-limiting examples of trigeminal sensate flavoring agents include capsaicin, citric acid, menthol, Sichuan buttons, erythritol, and cubebol. [0205] In some embodiments, the composition comprises a sensate which provides to the user of such composition a cooling effect. Suitable cooling agents include, but are not limited to, menthane, menthone, menthone ketals, menthone glycerol ketals, substituted p-menthanes, acyclic carboxamides, monomenthyl glutarate, substituted cyclohexanamides, substituted cyclohexane carboxamides, substituted ureas and sulfonamides, substituted menthanols, hydroxymethyl and hydroxymethyl derivatives of p-menthane, 2-mercapto-cyclo-decanone, hydroxycarboxylic acids with 2-6 carbon atoms, cyclohexanamides, menthyl acetate, menthyl salicylate, N-ethyl-p-menthane-3-carboxamide (WS-3), ethyl ester of N-[[5-methyl-2-(1- methylethyl)cyclohexyl]carbonyl]glycine (WS-5), WS-14, N,2,3-trimethyl-2-isopropyl butanamide (WS-23), WS-27, WS-30, (-)-Menthyloxyethanol (Coolact^® 5), WS-NA (FEMA 4693), WS-116 (FEMA 4603), N-ethyl-2,2-diisopropylbutanamide, isopulegol, menthyloxy propane diol, 3-(1-menthoxy)propane-1,2-diol, 3-(1-menthoxy)-2-methylpropane-1,2-diol, p- menthane-2,3-diol, p-menthane-3,8-diol, 6-isopropyl-9-methyl-1,4-dioxaspiro[4,5]decane-2- methanol, menthyl succinate and its alkaline earth metal salts, trimethylcyclohexanol, N-ethyl- 2-isopropyl-5-methylcyclohexanecarboxamide, Japanese mint oil, peppermint oil, 3-(1- menthoxy)ethan-1-ol, 3-(1-menthoxy)propan-1-ol, 3-(1-menthoxy)butan-1-ol, 1- menthylacetic acid N-ethylamide, 1-menthyl-4-hydroxypentanoate, 1-menthyl-3- hydroxybutyrate, menthyl glutarate, N,2,3-trimethyl-2-(1-methylethyl)-butanamide, N-ethyl- trans-2-cis-6-nonadienamide, N,N-dimethyl menthyl succinamide, N-(2-hydroxyethyl)-2,3- dimethyl-2-isopropylbutanamide, substituted p-menthanes, substituted p-menthane- carboxamides, 2-isopropanyl-5-methylcyclohexanol, menthyl ethylene glycol carbonate, menthone glycerol ketals (e.g., menthone 1,2-glycerol ketal), menthone (S)-lactic acid ketal, menthyl acetoacetate, 3-1-menthoxypropane-1,2-diol, menthyl lactate, eucalyptus extract, menthol propylene glycol carbonate, menthol ethylene glycol carbonate, menthol glyceryl ether, N-tert-butyl-p-menthane-3-carboxamide, p-menthane-3-carboxylic acid glycerol ester, methyl-2-isopropyl-bicyclo[2.2.1]heptane-2-carboxamide, (1R,2S,5R)-N-(4- (carbamoylmethyl)phenyl)-menthylcarboxamide, 2-[2-(p-menthan-3-yloxy)ethoxy]ethanol, (1R,2R,4R)-1-(2-Hydroxy-4-methylcyclohexyl)ethenone, 2-(p-tolyloxy)-N-(1H-pyrazol-5- yl)-N-((thiophen-2-yl)methyl)acetamide, menthol methyl ether, menthyl pyrrolidone carboxylate, 2,5-dimethyl-4-(1-pyrrolidinyl)-3(2H)-furanone, cyclic a-keto enamines, and cyclotene derivatives (e.g., 3-methyl-2-(1-pyrrolidinyl)-2-cyclopenten-1-one and 5-methyl-2- (1-pyrrolidinyl)-2-cyclopenten-1-one). Other compounds include the alpha-keto enamines disclosed in U.S. Pat. No. 6,592,884 to Hofmann et al., which is incorporated in its entirety herein. These and other suitable cooling agents are further described in the following U.S. patents, all of which are incorporated in their entirety by reference hereto: U.S. Pat. No. 4,230,688; 4,032,661; 4,459,425; 4,178,459; 4,296,255; 4,136,163; 5,009,893; 5,266,592; 5,698,181; 6,277,385; 6,627,233; 7,030,273. Still other suitable cooling agents are further described in US Patent Application Publications Nos.2005/0222256 and 2005/0265930, each of which are incorporated in their entirety by reference hereto. In some embodiments, the cooling agent comprises menthol, eucalyptus, mint, menthol, menthyl esters, eucolyptol, WS- 3, WS-23, WS-5, (1R,2S,5R)-N-(4-(cyanomethyl)phenyl)menthylcarboxamide (Evercool^TM 180), (1R,2S,5R)-N-(2-(pyridin-2-yl)ethyl)menthylcarboxamide (Evercool^TM 190), or a combination thereof. [0206] In some embodiments, the composition does not comprise a flavoring agent, and comprises only a cooling agent(s) to provide the desired user experience. In some embodiments, the cooling agent is WS-3, but it will be appreciated that other suitable cooling agents, including other cooling agents disclosed herein, can be used in addition to or in lieu of WS-3 in such embodiments. [0207] In some embodiments, the composition comprises a modulator or sensate which provides to the user of such composition a warming effect. Suitable warming agents include, but are not limited to, ethers of vanillyl alcohol (e.g., methyl, ethyl, n-propyl, isopropyl, n- butyl, isobutyl, isoamyl, n-hexyl), gingerol, shogaol, paradol, zingerone, capsaicin, dihydrocapsaicin, nordihydrocapsaicin, homocapsaicin, homodihydrocapsaicin, benzyl alcohol, and combinations thereof. In some embodiments, the warming agent comprises vanillyl butyl ether, vanillyl ethyl ether, capsaicin, or a combination thereof. [0208] Flavoring agents may be in any suitable form, for example, a liquid such as an oil, or a solid such as a powder or wax. In some instances, the flavoring agent may be provided in a spray-dried form or a liquid form. In some embodiments, a liquid flavorant is disposed (i.e., adsorbed or absorbed in or on) a porous particulate carrier, for example microcrystalline cellulose, which is then combined with the other composition ingredients. [0209] The amount of flavoring agent utilized in the composition can vary, but is typically up to about 10% by weight, and certain embodiments are characterized by a flavoring agent content of at least about 0.1% by weight, such as about 0.5 to about 10%, about 1 to about 5%, or about 2 to about 4% weight, based on the total weight of the composition. Taste modifiers [0210] In order to improve the organoleptic properties of a composition as disclosed herein, the composition may include one or more taste modifying agents ("taste modifiers") which may serve to mask, alter, block, or improve e.g., the flavor of a composition as described herein. Non-limiting examples of such taste modifiers include analgesic or anesthetic herbs, spices, and flavors which produce a perceived cooling (e.g., menthol, eucalyptus, mint), warming (e.g., cinnamon), or painful (e.g., capsaicin) sensation. Certain taste modifiers fall into more than one overlapping category. [0211] In some embodiments, the taste modifier modifies one or more of bitter, sweet, salty, or sour tastes. In some embodiments, the taste modifier targets pain receptors. In some embodiments, the composition comprises an ingredient having a bitter taste, and a taste modifier which masks or blocks the perception of the bitter taste. In some embodiments, the taste modifier is a substance which targets pain receptors (e.g., vanilloid receptors) in the user's mouth to mask e.g., a bitter taste of another component. Suitable taste modifiers include, but are not limited to, capsaicin, gamma-amino butyric acid (GABA), adenosine monophosphate (AMP), lactisole, or a combination thereof. [0212] When present, a representative amount of taste modifier is about 0.01% by weight or more, about 0.1% by weight or more, or about 1.0% by weight or more, but will typically make up less than about 10% by weight of the total weight of the composition, (e.g., from about 0.01%, about 0.05%, about 0.1%, or about 0.5%, to about 1%, about 5%, or about 10% by weight of the total weight of the composition). Salts [0213] In some embodiments, the composition may further comprise a salt (e.g., alkali metal salts), typically employed in an amount sufficient to provide desired sensory attributes to the composition. Non-limiting examples of suitable salts include sodium chloride, potassium chloride, ammonium chloride, flour salt, and the like. [0214] When present, a representative amount of salt is about 0.5 percent by weight or more, about 1.0 percent by weight or more, or at about 1.5 percent by weight or more, but will typically make up about 10 percent or less of the total weight of the composition, or about 7.5 percent or less or about 5 percent or less (e.g., about 0.5 to about 5 percent by weight). Sweeteners [0215] In order to improve the sensory properties of the composition according to the disclosure, one or more sweeteners may be added. The sweeteners can be any sweetener or combination of sweeteners, in natural or artificial form, or as a combination of natural and artificial sweeteners. Examples of natural sweeteners include fructose, sucrose, glucose, maltose, mannose, galactose, lactose, stevia, honey, and the like. Examples of artificial sweeteners include sucralose, isomaltulose, maltodextrin, saccharin, aspartame, acesulfame K, neotame, and the like. In some embodiments, the sweetener comprises one or more sugar alcohols. Sugar alcohols are polyols derived from monosaccharides or disaccharides that have a partially or fully hydrogenated form. Sugar alcohols have, for example, about 4 to about 20 carbon atoms and include erythritol, arabitol, ribitol, isomalt, maltitol, dulcitol, iditol, mannitol, xylitol, lactitol, sorbitol, and combinations thereof (e.g., hydrogenated starch hydrolysates). In some embodiments, the sweetener is sucralose, acesulfame K, or a combination thereof. [0216] When present, a sweetener or combination of sweeteners may make up from about 0.01 to about 20% or more of the of the composition by weight, for example, from about 0.01 to about 0.1, from about 0.1 to about 1%, from about 1 to about 5%, from about 5 to about 10%, or from about 10 to about 20% by weight, based on the total weight of the composition. In some embodiments, a combination of sweeteners is present at a concentration of from about 0.01% to about 0.1% by weight of the composition, such as about 0.01, about 0.02, about 0.03, about 0.04, about 0.05, about 0.06, about 0.07, about 0.08, about 0.09, or about 0.1% by weight of the composition. In some embodiments, a combination of sweeteners is present at a concentration of from about 0.1% to about 0.5% by weight of the composition, such as about 0.1, about 0.2, about 0.3, about 0.4, or about 0.5% by weight of the composition. In some embodiments, a combination of sweeteners is present at a concentration of from about 1% to about 3% by weight of the composition. Composition Binding agents [0217] A binder (or combination of binders) may be employed in certain embodiments. Typical binders can be organic or inorganic, or a combination thereof. Representative binders include povidone, sodium alginate, starch-based binders, pectin, carrageenan, pullulan, zein, and the like, and combinations thereof. A binder may be employed in amounts sufficient to provide the desired physical attributes and physical integrity to the composition. The amount of binder utilized in the composition can vary, but is typically up to about 30 weight percent, and certain embodiments are characterized by a binder content of at least about 0.1% by weight, such as about 1 to about 30% by weight, or about 5 to about 10% by weight, based on the total weight of the composition. [0218] Other suitable binders include a gum, for example, a natural gum. As used herein, a natural gum refers to polysaccharide materials of natural origin that have binding properties, and which are also useful as a thickening or gelling agents. Representative natural gums derived from plants, which are typically water soluble to some degree, include xanthan gum, guar gum, gum arabic, ghatti gum, gum tragacanth, karaya gum, locust bean gum, gellan gum, and combinations thereof. When present, natural gum binder materials are typically present in an amount of up to about 5% by weight, for example, from about 0.1, about 0.2, about 0.3, about 0.4, about 0.5, about 0.6, about 0.7, about 0.8, about 0.9, or about 1%, to about 2, about 3, about 4, or about 5% by weight, based on the total weight of the composition. Humectants [0219] In certain embodiments, one or more humectants may be employed in the composition. Examples of humectants include, but are not limited to, polyols such as glycerin, propylene glycol, and the like. Where included, the humectant is typically provided in an amount sufficient to provide desired moisture attributes to the composition. Further, in some instances, the humectant may impart desirable flow characteristics to the composition for depositing in a mold. [0220] When present, a humectant will typically make up about 5% or less of the weight of the composition (e.g., from about 0.5 to about 5% by weight). When present, a representative amount of humectant is about 0.1% to about 1% by weight, or about 1% to about 5% by weight, based on the total weight of the composition. Buffering agents [0221] In some embodiments, the composition of the present disclosure can comprise buffering agents. Examples of buffering agents that can be used include, but are not limited to, alkali metal buffers such as metal carbonates (e.g., potassium carbonate or sodium carbonate), metal bicarbonates such as sodium bicarbonate, alkali metal citrates, and the like. Non-limiting examples of suitable buffers include alkali or alkaline earth metal (e.g., sodium, potassium, calcium, magnesium) acetates, glycinates, phosphates, glycerophosphates, citrates, carbonates, hydrogen carbonates, borates, and mixtures thereof. In some embodiments, the buffer comprises acetate, phosphate or carbonate, such as an alkali metal acetate, phosphate, or carbonate. In some embodiments, the buffer comprises citrate. In some embodiments, the buffer comprises or is trisodium citrate. In some embodiments, the buffer is a mixture of trisodium citrate and citric acid. In some embodiments, the buffer is a solution of trisodium citrate and citric acid having a pH of about 6.3, such as a solution 0.5 molar in citrate. [0222] When present, the buffering agent is typically present in an amount less than about 5 percent based on the weight of the composition, for example, from about 0.5% to about 5%, such as, e.g., from about 0.75% to about 4%, from about 0.75% to about 3%, or from about 1% to about 2% by weight, based on the total weight of the composition. As described herein above, such buffering agents may be added in a quantity sufficient to provide a specific pH value or range, or to maintain the pH of the composition within a desired range or at a desired value. Colorants [0223] A colorant may be employed in amounts sufficient to provide the desired physical attributes to the composition. Natural or synthetic colorants, such as natural or synthetic dyes, food-grade colorants and pharmaceutical-grade colorants may be used. Examples of colorants include various dyes and pigments, such as caramel coloring and titanium dioxide. Natural colorants such as curcumin, beet juice extract, and spirulina, as well as a variety of synthetic pigments may also be used. The amount of colorant utilized in the composition can vary, but when present is typically up to about 3% by weight, such as from about 0.1%, about 0.5%, or about 1%, to about 3% by weight, based on the total weight of the composition. Oral care additives [0224] In some embodiments, the composition comprises an oral care ingredient (or mixture of such ingredients). Oral care ingredients provide the ability to inhibit tooth decay or loss, inhibit gum disease, relieve mouth pain, whiten teeth, or otherwise inhibit tooth staining, elicit salivary stimulation, inhibit breath malodor, freshen breath, or the like. For example, effective amounts of ingredients such as thyme oil, eucalyptus oil and zinc (e.g., such as the ingredients of formulations commercially available as ZYTEX® from Discus Dental) can be incorporated into the composition. Other examples of ingredients that can be incorporated in desired effective amounts within the present composition can include those that are incorporated within the types of oral care compositions set forth in Takahashi et al., Oral Microbiology and Immunology, 19(1), 61-64 (2004); U.S. Pat. No.6,083,527 to Thistle; and US Pat. Appl. Pub. Nos. 2006/0210488 to Jakubowski and 2006/02228308 to Cummins et al. Other example ingredients include those contained in formulations marketed as MALTISORB® by Roquette and DENTIZYME® by NatraRx. When present, a representative amount of oral care additive is at least about 1%, often at least about 3%, and frequently at least about 5% of the total dry weight of the composition. The amount of oral care additive within the composition will not typically exceed about 30%, often will not exceed about 25%, and frequently will not exceed about 20%, of the total dry weight of the composition. Processing aids [0225] If necessary for downstream processing of the composition, such as granulation, mixing, or molding, a flow aid can also be added to the composition in order to enhance flowability of the composition. In some embodiments, the composition (e.g., melt and chew forms) may be surface treated with anti-stick agents, such as oils, silicones, and the like. Example flow aids include microcrystalline cellulose, silica, silicified microcrystalline cellulose, polyethylene glycol, stearic acid, calcium stearate, magnesium stearate, zinc stearate, sodium stearyl fumarate, carnauba wax, and combinations thereof. In some embodiments, the flow aid is sodium stearyl fumarate. In some embodiments, the composition comprises silicified microcrystalline cellulose as a flow aid and/or to enhance compressibility for tableting. Silicified microcrystalline cellulose is a combination of microcrystalline cellulose and colloidal silicon dioxide, commercially available as PROSOLV^® SMCC from JRS Pharma. [0226] When present, a representative amount of flow aid may make up at least about 0.5 percent or at least about 1 percent, of the total dry weight of the composition. Typically, the amount of flow aid within the composition will not exceed about 5 percent, and frequently will not exceed about 3 percent, of the total dry weight of the composition. Lipids [0227] The composition can contain a lipid component, such as, for example, a fat, oil, or wax substance (or combination thereof). The lipid components used in the composition can be derived from animal or plant material and typically comprise mostly triglycerides along with lesser amounts of free fatty acids and mono- or di-glycerides. In certain embodiments, the lipid is a plant-derived fat material that is solid or semi-solid at room temperature (i.e., at about 25° C.) and which at least partially liquefies when subjected to the temperature of the oral cavity of the user. Such plant-derived fats are comprised primarily of saturated or unsaturated fatty acid chains (most of which are bound within triglyceride structures) having a carbon length of about 10 to about 26 carbon atoms, more typically about 14 to about 20 carbon atoms, and most often about 14 to about 18 carbon atoms. Example fats that can be used include palm oil, palm kernel oil, soybean oil, cottonseed oil, and mixtures thereof. According to some aspects, the lipid substance may be hydrogenated, partially hydrogenated, or non-hydrogenated. In some instances, the lipid substance may include a blend of lipid components. For example, the lipid substance may include a blend of palm oil and palm kernel oil. [0228] A variety of methods exist for determining the melting point of lipids. However, many naturally occurring lipids are not chemically homogenous and, therefore, do not have a true single melting point, i.e., the temperature of transition from the solid to the liquid state. Thus, lipids are sometimes characterized by a melting range. One test for determining the melting point of lipids is the Mettler dropping point method (ASTM Standard D3954, 2010, "Standard Test Method for Dropping Point of Waxes," ASTM International, West Conshohocken Pa., 2003, DOI 10.1520/D3954-94R10, www.astm.org.). Melting temperatures for lipids described herein, or products containing such lipids, refer to melting temperature points or ranges determined based on the Mettler dropping point method, unless otherwise specified. [0229] The melting point of the lipid component may be chosen so that the resulting composition has a melting point in an appropriate range to provide the desired melting characteristics when the product is placed in the oral cavity of the user. In some embodiments, it may be desirable to use a lipid with a higher melting point so that the final product remains substantially solid in the oral cavity during use, meaning the user must chew the product in order to break the product into smaller pieces. In other embodiments, a lower melting point can be selected such that the final product readily melts in the mouth of the user during use. Typically, the melting point of the lipid component will be about 29° C to about 49° C, often about 36° C to about 45° C, and most often about 38° C to about 41° C. In certain embodiments, the melting point of the product made using the lipid component will also have a melting point within the above ranges. [0230] Lipid substances capable of use pursuant to the present disclosure are available from, for example, Loders Croklaan and AarhusKarlshamn USA Inc. Example lipid substances include 108-24-B from AarhusKarlshamn USA Inc. (a non-hydrogenated lauric coating fat containing a blend of palm kernel oil and palm oil); PARAMOUNT X from Loders Croklaan (a partially hydrogenated vegetable oil containing a blend of palm kernel oil, soybean oil, and cottonseed oil); CENTERNAL 625 from Loders Croklaan (a vegetable fat); PARAMOUNT C from Loders Croklaan (a lauric coating fat containing partially hydrogenated palm kernel oil with lecithin); KAOKOTE 102 from Loders Croklaan (a lauric coating fat containing partially hydrogenated palm kernel oil); SILKO 35-08 from AarhusKarlshamn USA Inc. (an interesterified hydrogenated lauric fat containing palm kernel oil); CEBES 27-70 from AarhusKarlshamn USA Inc. (a fractionated lauric cocoa butter substitute containing hydrogenated palm kernel oil); CISAO 82-53 from AarhusKarlshamn USA Inc. (a non- hydrogenated palm oil); CEBES 29-21 from AarhusKarlshamn USA Inc. (a fractionated cocoa butter substitute containing palm kernel oil and palm oil); CEBES 27-55 from AarhusKarlshamn USA Inc. (a lauric based fat containing partially hydrogenated palm kernel oil and hydrogenated soybean oil); 108-48-B from AarhusKarlshamn USA Inc. (a non- hydrogenated lauric fat which is a blend of palm kernel oil and palm oil); CEBES 29-07 from AarhusKarlshamn USA Inc. (a fractionated non-hydrogenated cocoa butter substitute); CEBES 21-20 from AarhusKarlshamn USA Inc. (a fractionated lauric cocoa butter substitute); CEBES 29-07 from AarhusKarlshamn USA Inc. (a fractionated lauric cocoa butter substitute); and CISAO 78-33 from AarhusKarlshamn USA Inc. (a non-hydrogenated structuring fat). [0231] The relative amount of lipid substance within the composition may vary. In some embodiments, the amount of lipid substance within the composition is at least about 10 percent, at least about 20 percent, or at least about 30 percent, on a dry weight basis of the composition. In some embodiments, the amount of lipid material is less than about 60 percent, less than about 50 percent, or less than about 40 weight percent, on a dry weight basis. Example lipid weight ranges include about 10 to about 60 dry weight percent, more typically about 20 to about 40 dry weight percent. Other additives [0232] Other additives can be included in the disclosed composition. For example, the composition can be processed, blended, formulated, combined and/or mixed with other materials or ingredients. The additives can be artificial or can be obtained or derived from herbal or biological sources. Examples of further types of additives include thickening or gelling agents (e.g., fish gelatin), emulsifiers, preservatives, antioxidants, disintegration aids, or combinations thereof. See, for example, those representative components, combination of components, relative amounts of those components, and manners and methods for employing those components, set forth in US Pat. No. 9,237,769 to Mua et al., US Pat. No. 7,861,728 to Holton, Jr. et al., US Pat. App. Pub. No. 2010/0291245 to Gao et al., and US Pat. App. Pub. No.2007/0062549 to Holton, Jr. et al., each of which is incorporated herein by reference. [0233] In some embodiments, the composition comprises one or more antioxidants, one or more preservatives, one or more antimicrobial agents, or combinations thereof. Suitable antioxidants and preservatives include, but are not limited to, ascorbic acid (Vitamin C), sodium ascorbate, ascorbyl palmitate, butylated hydroxytoluene (BHT), butylated hydroxyanisole (BHA), tertiary butylhydroquinone (TBHQ), methyl paraben, propyl paraben, sodium propionate, potassium sorbate, sodium benzoate, propyl gallate, monosterol citrate, Vitamin E, derivatives of vitamin E, tocopherols, and combinations thereof. [0234] Typical inclusion ranges for such additional additives can vary depending on the nature and function of the additive and the intended effect on the final composition, with an example range of up to about 10% by weight, based on total weight of the composition (e.g., about 0.1 to about 5% by weight). [0235] The aforementioned additives can be employed together (e.g., as additive formulations) or separately (e.g., individual additive components can be added at different stages involved in the preparation of the final mixture). Furthermore, the aforementioned types of additives may be encapsulated as provided in the final product or composition. Example encapsulated additives are described, for example, in WO2010/132444 to Atchley, which has been previously incorporated by reference herein. Configured for Oral Use [0236] Provided herein are compositions configured for oral use. The term "configured for oral use" as used herein means that the composition or product including such composition is provided in a form such that during use, saliva in the mouth of the user causes one or more of the releasable components of the composition (e.g., flavoring agents and/or substituted 3-(1- methylpyrrolidin-2-yl)pyridine, optionally substituted 3-(azetidin-2-yl)pyridine, optionally 3- (azetidin-2-ylmethoxy)pyridine), or other active ingredient to pass into the mouth of the user. In some embodiments, the composition or product is adapted to deliver components to a user through mucous membranes in the user's mouth and, in some instances, said component is a flavoring agent and/or a substituted 3-(1-methylpyrrolidin-2-yl)pyridine, optionally substituted 3-(azetidin-2-yl)pyridine, optionally 3-(azetidin-2-ylmethoxy)pyridine, or other active ingredient as described herein that can be absorbed through the mucous membranes in the mouth when the composition or product is used. [0237] In some embodiments, the composition or product including such composition could have the potential to be used as an aid in smoking cessation, as a nicotine replacement therapy, and/or the treatment of nicotine addiction. [0238] Products configured for oral use as described herein may take various forms, including gels, pastilles, gums, lozenges, powders, and pouches. Certain products of the disclosure are in the form of solids. Certain products can exhibit, for example, one or more of the following characteristics: crispy, granular, chewy, syrupy, pasty, fluffy, smooth, and/or creamy. In some embodiments, the desired textural property can be selected from the group consisting of adhesiveness, cohesiveness, density, dryness, fracturability, graininess, gumminess, hardness, heaviness, moisture absorption, moisture release, mouthcoating, roughness, slipperiness, smoothness, viscosity, wetness, and combinations thereof. [0239] Any of the product formats disclosed herein may also be made into effervescing products by incorporating an effervescent material capable of causing effervescence in the oral cavity into the composition. Suitable effervescent materials may comprise an acid component and a base component, wherein the base component is a carbonate material, a bicarbonate material, or a mixture thereof, and the acid component is a tricarboxylic acid, a dicarboxylic acid, a monocarboxylic acid, or a combination thereof. Alternatively, suitable effervescent materials include those comprising a sugar material containing an entrapped gaseous component, such that release of the entrapped gaseous component occurs upon dissolution of the sugar material in the oral cavity. [0240] The compositions as disclosed herein can be formed into a variety of shapes, including pills, tablets, spheres, strips, films, sheets, coins, cubes, beads, ovoids, obloids, cylinders, bean- shaped, sticks, or rods. Cross-sectional shapes of the composition can vary, and example cross- sectional shapes include circles, squares, ovals, rectangles, and the like. [0241] The compositions of the present disclosure may be at least partially dissolvable. As used herein, the terms "dissolve," "dissolving," and "dissolvable" refer to compositions having aqueous-soluble components that interact with moisture in the oral cavity and enter into solution, thereby causing gradual consumption of the composition. In some embodiments, the dissolvable composition is capable of lasting in the user’s mouth for a given period of time until it completely dissolves. Dissolution rates can vary over a wide range, from about 1 minute or less to about 60 minutes. For example, fast release compositions typically dissolve and/or release the substituted 3-(1-methylpyrrolidin-2-yl)pyridine, optionally substituted 3-(azetidin- 2-yl)pyridine, optionally 3-(azetidin-2-ylmethoxy)pyridine, or other active ingredient in about 2 minutes or less, often about 1 minute or less (e.g., about 50 seconds or less, about 40 seconds or less, about 30 seconds or less, or about 20 seconds or less). Dissolution can occur by any means, such as melting, mechanical disruption (e.g., chewing), enzymatic or other chemical degradation, or by disruption of the interaction between the components of the composition. [0242] In some embodiments, the composition can be meltable as discussed, for example, in US Patent App. Pub. No.2012/0037175 to Cantrell et al., incorporated by reference herein in its entirety. As used herein, “melt,” “melting,” and “meltable” refer to the ability of the composition to change from a solid state to a liquid state. That is, melting occurs when a substance (e.g., a composition as disclosed herein) changes from solid to liquid, usually by the application of heat. The application of heat in regard to a composition as disclosed herein is provided by the internal temperature of a user's mouth. Thus, the term “meltable” refers to a composition that is capable of liquefying in the mouth of the user as the composition changes phase from solid to liquid, and is intended to distinguish compositions that merely disintegrate in the oral cavity through loss of cohesiveness within the composition that merely dissolve in the oral cavity as aqueous-soluble components of the composition interact with moisture. Generally, meltable compositions comprise a lipid as described herein above. In some embodiments, the composition in meltable form comprises a lipid in an amount of from about 35 to about 50% by weight, based on the total weight of the composition, and a sugar alcohol in an amount of from about 35 to about 55% by weight, based on the total weight of the composition. In some embodiments, the sugar alcohol is isomalt, erythritol, sorbitol, arabitol, ribitol, maltitol, dulcitol, iditol, mannitol, xylitol, lactitol, or a combination thereof. In some embodiments, the sugar alcohol is isomalt. [0243] In some embodiments, the composition is in the form of a compressed or molded pellet or tablet. Such pellets or tablets generally comprise at least one filler, at least one sugar alcohol, and may further include flavorants, binders, salts, sweeteners, buffering agents, colorants, humectants, oral care additives, preservatives, disintegration aids, flow aids, compressibility aids, or combinations thereof, each as described herein above. Generally, the composition in tablet form comprises a glucose-polysaccharide blend and a sugar alcohol. In some embodiments, the glucose-polysaccharide blend is present in an amount of from about 35 to about 50% by weight, based on the total weight of the composition; and the sugar alcohol is present in an amount of from about 30 to about 45% by weight, based on the total weight of the composition. Example pellet weights range from about 250 mg to about 1500 mg, such as about 250 mg to about 700 mg, or from about 700 mg to about 1500 mg. The pellet can have any of a variety of shapes, including traditional pill or tablet shapes. [0244] In some embodiments, the composition can be chewable, meaning the composition has a mild resilience or "bounce" upon chewing, and possesses a desirable degree of malleability. A composition in chewable form may be entirely dissolving or may be in the form of a non- dissolving gum in which only certain components (e.g., active ingredients, flavor, sweetener) dissolve, leaving behind a non-dissolving matrix. Chewable embodiments generally include a binder, such as a natural gum or pectin. In some embodiments, the composition in chewable form comprises pectin and an organic acid, along with one or more sugar alcohols in an amount by weight of at least 50%, based on the total weight of the composition. Generally, the pectin is present in an amount of from about 1 to about 3% by weight, based on the total weight of the composition. [0245] In some embodiments, the composition is in the form of a gum, such as a chewing gum. Chewing gum compositions generally comprise a gum base and one or more fillers, and may further comprise emulsifiers, flavoring agents, salts, sweeteners, humectants, binders, buffering agents, colorants, humectants, oral care additives, preservatives, or combinations thereof, each as described herein above. By the term "gum base" is meant the generally water- insoluble and hydrophobic ingredients that provide the desired texture to the gum. The chewing gum may comprise the gum base in an amount from about 5 to about 95 percent by weight. Generally, the gum base comprises an elastomer. Elastomers provide the rubbery, cohesive nature to the gum base and the overall chewing gum. Elastomers suitable for use in the gum base of the present disclosure may include natural, synthetic, or a combination thereof. Non- limiting examples of suitable natural elastomers include latex, chicle, crown gum, nispero, rosidinha, jelutong, perillo, niger gutta, tunu, balata, guttapercha, lechi caspi, sorva, gutta kay, massaranduba balata, massaranduba chocolate, nispero, rosindinha, gutta hang kang, chiquibul, pendare, leche de vaca, tunu, chilte, and mixtures thereof. Non-limiting examples of suitable synthetic elastomers include styrene-butadiene copolymers (SBR), polyisobutylene, isobutylene-isoprene copolymers, polyethylene, polyvinyl acetate, biodegradable polymers, and mixtures thereof. Further examples of synthetic elastomers include, but are not limited to, synthetic elastomers listed in Food and Drug Administration, CFR, Title 21, Section 172,615, the Masticatory Substances, Synthetic. [0246] Suitable bulking agents include sweeteners such as sugars, sugar alcohols, and combinations thereof. [0247] Gum bases, and particularly synthetic elastomer-based gum bases, may further comprise one or more of fillers, plasticizers, softeners, emulsifiers, waxes, anti-tacking agents, and further miscellaneous components such as antioxidants, colorants, flavoring agents, buffers, and the like. Suitable fillers include, but are not limited to, magnesium carbonate, calcium carbonate, ground limestone, silicates, such as magnesium and aluminum silicate, clay, alumina, talc, titanium oxide, mono-, di- and tri-calcium phosphate, cellulose polymers, and combinations thereof. In particular embodiments, the filler is calcium carbonate, talc, or a combination thereof. In one particular embodiment, the filler is talc. Suitable plasticizers include natural resins, synthetic resins, waxes, and combinations thereof. Suitable emulsifiers and/or softeners include, but are not limited to, tallow, hydrogenated tallow, hydrogenated and partially hydrogenated vegetable oils, cocoa butter, glycerol monostearate, glycerol acetate, glycerol diacetate (diacetin) glycerol triacetate (triacetin), lecithin, mono-, di- and triglycerides, acetylated monoglycerides, fatty acids (e.g., stearic, palmitic, oleic and linoleic acids), sorbitan fatty acid esters, lanolin, and combinations thereof. [0248] In some embodiments, the composition may be in the form of a dissolvable and lightly chewable pastille. As used herein, the term "pastille" refers to a dissolvable oral product made by solidifying a liquid or gel composition, such as a composition that includes a gelling or binding agent, so that the final product is a hardened solid gel. A pastille product may alternatively be referred to as a soft lozenge. In some embodiments, the pastille products of the disclosure are characterized by sufficient cohesiveness to withstand light chewing action in the oral cavity without rapidly disintegrating. The pastille products of the disclosure typically do not exhibit a highly deformable chewing quality as found in conventional chewing gum. See, for example, the pastille formulations, pastille configurations, pastille characteristics and techniques for formulating or manufacturing pastilles set forth in US Pat. Nos. 9,204,667 to Cantrell et al.; 9,775,376 to Cantrell et al.; 10,357,054 to Marshall et al.; which are incorporated herein by reference. [0249] In some embodiments, the products disclosed herein may be in the form of a dissolvable lozenge product configured for oral use. Lozenge products are generally described as "hard" and are distinguished in this manner from soft lozenges (i.e., pastilles). Example lozenge-type products have the form of a lozenge, tablet, microtab, or other tablet-type product. See, for example, the types of nicotine-containing lozenges, lozenge formulations, lozenge formats and configurations, lozenge characteristics and techniques for formulating or manufacturing lozenges set forth in US Pat. Nos.4,967,773 to Shaw; 5,110,605 to Acharya; 5,733,574 to Dam; 6,280,761 to Santus; 6,676,959 to Andersson et al.; 6,248,760 to Wilhelmsen; and 7,374,779; US Pat. Pub. Nos.2001/0016593 to Wilhelmsen; 2004/0101543 to Liu et al.; 2006/0120974 to Mcneight; 2008/0020050 to Chau et al.; 2009/0081291 to Gin et al.; and 2010/0004294 to Axelsson et al.; which are incorporated herein by reference. [0250] In some embodiments, the products disclosed herein may be in the form of a transparent or translucent lozenge. Transparency/ translucency can be determined by any means commonly used in the art; however, it is commonly measured by spectrophotometric light transmission over a range of wavelengths (e.g., from about 400-700 nm). Transmission measurements for such transparent or translucent lozenge products are typically higher than those of traditional (i.e., non-translucent) products. Translucency can also be confirmed by visual inspection by simply holding the product up to a light source and determining if light travels through the product in a diffuse manner. Translucent lozenge products generally comprise as the lozenge base a sugar substitute in an amount of at least about 80% by weight, and a sugar alcohol syrup. The amount and type of the sugar substitute can vary. In some embodiments, the sugar substitute is a non-hygroscopic sugar alcohol capable of forming a glassy matrix. For example, in some embodiments, the sugar substitute is isomalt. In some embodiments, the sugar substitute is present in an amount of at least about 85% by weight or at least about 90% by weight. In some embodiments, the sugar alcohol syrup is maltitol syrup. Although sugar alcohol syrups may be preferred, sugar syrups can, in some embodiments, be used in place of or in combination with the sugar alcohol syrup. For example, in some embodiments, corn syrup, golden syrup, and/or molasses can be used. [0251] In some embodiments, the products disclosed herein may be in the form of a film, such as an edible or dissolving film. Such films generally comprise a mixture of one or more fillers, emulsifiers, gelling agents, and binders to provide the desired film format, along with additional components such as buffers, humectants, salts, sweeteners, and the like. In some embodiments, the composition can be chewable, meaning the composition has a mild resilience or "bounce" upon chewing, and possesses a desirable degree of malleability. A composition in chewable form may be entirely dissolving or may be in the form of a non-dissolving gum in which only certain components (e.g., substituted 3-(1-methylpyrrolidin-2-yl)pyridine, optionally substituted 3-(azetidin-2-yl)pyridine, optionally 3-(azetidin-2-ylmethoxy)pyridine, or other active ingredient, flavor, sweetener) dissolve, leaving behind a non-dissolving matrix. [0252] In some embodiments, the composition can be meltable as discussed, for example, in US Patent App. Pub. No. 2012/0037175 to Cantrell et al., incorporated by reference herein in its entirety. As used herein, "melt," "melting," and "meltable" refer to the ability of the composition to change from a solid state to a liquid state. That is, melting occurs when a substance (e.g., a composition as disclosed herein) changes from solid to liquid, usually by the application of heat. The application of heat in regard to a composition as disclosed herein is provided by the internal temperature of a user's mouth. Thus, the term "meltable" refers to a composition that is capable of liquefying in the mouth of the user as the composition changes phase from solid to liquid and is intended to distinguish compositions that merely disintegrate in the oral cavity through loss of cohesiveness within the composition that merely dissolve in the oral cavity as aqueous-soluble components of the composition interact with moisture. [0253] Certain types of products disclosed herein (e.g., lozenges, tablets, and the like) also can have outer coatings composed of ingredients capable of providing acceptable outer coatings (e.g., an outer coating can be composed of ingredients such as carnauba wax, and pharmaceutically acceptable forms of shellacs, glazing compositions and surface polish agents). Application of a coating can be accomplished using techniques such as airless spraying, fluidized bed coating, use of a coating pan, or the like. Materials for use as a coating can be polymeric in nature, such as cellulosic material (e.g., cellulose butyrate phthalate, hydroxypropyl methylcellulose phthalate, and carboxymethyl ethylcellulose), and polymers and copolymers of acrylic acid, methacrylic acid, and esters thereof. [0254] Compositions can be co-extruded, laminated or formed so as to form products having sandwich-type forms, and hence the location of ingredients (e.g., substituted 3-(1- methylpyrrolidin-2-yl)pyridine, optionally substituted 3-(azetidin-2-yl)pyridine, optionally 3- (azetidin-2-ylmethoxy)pyridine), or other active ingredient can be controlled in order to provide the desired features such as performance, behavior, interaction or non-interaction with other ingredients, storage stability, and the like. In addition, mixtures of component ingredients can be formulated and manufactured into core/shell types of configurations (e.g., products that have an inner region and at least one additional overlayer), with the various regions of such products having differing overall compositions or properties. Thus, for example, the substituted 3-(1-methylpyrrolidin-2-yl)pyridine, optionally substituted 3-(azetidin-2-yl)pyridine, optionally 3-(azetidin-2-ylmethoxy)pyridine, or other active ingredient can have a relatively high concentration towards the inner region of the product, or a relatively high concentration towards the outer region of the product. Other configurations are contemplated herein, such as multi-layered compositions comprising two or more formulations having different organoleptic properties. Non-limiting embodiments of multi-layer compositions include but are not limited to lozenge/meltable, lozenge/chewable, lozenge/hard coating, meltable/lozenge, meltable/hard coating, molded/meltable, molded/lozenge, lozenge /meltable /hard coating, and molded/lozenge/meltable. In some embodiments, the composition is a core formulation surrounded by one or more continuous layers or a core formulation coated by one or more discontinuous (e.g., partial) layers so as to form a layered or side-by-side configuration of the two or more formulations. The number of layers can vary; for example, the multi-layered composition can in some embodiments comprise between two and ten layers, such as between two and five layers. Such layered or core-shell embodiments can be formed into a desired format (e.g., tablet, lozenge, pastille, gum, film, etc.) by pouring or otherwise introducing a first mixture into a mold, injection molding a first mixture, or other using other suitable means for providing a formulation. In some embodiments, a second mixture can be applied by spray coating, dip coating, or by forming the second mixture into a sheet that is applied to the first mixture as a sandwiched coating. Spray coating or dip coating can be conducted at a temperature such that the first mixture is maintained in substantially intact form. In some embodiments, a third mixture is applied as a coating on the second mixture. The various mixtures utilized for the layers or core and shell may vary in terms of physical properties (hardness, meltability, chewiness, dissolvability, and the like), flavor, presence or absence of substituted 3-(1-methylpyrrolidin-2-yl)pyridine, optionally substituted 3-(azetidin-2- yl)pyridine, optionally 3-(azetidin-2-ylmethoxy)pyridine, or other active ingredient, concentration of substituted 3-(1-methylpyrrolidin-2-yl)pyridine, optionally substituted 3- (azetidin-2-yl)pyridine, optionally 3-(azetidin-2-ylmethoxy)pyridine, or other active ingredient, or combinations thereof. [0255] In some embodiments, the composition of the present disclosure is disposed within a moisture-permeable container (e.g., a water-permeable pouch) to form a pouched oral product. Such pouched products are typically used by placing one pouch containing the composition in the mouth of a human subject/user. Generally, the pouch is placed somewhere in the oral cavity of the user, for example between lips and gums, in the same way as moist snuff products are generally used. Exposure to saliva then causes some of the components of the composition therein (e.g., flavoring agents and/or nicotine) to pass through e.g., the water-permeable pouch and provide the user with flavor and satisfaction, and the user is not required to spit out any portion of the composition. After about 10 minutes to about 60 minutes, typically about 15 minutes to about 45 minutes of use/enjoyment, substantial amounts of the composition have been absorbed by the human subject, and the pouch may be removed from the mouth of the human subject for disposal. The pouch generally is not chewed and the pouch is not swallowed, nor is the pouch intended for ingestion. In other words, certain components present in the composition (e.g., flavoring agents and/or substituted 3-(1-methylpyrrolidin-2-yl)pyridine, optionally substituted 3-(azetidin-2-yl)pyridine, optionally 3-(azetidin-2-ylmethoxy)pyridine), or other active ingredient are consumed during use of the pouched product, but the pouch itself is not ingested (unless the pouch is a dissolving pouch as described further herein below). [0256] Accordingly, in some embodiments, the composition as disclosed herein, and any other components noted above, are combined within a moisture-permeable packet or pouch that acts as a container for use of the composition to provide a pouched product configured for oral use. Some embodiments of the disclosure may be described with reference to FIG. 1, which provides an illustration of an example pouched product. Referring to FIG.1, there is shown an embodiment of a pouched product 100. The pouched product 100 includes a moisture- permeable container in the form of a pouch 102 housing a material 104 comprising the oral composition described herein. [0257] An example pouch 102 can be constructed of a fleece material, which is a fibrous material that can be formed from various types of fibers (e.g., conventional cellulosic fibers (e.g., such as viscose fibers, regenerated cellulose fibers, cellulose fibers, and wood pulps), cotton fibers, wool fibers, other natural fibers, polymer/synthetic-type fibers, and combinations thereof) capable of being formed into a fabric. For example, fleece materials may be provided in the form of a woven or nonwoven fabric. Suitable types of fleece materials, for example, are described in U.S. Patent No. 8,931,493 to Sebastian et al.; US Patent App. Pub. No. 2016/0000140 to Sebastian et al.; and US Patent App. Pub. No.2016/0073689 to Sebastian et al., which are all incorporated herein by reference. [0258] An example pouch may be manufactured from materials, and in such a manner, such that during use by the user, the pouch undergoes a controlled dispersion or dissolution. Such pouch materials may have the form of a mesh, screen, perforated paper, permeable fabric, or the like. For example, pouch material manufactured from a mesh-like form of rice paper, or perforated rice paper, may dissolve in the mouth of the user. As a result, the pouch and composition each may undergo complete dispersion within the mouth of the user during normal conditions of use, and hence the pouch and composition both may be consumed by the user. Other examples of pouch materials may be manufactured using water dispersible film forming materials (e.g., binding agents such as alginates, carboxymethylcellulose, xanthan gum, pullulan, and the like), as well as those materials in combination with materials such as ground cellulosics (e.g., fine particle size wood pulp). If desired, flavoring ingredients, disintegration aids, and other desired components, may be incorporated within, or applied to, the pouch material. [0259] The amount of material contained within each product unit, for example, a pouch, may vary. In some embodiments, the dry weight of the composition within each pouch is at least about 50 mg, for example, from about 50 mg to about 1.3 grams, from about 100 to 800 about mg, from about 200 to about 750 mg, or from about 700 to about 1330 mg. In some embodiments, the product is a small pouch, and the dry weight of the composition within each pouch may be from about 100 to about 300 mg. In some embodiments, the product is a large pouch, and the dry weight of the material within each pouch may be from about 700 mg to about 1.3 grams. [0260] If desired, other components can be contained within each pouch. For example, at least one flavored strip, piece or sheet of flavored water dispersible or water-soluble material (e.g., a breath-freshening edible film type of material) may be disposed within each pouch. Such strips or sheets may be folded or crumpled in order to be readily incorporated within the pouch. See, for example, the types of materials and technologies set forth in US Pat. Nos. 6,887,307 to Scott et al. and 6,923,981 to Leung et al.; and The EFSA Journal (2004) 85, 1-32; which are incorporated herein by reference. [0261] In some embodiments, the pouch may include one or more capsules, such as microcapsules. In some embodiments, the capsule(s) include at least a portion of the substituted 3-(1-methylpyrrolidin-2-yl)pyridine, optionally substituted 3-(azetidin-2-yl)pyridine, optionally 3-(azetidin-2-ylmethoxy)pyridine, or other active ingredient. The capsule can comprise a capsule wall that is formed of a material that is configured to allow for dispersal of the contents under desired conditions. For example, the capsule wall may comprise a material that is configured to dissolve or otherwise degrade under mouth conditions. As another non- limiting example, the capsule wall may comprise a material that is configured to be broken or otherwise degraded by shear forces (e.g., chewing). While suitable encapsulated materials may be described herein in relation to microcapsules, it is understood that such terminology is not intended to be viewed as limiting of the capsule sizes. [0262] The crush strength of suitable capsules can be sufficient to allow for normal handling and storage without significant degree of premature or undesirable breakage. Providing capsules that possess both suitable integrity during storage and the ability to rupture or otherwise break down at the time of use can be determined by experimentation, depending upon factors such as capsule size and type, and is a matter of design choice. See, for example, U.S. Pat. Pub. No.2007/0068540 to Thomas et al., which is incorporated herein by reference. [0263] In some embodiments, the capsule may include an outer shell incorporating a material such as wax, gelatin, cyclodextrin, or alginate, and an inner payload. In some embodiments, the inner payload (e.g., a substituted 3-(1-methylpyrrolidin-2-yl)pyridine, optionally substituted 3-(azetidin-2-yl)pyridine, optionally 3-(azetidin-2-ylmethoxy)pyridine), or other active ingredient is in particulate form or is present as an aqueous or non-aqueous solution or dispersion within water or an organic liquid such as an alcohol, oil, glycerin or combination thereof). Thus, for example, a plurality of such capsules may be incorporated within the pouch along with the composition to be retained therein, and during use of the product, a crushing or other destruction of the capsules allows the capsules to release the payload contained therein. [0264] The capsules may be uniform or varied in size, weight, and shape. A representative capsule can be generally spherical in shape. However, suitable capsules may have other types of shapes, such as generally rectilinear, oblong, elliptical, or oval shapes. In some embodiments, microcapsules may have diameters of less than about 100 microns, such as microcapsules having diameters in the range of about 1 to about 40 microns, or about 1 micron to about 20 microns. [0265] In some embodiments, larger capsules may be utilized. For example, a capsule utilized in the pouch product may have a size of about 0.5 mm to about 5 mm or about 0.6 mm to about 3 mm in diameter. [0266] The number of capsules incorporated into the pouched product can vary, depending upon factors such as the size of the capsules, the character or nature of the payload, the desired attributes of the composition within the pouch, and the like. In some embodiments, only a single capsule is included. The single capsule can be relatively large in size. In some embodiments, a plurality of capsules may be included. and may be positioned within the pouch fabric along with the composition. The plurality of capsules may be relatively small in size. In particular, microcapsules may be used. The number of capsules incorporated within pouched product, for example, can exceed about 5, can exceed about 10, can exceed about 20, can exceed about 40, and can even exceed about 100. In certain embodiments, the number of capsules/microcapsules can be greater than about 500, and even greater than about 1,000. [0267] The total weight of the capsules contained within the product may vary, but is typically greater than about 10 mg, often greater than about 20 mg, and can be greater than about 30 mg. The total weight of the capsules is typically less than about 200 mg, often less than about 100 mg, and can be less than about 50 mg. [0268] The capsules can be formed using any encapsulating technology known in the art. For example, microcapsules can be formed using any of various chemical encapsulation techniques such as solvent evaporation, solvent extraction, organic phase separation, interfacial polymerization, simple and complex coacervation, in-situ polymerization, liposome encapsulation, and nanoencapsulation. Alternatively, physical methods of encapsulation could be used, such as spray coating, pan coating, fluid bed coating, annular jet coating, spinning disk atomization, spray cooling, spray drying, spray chilling, stationary nozzle coextrusion, centrifugal head coextrusion, or submerged nozzle coextrusion. [0269] Regardless of the encapsulation methodology employed, the outer wall or shell material and solvents used to form the capsules can vary. Classes of materials that are typically used as wall or shell materials include proteins, polysaccharides, starches, waxes, fats, natural and synthetic polymers, and resins. Exemplary materials for use in the microencapsulation process used to form the microcapsules include gelatin, acacia (gum arabic), polyvinyl acetate, potassium alginate, carob bean gum, potassium citrate, carrageenan, potassium polymetaphosphate, citric acid, potassium tripolyphosphate, dextrin, polyvinyl alcohol, povidone, dimethylpolysiloxane, dimethyl silicone, refined paraffin wax, ethylcellulose, bleached shellac, modified food starch, sodium alginate, guar gum, sodium carboxymethylcellulose, hydroxypropyl cellulose, sodium citrate, hydroxypropylmethylcellulose, sodium ferrocyanide, sodium polyphosphates, locust bean gum, methylcellulose, sodium trimetaphosphate, methyl ethyl cellulose, sodium tripolyphosphate, microcrystalline wax, tannic acid, petroleum wax, terpene resin, tragacanth, polyethylene, xanthan gum, and polyethylene glycol. [0270] Microcapsules are commercially available, and exemplary types of microcapsule technologies are of the type set forth in Gutcho, Microcapsules and Microencapsulation Techniques (1976); Gutcho, Microcapsules and Other Capsules Advances Since 1975 (1979); Kondo, Microcapsule Processing and Technology (1979); Iwamoto et al., AAPS Pharm. Sci. Tech. 20023(3): article 25; U.S. Pat. No. 3,550,598 to McGlumphy; U.S. Pat. No. 4,889,144 to Tateno et al.; U.S. Pat. No.5,004,595 to Cherukuri et al.; U.S. Pat. No.5,690,990 to Bonner; U.S. Pat. No. 5,759,599 to Wampler et al.; U.S. Pat. No. 6,039,901 to Soper et al.; U.S. Pat. No.6,045,835 to Soper et al.; U.S. Pat. No.6,056,992 to Lew; U.S. Pat. No.6,106,875 to Soper et al.; U.S. Pat. No.6,117,455 to Takada et al.; U.S. Pat. No.6,325,859 to DeRoos et al.; U.S. Pat. No. 6,482,433 to DeRoos et al.; U.S. Pat. No. 6,612,429 to Dennen; and U.S. Pat. No. 6,929,814 to Bouwmeesters et al.; U.S. Pat. Appl. Pub. Nos.2006/0174901 to Karles et al. and 2007/0095357 to Besso et al.; and PCT WO2007/037962 to Holton et al.; each of which is incorporated herein by reference. Suitable types of microcapsules are available from sources such as Microtek Laboratories of Dayton, Ohio. Exemplary types of commercially available microencapsulating techniques include those marketed under the trade names ULTRASEAL™ and PERMASEAL™ available from Givaudan headquartered in Vernier, Switzerland. [0271] Representative types of capsules are of the type commercially available as “Momints” by Yosha! Enterprises, Inc. and “Ice Breakers Liquid Ice” from The Hershey Company. Representative types of capsules also have been incorporated in chewing gum, such as the type of gum marketed under the tradename “Cinnaburst” by Cadbury Adams USA. Representative types of capsules and components thereof also are set forth in U.S. Pat. No. 3,339,558 to Waterbury; U.S. Pat. No. 3,390,686 to Irby, Jr. et al.; U.S. Pat. No. 3,685,521 to Dock; U.S. Pat. No. 3,916,914 to Brooks et al.; U.S. Pat. No. 4,889,144 to Tateno et al. U.S. Pat. No. 6,631,722 to MacAdam et al.; and U.S. Pat. No. 7,115,085 to Deal; US Pat. Pub. Nos. 2004/0261807 to Dube et al.; 2006/0272663 to Dube et al.; 2006/01330961 to Luan et al.; 2006/0144412 to Mishra et al.; 2007/0012327 to Karles et al.; and 2007/0068540 to Thomas et al.; PCT WO 03/009711 to Kim; PCT WO2006/136197 to Hartmann et al.; PCT WO 2006/136199 to Mane et al., PCT WO 2007/010407; and PCT WO 2007/060543, as well as within filtered cigarettes that have been marketed under the tradename “Camel Lights with Menthol Boost” by R. J. Reynolds Tobacco Company, which are incorporated herein by reference. See also, the types of capsules and components thereof set forth in U.S. Pat. No. 5,223,185 to Takei et al.; U.S. Pat. No.5,387,093 to Takei; U.S. Pat. No.5,882,680 to Suzuki et al.; U.S. Pat. No.6,719,933 to Nakamura et al. and U.S. Pat. No.6,949,256 to Fonkwe et al.; and U.S. Pat. App. Pub. Nos. 2004/0224020 to Schoenhard; 2005/0123601 to Mane et al.; 2005/0196437 to Bednarz et al.; and 2005/0249676 to Scott et al.; which are incorporated herein by reference. The capsules may be colored, provided with smooth or rough surfaces, have rigid or pliant shells, have brittle or durable shells, or other desired features or characters. [0272] In pouched embodiments comprising a fleece material as the pouch, the amount of substituted 3-(1-methylpyrrolidin-2-yl)pyridine, optionally substituted 3-(azetidin-2- yl)pyridine, optionally 3-(azetidin-2-ylmethoxy)pyridine, or other active ingredient present within the fleece material may vary. For example, some of the substituted 3-(1- methylpyrrolidin-2-yl)pyridine, optionally substituted 3-(azetidin-2-yl)pyridine, optionally 3- (azetidin-2-ylmethoxy)pyridine, or other active ingredient may migrate from the composition into the fleece during storage. In some embodiments, a portion of the substituted 3-(1- methylpyrrolidin-2-yl)pyridine, optionally substituted 3-(azetidin-2-yl)pyridine, optionally 3- (azetidin-2-ylmethoxy)pyridine, or other active ingredient is added to the fleece material during manufacture. Accordingly, the amount of substituted 3-(1-methylpyrrolidin-2-yl)pyridine, optionally substituted 3-(azetidin-2-yl)pyridine, optionally 3-(azetidin-2-ylmethoxy)pyridine, or other active ingredient present within the fleece (i.e., adsorbed or absorbed) may range from 0% up to 75% or more by weight, based on the total amount of substituted 3-(1- methylpyrrolidin-2-yl)pyridine, optionally substituted 3-(azetidin-2-yl)pyridine, optionally 3- (azetidin-2-ylmethoxy)pyridine, or other active ingredient present in the product as a whole. In some embodiments, the fleece includes less than 10%, such as less than 5%, less than 1%, less than 0.1%, or even 0% of the total substituted 3-(1-methylpyrrolidin-2-yl)pyridine, optionally substituted 3-(azetidin-2-yl)pyridine, optionally 3-(azetidin-2-ylmethoxy)pyridine, or other active ingredient present in the product by weight. In some embodiments, at least a portion of the total amount of substituted 3-(1-methylpyrrolidin-2-yl)pyridine, optionally substituted 3- (azetidin-2-yl)pyridine, optionally 3-(azetidin-2-ylmethoxy)pyridine, or other active ingredient in the product by weight is present in the fleece (i.e., adsorbed or absorbed), such as at least 1% and up to 75% or more. In some embodiments, the fleece comprises from about 1%, about 5%, about 10%, about 20%, about 30%, about 40%, about 50%, about 60%, about 70%, about 80%, or about 90% of the total amount of substituted 3-(1-methylpyrrolidin-2-yl)pyridine, optionally substituted 3-(azetidin-2-yl)pyridine, optionally 3-(azetidin-2-ylmethoxy)pyridine, or other active ingredient present by weight in the product. Preparation of the composition [0273] Compositions of the disclosure, regardless of format (e.g., granular, pouched, pastille, melt, chew, gum, and the like) are generally prepared by mixing a substituted 3-(1- methylpyrrolidin-2-yl)pyridine, optionally substituted 3-(azetidin-2-yl)pyridine, optionally 3- (azetidin-2-ylmethoxy)pyridine, or other active ingredient as described herein with additional composition components (e.g., water, fillers, sweeteners, binders, flavoring agents, buffers, salts, and the like). The manner by which the various components of the composition are combined may vary. As such, the overall mixture of the various components may be relatively uniform in nature. The components noted above, which may be in liquid or dry solid form, can be admixed in a pretreatment step prior to mixture with any remaining components of the composition, or simply mixed together with all other liquid or dry components. [0274] In some embodiments, the method of preparing the composition comprises: combining one or more fillers, one or more salts, and one or more sweeteners to form a dry blend; combining a dilute aqueous solution of substituted 3-(1-methylpyrrolidin-2- yl)pyridine, optionally substituted 3-(azetidin-2-yl)pyridine, optionally 3-(azetidin-2- ylmethoxy)pyridine, or other active ingredient with water and optionally a humectant to form a solution; combining the solution with the dry blend to form a mixture; mixing the resulting mixture to form a wet blend; and optionally, adding flavoring agent and water to the wet blend form the composition. [0275] A non-limiting flow chart depicting such a method 200 of forming the composition is provided in FIG. 2. Such a method 200 is generally suitable for forming the composition in a particulate form, suitable for e.g., enclosing in a pouch to form a pouched product. With reference to FIG.2, in some embodiments, one or more fillers, one or more salts, one or more sweeteners, and optionally a buffer, are provided 210 and combined 220 to form a dry blend. With continued reference to FIG. 2, in some embodiments, the substituted 3-(1- methylpyrrolidin-2-yl)pyridine, optionally substituted 3-(azetidin-2-yl)pyridine, optionally 3- (azetidin-2-ylmethoxy)pyridine, or other active ingredient is provided as a dilute aqueous solution, for example, a solution in water from about 4 to about 20% by weight of the substituted 3-(1-methylpyrrolidin-2-yl)pyridine, optionally substituted 3-(azetidin-2- yl)pyridine, optionally 3-(azetidin-2-ylmethoxy)pyridine, or other active ingredient. In some embodiments, the substituted 3-(1-methylpyrrolidin-2-yl)pyridine, optionally substituted 3- (azetidin-2-yl)pyridine, optionally 3-(azetidin-2-ylmethoxy)pyridine, or other active ingredient in solution is present in the free base form. In some embodiments, the solution includes from about 8 to about 14% of free base substituted 3-(1-methylpyrrolidin-2-yl)pyridine, optionally substituted 3-(azetidin-2-yl)pyridine, optionally 3-(azetidin-2-ylmethoxy)pyridine, or other active ingredient by weight, such as from about 8, about 9, about 10, or about 11, to about 12, about 13, or about 14% by weight, based on the total weight of the solution. With continued reference to FIG. 2, in some embodiments, a dilute aqueous solution of substituted 3-(1- methylpyrrolidin-2-yl)pyridine, optionally substituted 3-(azetidin-2-yl)pyridine, optionally 3- (azetidin-2-ylmethoxy)pyridine, or other active ingredient is combined 230 with water and optionally a humectant (e.g., glycerin) to form a solution. The solution is then combined 240 with the dry blend, either by addition of the solution to the dry blend, or addition of the dry blend to the solution, and mixed to form a wet blend. Water and optional flavoring agent are then added 250 to the wet blend and mixed to form the composition. [0276] In some embodiments, the substituted 3-(1-methylpyrrolidin-2-yl)pyridine, optionally substituted 3-(azetidin-2-yl)pyridine, optionally 3-(azetidin-2-ylmethoxy)pyridine, or other active ingredient is provided as a solid, such as solid free base or a salt or co-crystal as disclosed herein. Accordingly, in some embodiments, the substituted 3-(1-methylpyrrolidin-2- yl)pyridine, optionally substituted 3-(azetidin-2-yl)pyridine, optionally 3-(azetidin-2- ylmethoxy)pyridine, or other active ingredient in solid form is combined with the dry blend, or may be combined with water and optionally a humectant (e.g., glycerin) to form a solution. The solution is then combined 240 with the dry blend, either by addition of the solution to the dry blend, or addition of the dry blend to the solution, and mixed to form a wet blend. Water and optional flavoring agent are then added 250 to the wet blend and mixed to form the composition. [0277] In some embodiments, the substituted 3-(1-methylpyrrolidin-2-yl)pyridine, optionally substituted 3-(azetidin-2-yl)pyridine, optionally 3-(azetidin-2-ylmethoxy)pyridine, or other active ingredient is sorbed onto a porous particulate carrier material, such as microcrystalline cellulose (mcc) prior to incorporation within a composition of the disclosure. In some embodiments, the mcc material has an average particle size range of about 15 to about 250 microns. The particulate carrier material with the sorbed substituted 3-(1-methylpyrrolidin-2- yl)pyridine, optionally substituted 3-(azetidin-2-yl)pyridine, optionally 3-(azetidin-2- ylmethoxy)pyridine, or other active ingredient can then be combined with further composition components as described herein. [0278] In some embodiments, the substituted 3-(1-methylpyrrolidin-2-yl)pyridine, optionally substituted 3-(azetidin-2-yl)pyridine, optionally 3-(azetidin-2-ylmethoxy)pyridine, or other active ingredient is complexed with a cyclodextrin, such as beta-cyclodextrin or derivative thereof, prior to incorporation within a composition of the disclosure. For example, in some embodiments, a slurry of beta-cyclodextrin, substituted 3-(1-methylpyrrolidin-2-yl)pyridine, optionally substituted 3-(azetidin-2-yl)pyridine, optionally 3-(azetidin-2-ylmethoxy)pyridine, or other active ingredient, and water is heated to form a solution. Upon cooling, the precipitate is collected and dried to form a free-flowing powder. The ratio of beta-cyclodextrin to substituted 3-(1-methylpyrrolidin-2-yl)pyridine, optionally substituted 3-(azetidin-2- yl)pyridine, optionally 3-(azetidin-2-ylmethoxy)pyridine, or other active ingredient may vary, but is typically an approximately 1:1 molar ratio. Other cyclodextrins, such as hydroxy substituted and sulfo-beta ether cyclodextrins are also contemplated herein. [0279] In some embodiments, the substituted 3-(1-methylpyrrolidin-2-yl)pyridine, optionally substituted 3-(azetidin-2-yl)pyridine, optionally 3-(azetidin-2-ylmethoxy)pyridine, or other active ingredient is complexed with pectin prior to incorporation within a composition of the disclosure. For example, in some embodiments, the substituted 3-(1-methylpyrrolidin-2- yl)pyridine, optionally substituted 3-(azetidin-2-yl)pyridine, optionally 3-(azetidin-2- ylmethoxy)pyridine, or other active ingredient in water is mixed with apple-derived pectin in an amount sufficient to form a thick paste. [0280] The various components of the composition (e.g., filler, substituted 3-(1- methylpyrrolidin-2-yl)pyridine, optionally substituted 3-(azetidin-2-yl)pyridine, optionally 3- (azetidin-2-ylmethoxy)pyridine, or other active ingredient, optionally in a dilute aqueous solution, flavoring, sweeteners, salts, and the like) may be contacted, combined, or mixed together using any mixing technique or equipment known in the art. Any mixing method that brings the composition ingredients into intimate contact can be used, such as a mixing apparatus featuring an impeller or other structure capable of agitation. Examples of mixing equipment include casing drums, conditioning cylinders or drums, liquid spray apparatus, conical-type blenders, ribbon blenders, mixers available as FKM130, FKM600, FKM1200, FKM2000 and FKM3000 from Littleford Day, Inc., Plough Share types of mixer cylinders, Hobart mixers, and the like. See also, for example, the types of methodologies set forth in US Pat. Nos. 4,148,325 to Solomon et al.; 6,510,855 to Korte et al.; and 6,834,654 to Williams, each of which is incorporated herein by reference. Manners and methods for formulating compositions will be apparent to those skilled in the art. See, for example, the types of methodologies set forth in US Pat. No. 4,148,325 to Solomon et al.; US Pat. No.6,510,855 to Korte et al.; and US Pat. No.6,834,654 to Williams, US Pat. Nos.4,725,440 to Ridgway et al., and 6,077,524 to Bolder et al., each of which is incorporated herein by reference. [0281] In some embodiments, the composition is in the form of a gum, chew, pastille, lozenge, tablet, film, or melt. Methods of preparing such forms are generally known in the art and non- limiting methods are provided in the examples below. In each instance, the method generally comprises combining a dilute aqueous solution of substituted 3-(1-methylpyrrolidin-2- yl)pyridine, optionally substituted 3-(azetidin-2-yl)pyridine, optionally 3-(azetidin-2- ylmethoxy)pyridine, or other active ingredient with other appropriate components appropriate to the particular composition. [0282] In some embodiments, the composition is in the form of a translucent or transparent lozenge. The manners and methods used to formulate and manufacture the translucent lozenge product can vary. For example, the composition can be prepared via any method commonly used for the preparation of hard-boiled confections. Exemplary methods for the preparation of hard confections can be found, for example, in LFRA Ingredients Handbook, Sweeteners, Janet M. Dalzell, Ed., Leatherhead Food RA (December 1996), pp. 21-44, which is incorporated herein by reference. Typically, a translucent lozenge comprises substituted 3-(1- methylpyrrolidin-2-yl)pyridine, a sugar substitute, and a sugar alcohol, and may contain various additional substances (e.g., salts, preservatives, further sweeteners, water, organic acids, buffers, flavorings, and the like) as described herein. Typically, a mixture of composition components is formed and is heated until it melts. Subsequently, the mixture is heated to or past the hard crack stage. In confectionary making, the hard crack stage is defined as the temperature at which threads of the heated mixture (obtained by pulling a sample of cooled syrup between the thumb and forefinger) are brittle or as the temperature at which trying to mold the syrup results in cracking. The temperature at which the hard crack stage is achieved can vary, depending on the specific makeup of the product mixture but generally is between about 145° C and about 170° C. Typically, the mixture is not heated above about 171° C, which is the temperature at which caramelization begins to occur. Typically, the mixture is heated to the hard crack stage temperature or above and then allowed to cool. The heating can be conducted at atmospheric pressure or under vacuum. The mixture is then formed into the desired shape. In some embodiments, the mixture is poured directly into molds, formed (e.g., rolled or pressed) into the desired shape, or extruded. If desired, the mixture can be extruded or injection molded. In certain embodiments, the mixture is formed or extruded into a mold of desired shape in an enclosed system, which may require decreased temperature and which may limit evaporation of certain mixture components. For example, such a system may limit the evaporation of volatile components including, but not limited to, flavorants. Other methods of producing lozenges are also intended to be encompassed herein. [0283] Many modifications and other embodiments of the disclosure will come to mind to one skilled in the art to which this disclosure pertains having the benefit of the teachings presented in the foregoing description. Therefore, it is to be understood that the disclosure is not to be limited to the specific embodiments disclosed and that modifications and other embodiments are intended to be included within the scope of the appended claims. Although specific terms are employed herein, they are used in a generic and descriptive sense only and not for purposes of limitation. EXAMPLES [0284] Aspects of the present disclosure are more fully illustrated by the following examples, which are set forth to illustrate certain aspects of the present disclosure and are not to be construed as limiting thereof. Any of the active ingredients noted in the examples below could be replaced with another active ingredient compound (or combination of compounds) disclosed herein. For example, the active ingredient in any of these examples could be replaced with cytisine, varenicline, acetylcholine, choline, epibatidine, iobeline, analogs thereof, or combinations thereof. Example 1. Preparation of a pouched oral product [0285] Pouched oral products comprising a composition according to present disclosure comprising 3-(1,2-dimethylpyrrolidin-2-yl)pyridine as the active ingredient are prepared. The composition included 3-(1,2-dimethylpyrrolidin-2-yl)pyridine in an amount from about 0.5 mg to about 20 mg, microcrystalline cellulose (mcc), sweeteners, water, and additional components as disclosed herein (salt, humectant, buffer, flavoring agent). The composition has the formulation provided in Table 2. [0286] To prepare the composition, a dry blend of mcc, salt, sweeteners, and optionally sodium benzoate, benzoic acid, or both was prepared by combining the components in a mixer. Separately, a wet blend was prepared by combining water, 3-(1,2-dimethylpyrrolidin-2- yl)pyridine, propylene glycol, optional citrate buffer, and flavoring agent in a blender. The dry and wet blends were mixed in a mixer to form a homogenous composition. Portions of the composition (480 mg) were placed in fleece pouches. Additional water was added to the pouches to achieve the desired total product moisture content (oven volatiles; about 32 to 48% by weight). Table 2. Composition ingredients Component % w/w 3-(1,2-dimethylpyrrolidin-2- 0.1-4 yl)pyridine microcrystalline cellulose 55-80 water 8-12 sweetener 1.5-3.5 salt (e.g., sodium chloride) 5-7 propylene glycol 5-9 benzoic acid 0-3 sodium benzoate 0-12 trisodium citrate, 0.5M (17% w/w) 0-15 flavoring agent 2-3 Example 2. Preparation of Flavored Chewing Gum [0287] Chewing gum tablets containing a flavoring agent and from about 0.5 mg to about 20 mg of 3-(1,2-dimethylpyrrolidin-2-yl)pyridine are prepared using the formulation components provided in Table 3. [0288] Sorbitol, isomalt, and sodium benzoate are combined to give a dry mixture. Separately, maltitol syrup, glycerin, and 3-(1,2-dimethylpyrrolidin-2-yl)pyridine solution are combined to form a liquid mixture. The gum base (Artica T; CAFOSA Gum S/A, Barcelona, Spain) is warmed in a microwave oven under low power for approximately five minutes to soften. The heated, softened gum base is mixed by hand until uniform and transferred to the bowl of a commercial mixer. Approximately 1/3 of the liquid mixture is added to the gum base followed by two minutes of mixing. Approximately 1/3 of the dry mixture, along with sucralose, is added to the gum base-liquid mixture followed by two minutes of mixing. Additions of the dry and liquid mixtures are each repeated twice, followed in each case by a further two minutes of mixing to incorporate the remaining dry and liquid mixtures. The flavoring agent is added to the mixture followed by mixing for 45 seconds. The mixture is removed from the mixer bowl and dusted with mannitol powder, then run through a sheeter to provide a uniform thickness of the composition. Square tablets weighing 1.65 g each are die punched from the composition sheet. Table 3. Oral gum composition components and amounts Component % w/w gum base 20-30 sorbitol 29-43 maltitol (75% aqueous) 12-18 isomalt 12-18 Component % w/w glycerin 1.2-1.8 sucralose 0.3-0.6 flavoring agent 2-4 3-(1,2-dimethylpyrrolidin-2- 0.02-1.1 yl)pyridine sodium benzoate 0-3.5 benzoic acid 0-1 mannitol 0.8-1.2 Example 3. Preparation of Tablet [0289] A composition in tablet form is prepared from a composition containing a mixture of fillers, 3-(1,2-dimethylpyrrolidin-2-yl)pyridine, and additional components as disclosed herein (salt, sweeteners, processing aid, etc.). The fillers, sweetener, salt, 3-(1,2-dimethylpyrrolidin- 2-yl)pyridine, and other components are combined and mixed thoroughly. The mixture is compressed and tableted using a Fette 1200i tablet press. The tablets are coated with wax and shellac. The ingredients of the composition and their concentrations in the composition in weight % are provided in Table 4. The tablets each weigh 1000 mg. Table 4. Tablet ingredients Ingredient %w/w isomalt 32-48 Emdex® filler 35-55 3-(1,2-dimethylpyrrolidin-2- 0.05-1.9 yl)pyridine sodium benzoate 0-5.8 benzoic acid 0-1.3 sweetener 0.1-0.5 salt 0.2-0.4 sodium stearyl fumarate 0.5-1.5 flavorant 1-1.5 Carnauba wax 0.05-0.15 shellac 0.2-0.4 Example 4. Preparation of a Chewable [0290] A composition in chewable form is prepared from a composition containing a mixture of fillers, 3-(1,2-dimethylpyrrolidin-2-yl)pyridine, and additional components as disclosed herein (salt, sweeteners, flavoring agent, water, binder, gelation agent, and the like). The ingredients of the composition and their concentrations in the composition in weight% are provided in Table 5. [0291] The pectin binder is pre-blended with a portion of the isomalt. Water is added, and the mixture heated to boiling with stirring. Maltitol syrup and any remaining isomalt are added to the boiling mixture, along with the 3-(1,2-dimethylpyrrolidin-2-yl)pyridine, followed by trisodium citrate. The mixture is cooked to 78 brix. Heat is removed, and sweetener (e.g., sucralose and acesulfame K, colorant and flavorant are added, along with the citric acid and dicalcium phosphate, the mixture thoroughly combined, and the composition deposited into starch molds for storage at ambient temperature. The chews each weigh 2600 mg. Table 5. Chewable ingredients Ingredient %w/w isomalt 12-20 maltitol syrup 48-72 3-(1,2-dimethylpyrrolidin-2- 0.02-0.7 yl)pyridine water 12-18 dicalcium phosphate 0.4-0.6 citric acid 0.5-1.5 trisodium citrate 0.5-1.5 sodium benzoate 0-2.2 benzoic acid 0-0.5 flavorant 0.6-0.9 pectin 1-2 sweetener 0.05-0.5 colorant 0.05-0.15 Example 5. Preparation of a Meltable [0292] A composition in meltable form is prepared from a composition containing a filler, a lipid, 3-(1,2-dimethylpyrrolidin-2-yl)pyridine, and additional components as disclosed herein (salt, sweeteners, flavoring agent). The ingredients of the composition and their concentrations in the composition in weight % are provided in Table 6. [0293] A portion of the palm oil is melted and mixed with the isomalt in a mixer. The mixture is transferred to a dry roll mill and milled until the particle size is less than 20 microns. In a mixer, the milled isomalt-palm oil is combined with the remaining portion of palm oil. The base is warmed to a fluid consistency. Sunflower oil, the dry ingredients, and flavor are mixed in. The isomalt-palm oil-ingredient mixture is transferred to a heated depositing funnel. The appropriate weight of the samples is deposited into a shape mold. If needed, the mold is placed on a vibrator to ensure even filling. The product is allowed to cool and solidify, then removed from the mold. The melts each weigh 1300 mg. Table 6. Meltable ingredients Ingredient %w/w isomalt 35-55 lipid (e.g., palm oil) 32-48 3-(1,2-dimethylpyrrolidin-2- 0.04-1.4 yl)pyridine salt 0.5-1.5 sunflower lecithin 0.25-0.5 sunflower oil 2-3.5 sweetener 0.05-0.5 flavor 0.5-1.5 sodium benzoate 0-4.4 benzoic acid 0-1 Example 6. Preparation of a Pastille [0294] An oral product in the form of a pastille is prepared. An aqueous mixture is prepared. The aqueous mixture is formed by admixing water, a salt, a sweetener (e.g., sucralose), a humectant (e.g., glycerin), and a flavoring agent. Next, a gum (e.g., gum arabic) solution is heated to a temperature of about 71°C and a solution of 3-(1,2-dimethylpyrrolidin-2- yl)pyridine is stirred into the heated gum component. The heated gum is then added to the aqueous composition to form a mixture. Then, at least one sugar alcohol (e.g., including isomalt, maltitol, and/or erythritol) is heated to a temperature of about 175°C and then cooled to a temperature of about 150°C. The cooled sugar alcohol is then added to the mixture and stirred in to form a pastille composition which is allowed to cool. [0295] The pastille composition is then heated to about 71°C and deposited into a starch mold. The pastille composition remains in the starch mold for about 24 hours at about 60°C. The pastille composition is allowed to cool and then removed from the starch mold. The oral composition is then cured at ambient room temperature for about 24 hours to provide the pastille product weighing about 1900 mg each. Table 7 below illustrates the relative percentages of each individual component in the pastille. Table 7 – Pastille ingredients Ingredient % (w/w) isomalt 20-35 maltitol 1-10 erythritol 0.1-2 glycerin 0.1-2 water 5-15 salt 1-3 Ingredient % (w/w) sweetener 0.01-1 3-(1,2-dimethylpyrrolidin- 0.03-1 2-yl)pyridine flavor 0.1-2 sodium benzoate 0-3 benzoic acid 0-0.7 gum arabic solution 35-55 Example 7. Preparation of a Translucent Lozenge [0296] An oral product in the form of a translucent lozenge is prepared. Isomalt and maltitol syrup are heated to melting without stirring to hard crack temperature (e.g., 165°C). The melt is cooled to approximately 143°C with very slight, discontinuous stirring. Other components (e.g., 3-(1,2-dimethylpyrrolidin-2-yl)pyridine, buffer, salts, sweeteners, and/or flavorants) are added to the mixture and folded in carefully with a spatula without introducing much air into the melt. The melt is further cooled to about 120°C. The mixture is poured into a glass beaker, the contents are poured from the beaker in a chord on a metal brick, in breakaway molds with niches of suitable dimensions, or in molds (for individual lozenges, weighing about 2000 mg each). Optionally, the mixture is reheated in order to obtain a suitable viscosity of the melt. The melt is cooled for a time suitable for solidifying (e.g., at room temperature). Table 8 below illustrates the relative percentages of each individual component in the lozenge. Table 8 – Lozenge ingredients Ingredient % (w/w) isomalt 90-95 maltitol 0.5-2 water 3-5 salt 1-3 sweetener 0.01-1 3-(1,2-dimethylpyrrolidin- 0.03-1 2-yl)pyridine flavor 0.1-2 citric acid 0.05 sodium benzoate 0-3 benzoic acid 0-0.6 Example 8. Preparation of a dry pouched oral product [0297] A pouched oral product having a low moisture level and comprising a composition according to the present disclosure is prepared. The composition includes 3-(1,2- dimethylpyrrolidin-2-yl)pyridine as the active ingredient, with each pouch comprising from about 0.5 mg to about 20 mg of the 3-(1,2-dimethylpyrrolidin-2-yl)pyridine. The composition further includes microcrystalline cellulose (mcc), sweeteners, water, and additional components as disclosed herein (salt, humectant, buffer, flavoring agent). The composition has the formulation provided in Table 9. To prepare the composition, a blend of 3-(1,2- dimethylpyrrolidin-2-yl)pyridine, mcc, salt, maltitol, hydroxypropyl cellulose, sodium benzoate, sweeteners and flavoring agent is mixed in a blender. The resulting composition has a moisture content (oven volatiles) of approximately 4 to 7.5% by weight. Portions of the composition (370 mg) are placed in fleece pouches. Table 9. Composition ingredients Ingredient % w/w microcrystalline cellulose 30-42 3-(1,2-dimethylpyrrolidin-2- yl)pyridine 0.1-5 maltitol 54 sweetener 0.03-0.3 sodium chloride 1-3 sodium benzoate 0-15.5 benzoic acid 0-3.5 hydroxypropyl cellulose 2-4 flavoring agent 0-3 Example 9. Preparation of a pouched oral product [0298] Pouched oral products comprising a composition according to present disclosure comprising an optionally substituted 3-(azetidin-2-yl)pyridine or 3-(azetidin-2- ylmethoxy)pyridine as the active ingredient are prepared. The composition includes an optionally substituted 3-(azetidin-2-yl)pyridine or 3-(azetidin-2-ylmethoxy)pyridine in an amount from about 0.005% to about 1% by weight (such as from about 0.03 mg to about 5 mg), microcrystalline cellulose (mcc), sweeteners, water, and additional components as disclosed herein (salt, humectant, buffer, flavoring agent). The composition has the formulation provided in Table 10. [0299] To prepare the composition, a dry blend of mcc, salt, sweeteners, and optionally sodium benzoate, benzoic acid, or both was prepared by combining the components in a mixer. Separately, a wet blend was prepared by combining water, the optionally substituted 3- (azetidin-2-yl)pyridine or 3-(azetidin-2-ylmethoxy)pyridine, propylene glycol, optional citrate buffer, and flavoring agent in a blender. The dry and wet blends were mixed in a mixer to form a homogenous composition. Portions of the composition (480 mg) were placed in fleece pouches. Additional water was added to the pouches to achieve the desired total product moisture content (oven volatiles; about 32 to 48% by weight). Table 10. Composition ingredients Component % w/w optionally substituted 3-(azetidin-2-yl)pyridine 0.005-1 or 3-(azetidin-2-ylmethoxy)pyridine microcrystalline cellulose 55-80 water 8-12 sweetener 1.5-3.5 salt (e.g., sodium chloride) 5-7 propylene glycol 5-9 benzoic acid 0-0.8 sodium benzoate 0-3.5 trisodium citrate, 0.5M (17% w/w) 0-15 flavoring agent 2-3 Example 10. Preparation of Flavored Chewing Gum [0300] Chewing gum tablets containing a flavoring agent and an optionally substituted 3- (azetidin-2-yl)pyridine or 3-(azetidin-2-ylmethoxy)pyridine in an amount from about 0.002% to about 0.3% by weight (such as from about 0.01 mg to about 5 mg) are prepared using the formulation components provided in Table 11. [0301] Sorbitol, isomalt, and sodium benzoate are combined to give a dry mixture. Separately, maltitol syrup, glycerin, and the optionally substituted 3-(azetidin-2-yl)pyridine or 3-(azetidin- 2-ylmethoxy)pyridine are combined to form a liquid mixture. The gum base (Artica T; CAFOSA Gum S/A, Barcelona, Spain) is warmed in a microwave oven under low power for approximately five minutes to soften. The heated, softened gum base is mixed by hand until uniform and transferred to the bowl of a commercial mixer. Approximately 1/3 of the liquid mixture is added to the gum base followed by two minutes of mixing. Approximately 1/3 of the dry mixture, along with sucralose, is added to the gum base-liquid mixture followed by two minutes of mixing. Additions of the dry and liquid mixtures are each repeated twice, followed in each case by a further two minutes of mixing to incorporate the remaining dry and liquid mixtures. The flavoring agent is added to the mixture followed by mixing for 45 seconds. The mixture is removed from the mixer bowl and dusted with mannitol powder, then run through a sheeter to provide a uniform thickness of the composition. Square tablets weighing 1.65 g each are die punched from the composition sheet. Table 11. Oral gum composition components and amounts Component % w/w gum base 20-30 sorbitol 29-43 maltitol (75% aqueous) 12-18 isomalt 12-18 glycerin 1.2-1.8 sucralose 0.3-0.6 flavoring agent 2-4 optionally substituted 3-(azetidin-2-yl)pyridine or 3- 0.002-0.3 (azetidin-2-ylmethoxy)pyridine sodium benzoate 0-1 benzoic acid 0-0.8 mannitol 0.8-1.2 Example 11. Preparation of Tablet [0302] A composition in tablet form is prepared from a composition containing a mixture of fillers, an optionally substituted 3-(azetidin-2-yl)pyridine or 3-(azetidin-2-ylmethoxy)pyridine in an amount from about 0.003% to about 0.5% by weight (such as from about 0.01 mg to about 5 mg), and additional components as disclosed herein (salt, sweeteners, processing aid, etc.). The fillers, sweetener, salt, optionally substituted 3-(azetidin-2-yl)pyridine or 3-(azetidin- 2-ylmethoxy)pyridine, and other components are combined and mixed thoroughly. The mixture is compressed and tableted using a Fette 1200i tablet press. The tablets are coated with wax and shellac. The ingredients of the composition and their concentrations in the composition in weight % are provided in Table 12. The tablets each weigh 1000 mg. Table 12. Tablet ingredients Ingredient %w/w isomalt 32-48 Emdex® filler 35-55 optionally substituted 3-(azetidin-2-yl)pyridine or 3- 0.003-0.5 (azetidin-2-ylmethoxy)pyridine sodium benzoate 0-1.7 benzoic acid 0-0.4 sweetener 0.1-0.5 salt 0.2-0.4 sodium stearyl fumarate 0.5-1.5 flavorant 1-1.5 Carnauba wax 0.05-0.15 shellac 0.2-0.4 Example 12. Preparation of a Chewable [0303] A composition in chewable form is prepared from a composition containing a mixture of fillers, an optionally substituted 3-(azetidin-2-yl)pyridine or 3-(azetidin-2- ylmethoxy)pyridine in an amount from about 0.001% to about 0.2% by weight (such as from about 0.03 mg to about 5 mg), and additional components as disclosed herein (salt, sweeteners, flavoring agent, water, binder, gelation agent, and the like). The ingredients of the composition and their concentrations in the composition in weight% are provided in Table 13. [0304] The pectin binder is pre-blended with a portion of the isomalt. Water is added, and the mixture heated to boiling with stirring. Maltitol syrup and any remaining isomalt are added to the boiling mixture, along with the 3 optionally substituted 3-(azetidin-2-yl)pyridine or 3- (azetidin-2-ylmethoxy)pyridine, followed by trisodium citrate. The mixture is cooked to 78 brix. Heat is removed, and sweetener (e.g., sucralose and acesulfame K, colorant and flavorant are added, along with the citric acid and dicalcium phosphate, the mixture thoroughly combined, and the composition deposited into starch molds for storage at ambient temperature. The chews each weigh 2600 mg. Table 13. Chewable ingredients Ingredient %w/w isomalt 12-20 maltitol syrup 48-72 optionally substituted 3-(azetidin-2-yl)pyridine or 3- 0.001-0.2 (azetidin-2-ylmethoxy)pyridine water 12-18 dicalcium phosphate 0.4-0.6 citric acid 0.5-1.5 trisodium citrate 0.5-1.5 sodium benzoate 0-0.6 benzoic acid 0-0.5 flavorant 0.6-0.9 pectin 1-2 sweetener 0.05-0.5 colorant 0.05-0.15 Example 13. Preparation of a Meltable [0305] A composition in meltable form is prepared from a composition containing a filler, a lipid, an optionally substituted 3-(azetidin-2-yl)pyridine or 3-(azetidin-2-ylmethoxy)pyridine in an amount from about 0.002% to about 0.4% by weight (such as from about 0.03 mg to about 5 mg), and additional components as disclosed herein (salt, sweeteners, flavoring agent). The ingredients of the composition and their concentrations in the composition in weight % are provided in Table 14. [0306] A portion of the palm oil is melted and mixed with the isomalt in a mixer. The mixture is transferred to a dry roll mill and milled until the particle size is less than 20 microns. In a mixer, the milled isomalt-palm oil is combined with the remaining portion of palm oil. The base is warmed to a fluid consistency. Sunflower oil, the dry ingredients, and flavor are mixed in. The isomalt-palm oil-ingredient mixture is transferred to a heated depositing funnel. The appropriate weight of the samples is deposited into a shape mold. If needed, the mold is placed on a vibrator to ensure even filling. The product is allowed to cool and solidify, then removed from the mold. The melts each weigh 1300 mg. Table 14. Meltable ingredients Ingredient %w/w isomalt 35-55 lipid (e.g., palm oil) 32-48 optionally substituted 3-(azetidin-2-yl)pyridine or 3- 0.002- (azetidin-2-ylmethoxy)pyridine 0.4 salt 0.5-1.5 sunflower lecithin 0.25-0.5 sunflower oil 2-3.5 sweetener 0.05-0.5 flavor 0.5-1.5 sodium benzoate 0-1.3 benzoic acid 0-0.3 Example 14. Preparation of a Pastille [0307] An oral product in the form of a pastille is prepared including an optionally substituted 3-(azetidin-2-yl)pyridine or 3-(azetidin-2-ylmethoxy)pyridine in an amount from about 0.001% to about 0.3% by weight (such as from about 0.03 mg to about 5 mg). An aqueous mixture is prepared by admixing water, a salt, a sweetener (e.g., sucralose), a humectant (e.g., glycerin), and a flavoring agent. Next, a gum (e.g., gum arabic) solution is heated to a temperature of about 71°C and a solution of the optionally substituted 3-(azetidin-2-yl)pyridine or 3-(azetidin-2-ylmethoxy)pyridine is stirred into the heated gum component. The heated gum is then added to the aqueous composition to form a mixture. Then, at least one sugar alcohol (e.g., including isomalt, maltitol, and/or erythritol) is heated to a temperature of about 175°C and then cooled to a temperature of about 150°C. The cooled sugar alcohol is then added to the mixture and stirred in to form a pastille composition which is allowed to cool. [0308] The pastille composition is then heated to about 71°C and deposited into a starch mold. The pastille composition remains in the starch mold for about 24 hours at about 60°C. The pastille composition is allowed to cool and then removed from the starch mold. The oral composition is then cured at ambient room temperature for about 24 hours to provide the pastille product weighing about 1900 mg each. Table 15 below illustrates the relative percentages of each individual component in the pastille. Table 15 – Pastille ingredients Ingredient % (w/w) isomalt 20-35 maltitol 1-10 erythritol 0.1-2 glycerin 0.1-2 water 5-15 salt 1-3 sweetener 0.01-1 optionally substituted 3-(azetidin-2-yl)pyridine 0.001-0.3 or 3-(azetidin-2-ylmethoxy)pyridine flavor 0.1-2 sodium benzoate 0-0.9 benzoic acid 0-0.2 gum arabic Solution 35-55 Example 15. Preparation of a Translucent Lozenge [0309] An oral product in the form of a translucent lozenge is prepared including an optionally substituted 3-(azetidin-2-yl)pyridine or 3-(azetidin-2-ylmethoxy)pyridine in an amount from about 0.001% to about 0.25% by weight (such as from about 0.03 mg to about 5 mg). Isomalt and maltitol syrup are heated to melting without stirring, to hard crack temperature (e.g., 165°C). The melt is cooled to approximately 143°C with very slight, discontinuous stirring. Other components (e.g., optionally substituted 3-(azetidin-2-yl)pyridine or 3-(azetidin-2- ylmethoxy)pyridine, buffer, salts, sweeteners, and/or flavorants) are added to the mixture and folded in carefully with a spatula without introducing much air into the melt. The melt is further cooled to about 120°C. The mixture is poured into a glass beaker, the contents are poured from the beaker in a chord on a metal brick, in breakaway molds with niches of suitable dimensions, or in molds (for individual lozenges, weighing about 2000 mg each). Optionally, the mixture is reheated in order to obtain a suitable viscosity of the melt. The melt is cooled for a time suitable for solidifying (e.g., at room temperature). Table 16 below illustrates the relative percentages of each individual component in the lozenge. Table 16 – Lozenge ingredients Ingredient % (w/w) isomalt 90-95 maltitol 0.5-2 water 3-5 salt 1-3 sweetener 0.01-1 optionally substituted 3-(azetidin-2-yl)pyridine or 3- 0.001-0.25 (azetidin-2-ylmethoxy)pyridine flavor 0.1-2 citric acid 0.05 sodium benzoate 0-0.8 benzoic acid 0-0.2 Example 16. Preparation of a dry pouched oral product [0310] A pouched oral product having a low moisture level and comprising a composition according to the present disclosure is prepared. The composition includes an optionally substituted 3-(azetidin-2-yl)pyridine or 3-(azetidin-2-ylmethoxy)pyridine in an amount from about 0.001% to about 0.3% by weight (such as from about 0.03 mg to about 5 mg). The composition further includes microcrystalline cellulose (mcc), sweeteners, water, and additional components as disclosed herein (salt, humectant, buffer, flavoring agent). The composition has the formulation provided in Table 17. To prepare the composition, a blend of the optionally substituted 3-(azetidin-2-yl)pyridine or 3-(azetidin-2-ylmethoxy)pyridine, mcc, salt, maltitol, hydroxypropyl cellulose, sodium benzoate, sweeteners and flavoring agent is mixed in a blender. The resulting composition has a moisture content (oven volatiles) of approximately 4 to 7.5% by weight. Portions of the composition (370 mg) are placed in fleece pouches. Table 17. Composition ingredients Ingredient % w/w microcrystalline cellulose 30-42 optionally substituted 3-(azetidin-2-yl)pyridine or 0.001-0.3 3-(azetidin-2-ylmethoxy)pyridine maltitol 54 Ingredient % w/w sweetener 0.03-0.3 sodium chloride 1-3 sodium benzoate 0-0.8 benzoic acid 0-0.2 hydroxypropyl cellulose 2-4 flavoring agent 0-3

Claims

CLAIMS 1. A composition configured for oral use, the composition comprising: a filler component; water in an amount from about 1 to about 60% by weight, based on the total weight of the composition; and a substituted 3-(1-methylpyrrolidin-2-yl)pyridine having a structure according to Formula I: , wherein: R¹ and R² are each independently selected from the group consisting of hydrogen, alkyl, alkoxy, cycloalkyl, alkenyl, alkynyl, aryl, alkylaryl, amino, halogen, and cyano, wherein any of said alkyl, alkoxy, cycloalkyl, alkenyl, alkenyl, alkynyl, aryl, alkylaryl, and amino may optionally be substituted; R³ is selected from the group consisting of hydrogen and CH3; R⁴ is selected from the group consisting of hydrogen and C₁-C₃ alkyl; and at least one of R³ and R⁴ is not hydrogen.

2. The composition of claim 1, wherein: R¹ is hydrogen or C₁-C₃ alkyl; and R² is H.

3. The composition of claim 2, wherein R¹ is H, and wherein: R³ is H and R⁴ is CH3; R³ is CH₃ and R⁴ is H; or R³ and R⁴ are both CH3.

4. The composition of claim 3, wherein R³ is H and R⁴ is CH3.

5. The composition of claim 3, wherein R³ is CH3 and R⁴ is H.

6. The composition of claim 2, wherein R¹ is CH3, and wherein: R³ is H and R⁴ is CH₃; or R³ is CH3 and R⁴ is H.

7. The composition of claim 6, wherein R³ is CH3 and R⁴ is H.

8. The composition of any one of claims 1-7, wherein the substituted 3-(1- methylpyrrolidin-2-yl)pyridine is racemic.

9. The composition of any one of claims 1-7, wherein the substituted 3-(1- methylpyrrolidin-2-yl)pyridine has an (R)-configuration or an (S)-configuration at the 2' position, such as wherein the substituted 3-(1-methylpyrrolidin-2-yl)pyridine has an (S)- configuration at the 2' position.

10. The composition of any one of claims 1-9, wherein the substituted 3-(1- methylpyrrolidin-2-yl)pyridine has a calculated logP of about 1 or greater, such as from about 1.2 to about 1.7.

11. The composition of any one of claims 1-10, wherein the composition is substantially free of 3-(1-methylpyrrolidin-2-yl)pyridine, such as wherein the composition is completely free of 3-(1-methylpyrrolidin-2-yl)pyridine.

12. The composition of any one of claims 1-11, further comprising an organic acid, an alkali metal salt of an organic acid, or a combination thereof; optionally, wherein the organic acid has a logP value from about 0 to about 12, from about 3 to about 12, from about 3 to about 10, or from about 3 to about 8; and optionally, wherein at least a portion of the substituted 3- (1-methylpyrrolidin-2-yl)pyridine is present in the form of an ion pair with the organic acid, the alkali metal salt of an organic acid, or a combination thereof.

13. The composition of any one of claims 1-12, wherein at least a portion of the substituted 3-(1-methylpyrrolidin-2-yl)pyridine is present in the form of a salt, a co-crystal, or a salt co- crystal.

14. The composition of any one of claims 1-13, wherein at least a portion of the substituted 3-(1-methylpyrrolidin-2-yl)pyridine is bound to a polymeric resin.

15. The composition of any one of claims 1-14, wherein the substituted 3-(1- methylpyrrolidin-2-yl)pyridine is present in an amount from about 0.05 to about 5% by weight of the composition, calculated as the free base and based on the total weight of the composition.

16. The composition of any one of claims 1-15, wherein the filler component is cellulosic; optionally, wherein the filler component comprises microcrystalline cellulose.

17. The composition of any one of claims 1-16, further comprising one or more flavoring agents, one or more salts, one or more sweeteners, one or more binding agents, one or more humectants, one or more gums, or combinations thereof.

18. The composition of any one of claims 1-17, in the form of a gel, pastille, gum, chew, melt, tablet, lozenge, film, granular material, or powder.

19. The composition of any one of claims 1-18, enclosed in a pouch to form a pouched product.

20. The composition of claim 19, having a moisture content from about 30 to about 60% by weight, based on the weight of the pouched product.

21. A composition configured for oral use, the composition comprising: 3-(1,2-dimethylpyrrolidin-2-yl)pyridine in an amount from about 0.05 to about 5% by weight, based on the total weight of the composition; a filler component; and water in an amount from about 1 to about 60% by weight, or from about 30 to about 50% by weight, based on the total weight of the composition.

22. A composition configured for oral use, the composition comprising: 5-(1,2-dimethylpyrrolidin-2-yl)-2-methylpyridine in an amount from about 0.05 to about 5% by weight, based on the total weight of the composition; a filler component; and water in an amount from about 1 to about 60% by weight, or from about 30 to about 50% by weight, based on the total weight of the composition.

23. The composition of claim 21 or 22, wherein the filler component is cellulosic; optionally, wherein the filler component comprises microcrystalline cellulose.

24. The composition of any one of claims 1-23, further comprising a buffer; optionally, wherein the buffer is an alkali metal citrate.

25. The composition of any one of claims 1-24, wherein at least about 60% of a total amount of substituted 3-(1-methylpyrrolidin-2-yl)pyridine by weight present in the composition is released when said composition is placed in 500 mL of phosphate buffer at pH 7.4, at 37°C for 50 minutes in a basket-type USP dissolution apparatus at a stirring speed of 50 RPM.

26. The composition of claim 25, wherein at least about 20% of a total amount of substituted 3-(1-methylpyrrolidin-2-yl)pyridine by weight present in the composition is released at 10 minutes.

27. A composition configured for oral use, the composition comprising: a filler component; water in an amount from about 1 to about 60% by weight, based on the total weight of the composition; and an azetidinyl pyridine having a structure according to Formula II: , wherein: L is a bond or -OCH2-*, where the asterisk indicates an attachment point to the azetidine ring; R⁵, R⁶, R⁷, and R⁸ are each independently selected from the group consisting of hydrogen, alkyl, alkoxy, halogen, and cyano; R⁹ is H or CH3; and R¹⁰ is H or CH₃.

28. The composition of claim 27, wherein L is a bond.

29. The composition of claim 28, wherein R⁵ is CH₃, F, Cl, Br, OCH₃, OEt, or CN.

30. The composition of claim 28, wherein: R⁵ is H or CH3; and R⁶, R^7, and R⁸ are each H.

31. The composition of claim 30, wherein: R⁹ and R¹⁰ are both H; R⁹ and R¹⁰ are both CH3; R⁹ is H and R¹⁰ is CH3; or R⁹ is CH3 and R¹⁰ is H.

32. The composition of any one of claims 27-31, wherein the 3-(azetidin-2-yl) pyridine has a structure selected from the group consisting of: .

33. The composition of any one of claims 1-31, wherein the 3-(azetidin-2-yl) pyridine has a structure selected from the group consisting of:

.

34. The composition of claim 27, wherein L is -OCH₂-*.

35. The composition of claim 34, wherein R⁵ is CH₃, F, Cl, Br, OCH₃, OEt, or CN.

36. The composition of claim 34, wherein: R⁵ is H or CH3; and R⁶, R^7, and R⁸ are each H.

37. The composition of claim 36, wherein: R⁹ and R¹⁰ are both H; R⁹ and R¹⁰ are both CH3; R⁹ is H and R¹⁰ is CH3; or R⁹ is CH3 and R¹⁰ is H.

38. The composition of any one of claims 34-37, wherein the 3-(azetidin-2-yl) pyridine has a structure selected from the group consisting of: .

39. The composition of any one of claims 34-38, wherein the 3-(azetidin-2-yl) pyridine has a structure selected from the group consisting of:

.

40. The composition of any one of claims 27-39, wherein the composition is substantially free of 3-(1-methylpyrrolidin-2-yl)pyridine, such as wherein the composition is completely free of 3-(1-methylpyrrolidin-2-yl)pyridine.

41. The composition of any one of claims 27-40, further comprising an organic acid, an alkali metal salt of an organic acid, or a combination thereof; optionally, wherein the organic acid has a logP value from about 0 to about 12, from about 3 to about 12, from about 3 to about 10, or from about 3 to about 8; and optionally, wherein at least a portion of the substituted 3- (1-methylpyrrolidin-2-yl)pyridine is present in the form of an ion pair with the organic acid, the alkali metal salt of an organic acid, or a combination thereof.

42. The composition of any one of claims 27-41, wherein at least a portion of the azetidinyl pyridine is present in the form of a salt, a co-crystal, or a salt co-crystal.

43. The composition of any one of claims 27-42, wherein at least a portion of the azetidinyl pyridine is bound to a polymeric resin.

44. The composition of any one of claims 27-43, wherein the azetidinyl pyridine is present in an amount from about 0.001 to about 1% by weight of the composition, calculated as the free base and based on the total weight of the composition.

45. The composition of any one of claims 27-44, wherein the filler component is cellulosic; optionally, wherein the filler component comprises microcrystalline cellulose.

46. The composition of any one of claims 27-45, further comprising one or more flavoring agents, one or more salts, one or more sweeteners, one or more binding agents, one or more humectants, one or more gums, or combinations thereof.

47. The composition of any one of claims 27-46, in the form of a gel, pastille, gum, chew, melt, tablet, lozenge, film, granular material, or powder.

48. The composition of any one of claims 27-47, enclosed in a pouch to form a pouched product.

49. The composition of claim 48, having a moisture content from about 30 to about 60% by weight, based on the weight of the pouched product.